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Abstract 
Oxidative stress attributable to the activation of a Nox2-containing NADPH oxidase is involved in 
dietary obesity-associated cardiovascular diseases. However, the mechanism of Nox2 activation in 
dietary obesity remains unclear. In this project age-matched apolipoprotein E knockout (ApoEKO) 
and Nox2/ApoE double knockout (D-KO) mice were used to investigate high-fat diet (HFD)-
induced obesity-related metabolic disorders, Nox2 activation, endothelial and adipose tissue 
dysfunction.  
Compared to NCD, HFD ApoEKO mice developed insulin resistance, increased systemic oxidative 
stress and vascular dysfunction which was accompanied by increased Nox2 expression, activated 
mitogen-activated protein kinase (MAPK) and attenuated Akt/endothelial nitric oxide synthesis 
(eNOS) pathways. Akt was decreased, vascular cell adhesion molecule-1 was increased and 
macrophages were recruited indicating endothelial cell activation and inflammation, attenuating the 
phosphatidylinositol-3-kinase/Akt/eNOS branch in favour of the MAPK. In vitro experiments 
showed that in response to high glucose/insulin challenge, ApoEKO aortas increased significantly 
the levels of Nox2 expression, activation of stress signalling pathways and the cells were senescent. 
Finally, the relationship of Nox2-derived reactive oxygen species due to obesity and adipose tissue 
dysfunction was examined for the first time in ApoEKO mice. It was found that adipose tissue in 
obesity is infiltrated by macrophages and intercellular adhesion molecule-1 is increased. Insulin 
receptor is decreased whereas ERK phosphorylation is increased and eNOS phosphorylation is 
decreased suggesting impaired insulin signalling. Uncoupled protein-1 levels also decreased. 
Nox2/ApoE D-KO mice did not exhibit any of the delirious effects of HFD/ insulin resistance and 
were protected from adipose tissue inflammation.  
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In conclusion, this project demonstrated a crucial role for metabolic disorders in systemic Nox2 
activation, inflammation, endothelial dysfunction and insulin receptor function in HFD ApoEKO 
mice. Also, it provides novel insights into mechanisms underlying adipose tissue dysfunction. 
Therefore, Nox2 targeting may represent an effective therapy to preserve endothelial and adipose 
tissue function and improve global metabolism in dietary obesity.  
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Chapter 1 
General Introduction 
1.1 Obesity 
According to the International Diabetes Federation, the metabolic syndrome is a cluster of the most 
dangerous heart attack risk factors: dyslipidaemia, hypertension, and raised fasting glucose levels 
(Alberti et al., 2009; Lorenzo et al., 2007; International Diabetes Federation 2, 2006; Grundy et al., 
2004). People with central obesity and any two of these key abnormalities have two-three times 
bigger risk of being affected by a heart attack or stroke and three-five times greater risk of 
developing type-2 diabetes (Lorenzo et al., 2007). The risk of having metabolic syndrome is 
closely linked to overweight and obesity and a lack of physical activity (NIH, 2015).  
In the Western world, the main contributors to obesity are the increased availability of energy-
dense foods and physical inactivity, often on a background of genetic susceptibility (Woodhouse, 
2008; Wilding, 2001). The obesity epidemic in the Western world is spiralling out of control and is 
on the cusp of pandemic proportions (Wang and Liao, 2012; Swinburn et al., 2011). More 
disturbingly, the preventive measures undertaken to combat obesity have proved futile in reversing 
the trend. Obesity is a global problem, its prevalence is increasing all over the world and it is 
associated with an increased risk of premature death (Adams et al., 2006). In 2014, about 266 
million men and 375 million women were obese in the world, compared with 34 million men and 
71 million women in 1975 (NCD Risk Factor Collaboration, 2016). By the year 2030, it is 
estimated that the prevalence of overweight and obese individuals will be increased; reaching 80% 
of the world population (see Fig. 1).  
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Figure 1.1: Trends in obesity from 1990 to 2030 (WHO Statistics). 
 
If such trends continue, it has been estimated that 75% of Americans and 70% of British people 
will be overweight or obese by 2030 (Wang et al., 2011). Furthermore, the rising levels of obesity 
now affect all age group as the number of overweight 6 month old American infants has increased a 
staggering 74% from 1980 to 2001  (Cromie, 2006). More disturbingly, the challenge to overcome 
obesity and its consequences is proving daunting to health organisations as recently the United 
Nations announced that non-communicable diseases including type-2 diabetes, hypertension and 
heart disease posed a greater threat to the developing world than acute infectious diseases including 
HIV (United Nations, 2011). 
Obesity and its association with acute and chronic health disorders are not only life threatening to 
obese individuals but also have a severe impact on the economy of countries due to increased 
healthcare costs and loss of workforce productivity (Sattar and Lean, 2007). In the United 
Kingdom, the direct costs caused by obesity have contributed to a significant burden on the 
National Health Service (NHS). It is estimated that £5.1 billion per year is spent to manage obesity-
3 
 
related disorders (UK Department of Health, 2013). Similarly, in 2008, the United States of 
America estimated the medical costs of obesity as $147 billion. This rise in obesity threatens to 
bankrupt the USA healthcare system (Hammond and Levine, 2010). In addition to the obesity 
related medical costs, there are indirect costs which are attributable to the overall economic impact 
of obesity. Of these, productivity plays a large role. There is widespread consensus showing 
productivity losses due to obesity result in substantial costs to the economy. Absenteeism 
(productivity costs due to employees being absent from work for obesity-related reasons) was 
estimated at $3.9 billion in 2004.  Presenteeism (decreased productivity of obese employees while 
at work) is estimated to cost the United States economy $7.8 billion a year (Ricci and Chee, 2005). 
Moreover, in some cases obesity is adversely affecting military security. Recent findings show that 
27% of all Americans aged 17-24 were too overweight to serve in the military as overweight 
soldiers were incapable of completing normal activities and functions required of soldiers (Popkin, 
2011). 
Body mass index (BMI) is the traditional method used clinically to measure obesity. It is used as an 
estimation of the degree of adiposity and as a predictor of developing related metabolic diseases. It 
is calculated by dividing the weight (in kilograms) by the height (in metres) squared (WHO, 2004). 
A healthy BMI lies in the range of 20-24.9 (see Table 1) as it is associated with the lowest 
morbidity and mortality risk (de Onis and Habicht, 1996) and a high BMI value indicates excessive 
body fat and relates to increased risks of developing metabolic diseases and mortality. However, a 
high BMI value does not always relate to excessive body fat as individuals especially athletes with 
a large muscle mass can have a BMI of up to 30 (Thang et al., 2006). To counteract this limitation, 
BMI used in combination with waist circumference provides a more accurate diagnosis. Waist 
circumference gives a better prediction of visceral fat and an increase in visceral fat increases the 
risk of metabolic diseases (Thang et al., 2006). 
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Table 1: The classification of body weight using BMI according to WHO.  
 
 
1.2 Obesity and cardiovascular disease  
One of the most dramatic aspects of the obesity pandemic is that excessive fat, particularly when 
presenting with a central distribution, is a major modifiable risk factor for cardiovascular disease 
(CVD) and increases the risk of developing conditions such as type-2 diabetes, dyslipidaemia 
(raised triglycerides and lowered high-density lipoprotein cholesterol) and hypertension which 
affects vascular homeostasis (Wang et al., 2011; Li et al., 2007) (see Fig. 2).  
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Figure 1.2: Parameters known to increase the risk for CVD development (WHO Statistics). 
 
Recent reports show that CVDs are the major cause of mortality in the western world, each year 
contributing to a third of all worldwide deaths (WHO, 2008). Additionally, data show 60.5% 
increase of individuals with diabetes worldwide over a twenty-five year period (International 
Diabetes Federation, 2009). For this reason, it is of the essence to identify and understand the 
underlying molecular mechanisms throughout disease progression and utilise these findings for 
future drug or therapeutic measures. 
CVDs are a heterogeneous group of disorders which affect the normal functionality of the heart and 
blood vessels which include atherosclerosis, myocardial infarction, stroke and hypertension 
(Pellegrino, 2016). A major CVD which threatens human health worldwide is atherosclerosis. It 
has been estimated that atherosclerosis causes 75% of cardiovascular related deaths. 
Atherosclerosis is a chronic inflammatory disease affecting the arterial wall, resulting in lesion 
formations called atheromas which could narrow the blood vessel lumen (Koltsova et al., 2012). 
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Atheromas are characterised by accumulation of low density lipoprotein (LDL) and cholesterol in 
the centre with a thick white fibrous cap surrounding it. 
The pathogenesis of atherosclerosis isn’t completely understood. Despite this, it’s widely accepted 
that hyperlipidaemia triggers an immunological response (Hansson and Libby, 2006). Hansson and 
Libby examined immune responses in atherosclerosis and concluded that following the initial 
immunological response, subsequent T-cells and macrophages are recruited and activated under the 
influence of cytokines such as interleukins (IL-2, IL-6, IL-18), interferon-gamma (IFN-γ) and 
tumour necrosis factor-alpha (TNF-α). Further activation of T-cells contributes to inflammation at 
the site and a vicious cycle commences, leading to lipid accumulation and plaque formaton. 
Importantly, endothelial damage/dysfunction is one of the earliest factors preceding atherosclerotic 
plaque formation. Atheromas can rupture exposing pro-thrombotic material to the blood causing 
ischemic stroke or myocardial infarction. Scientists continue to explore the pathogenesis of 
metabolic diseases using experimental animal models. It is now well established that reactive 
oxygen species (ROS) play an important role in the development of CVDs (Zhang et al., 2010). 
The use of experimental models in obesity will be discussed in detail in section 1.7, whereas the 
role of ROS in CVDs will be further discussed in section 1.9. 
1.3 Reactive Oxygen Species  
Oxidative stress is the excessive levels of free radicals resulting in alterations in normal cellular 
function eventually causing disease. Oxidative stress is recognised as a dominant mechanism 
proposed to be involved in obesity-associated CVDs (Seddon et al., 2007). Reactive oxygen 
species are generated as by-products of normal metabolism and include superoxide anion (O2 
.-
), 
hydrogen peroxide (H2O2), hydroxyl radical (OH
.
), hypochlorous acid (HOCl) and peroxynitrite 
(ONOO
-
) (Thannickal and Fanburg, 2000). ROS are generated when ground state oxygen is 
converted to more reactive forms by electron transfer or energy transfer (see Fig. 3). ROS 
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generation is a normal metabolic end-point of metabolising oxygen and is involved in a range of 
biochemical processes such as cellular signalling and host defence or immunity (Murphy et al., 
2011). 
 
 
Figure 1.3: Biochemical reactions of ROS formation. (O2 
.-
) superoxide anion, (H2O2)  
hydrogen peroxide, (OH
.
)  hydroxyl radical, (HOCl) hypochlorous acid and (ONOO
-
) 
peroxynitrite. 
 
Superoxide is the primary and major form of ROS production in the body (Powers and Jackson, 
2008). Its two unpaired electrons are situated in different molecular orbitals and have parallel spin 
states (Madamanchi et al., 2005). However, this negatively charged radical is unstable in aqueous 
solution with a half-life of a few seconds and is generally restricted to the cell compartment in 
which it is produced due to poor cell membrane permeability (Li and Shah, 2003). 
Superoxide can be dismutated to H2O2, a more stable and diffusible form of ROS, by the enzyme 
superoxide dismutase (SOD) following the reaction 2O2
.-
 + 2H
+
  H2O2 + O2. Hydrogen peroxide 
can be then removed by catalase which converts H2O2 to water and oxygen (2H2O2  2H2O + O2) 
or by glutathione peroxidise (GPx) which converts H2O2 to water during oxidation of the tripeptide 
8 
 
glutathione (GSH) (2GSH + H2O2  GSSG + 2H2O) (Valko et al., 2006). The hydroxyl radical 
can be created from H2O2 by either the Fenton reaction (Fe
2+
 + H2O2  Fe
3+
 + OH
.
 + OH
-
) or by 
the Haber Weiss reaction which combines the Fenton reaction with the reduction of Fe
3+
 by 
superoxide (Fe
3+
 + O2
.-
  Fe2+ + O2) to give the overall reaction O2
.-
 + H2O2  O2 + OH
.
 + OH
-
 
(Kehrer, 2000; Winterbourn, 1995) The Fenton derived OH
.
 has been shown to be a major 
contributor to atherosclerosis especially due to high levels of lipid peroxidation (Tangvarasittichai, 
2015). More specifically, LDL can be oxidatively modified, taken up by macrophage scavenger 
receptors promoting cholesterol accumulation and foam cell formation, monocyte recruitment, 
exerting cytotoxic effects towards endothelial cells and stimulating monocyte adhesion to the 
endothelium (Jialal and Devaraj, 1996). 
Hypochlorous acid is created by a haem protein released by phagocytes called myeloperoxidase by 
using H2O2 to oxidise chloride (H2O2 + Cl
-
 + H
+
  HOCl + H2O) (Bergt et al., 2004).  
Peroxynitrite is formed from the reaction between superoxide and nitric oxide (NO) (O2
.-
 + NO
.
  
ONOO
-
), which is 6 times faster than the dismutation of superoxide by SOD (Guzik et al., 2002) 
and plays an important role in the pathogenesis of endothelial dysfunction (Li and Shah, 2003). 
Increase in ROS levels decreases NO bioavailability a major mediator of normal vascular 
homeostasis and contributor to maintaining artery dilation as discussed in section 1.9.1. 
1.4 Sources of ROS 
Within the vessel wall, several enzymes are able to generate ROS, including mitochondrial 
transport enzymes (Starkov, 2008; Therade-Matharan et al., 2005), xanthine oxidase (Kelley et al., 
2010; Meneshian and Bulkley, 2002), uncoupled endothelial nitric oxide synthase (eNOS) 
(Porasuphatana et al., 2003; Vásquez-Vivar et al., 1998), cytochrome P-450 (Fleming, 2001) and 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme (Brandes et al., 2010; 
9 
 
Bedard and Krause, 2007; Seddon et al., 2007). However, while many of these enzymes generate 
ROS as by-products, the NADPH oxidase enzymes have been discovered to produce ROS as their 
primary function. Superoxide is considered as the ‘primary’ ROS and can react with several 
different molecules to form other ROS such as H2O2, the OH
.
, HOCl and ONOO
-
. 
1.4.1 Mitochondrial enzymes 
The process of mitochondrial oxidative phosphorylation ultimately results in the condensation of 
inorganic phosphate and adenosine diphosphate (ADP) to produce adenosine triphosphate (ATP), a 
readily utilisable energy source. This process involves an electron transport chain which consists of 
multi-subunit polypeptide complexes: complex I (NADH-ubiquinone oxidoreductase), complex II 
(succinate-ubiquinone oxidoreductase), complex III (ubiquinol-cytochrome c reductase), complex 
IV (cytochrome c oxidase), coenzyme Q (ubiquinone) and cytochrome c (Madamanchi et al., 
2005).  
The process begins at either complex I where NADH is oxidised to NAD
+
 or at complex II where 
FADH2 is oxidised to FAD (Flavin adenine dinucleotide). The electrons from NADH and FADH2 
are then transferred to coenzyme Q and at complex I energy is dissipated by the ejection of protons 
into the intermembrane space (Madamanchi et al., 2005). There is no ejection of protons from 
complex II because the transfer of electrons from FADH2 is not associated with a significant 
decrease in free energy (Cooper, 2000). The electrons are then transferred from coenzyme Q to 
complex III, where more protons are ejected, then onto cytochrome c and lastly onto complex IV 
where they are used to reduce molecular oxygen to water, with a final ejection of protons into the 
intermembrane space. The movement of protons into the intermembrane space by complexes I, III 
and IV creates a chemiosmotic or electrochemical gradient across the mitochondrial inner 
membrane, which drives the production of ATP. The potential energy stored in this proton gradient, 
which originates from the oxidation and reduction reactions in the electron transport chain, is 
10 
 
released when the protons flow back into the matrix via the F0 subunit of ATP synthase (complex 
V) (Feniouk et al., 2005). At the F1 subunit of ATP synthase, ADP is phosphorylated to ATP in a 
spontaneous manner and the energy released from proton flow is used in the dissociation of ATP 
from the F1 subunit (Cross, 2004; Boyer et al., 1973).  The NAD
+
 and FAD are reduced back to 
NADH and FADH2 in the citric acid cycle and the electron transport chain can begin again (see 
Fig. 4).  
 
Figure 1.4: Electron transport chain during oxidative phosphorylation in mitochondria. 
At various points along the electron transport chain electrons can directly react with molecular 
oxygen to produce superoxide and other ROS. The two major sites for ROS production are 
believed to be at complex I and complex III (Madamanchi et al., 2005). Although evidence 
suggests that mitochondrial dysfunction is linked with CVDs such as hypertension and 
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atherosclerosis (Ramachandran et al., 2002), the causal roles of mitochondrial O2 
.-
 for vascular 
disease in vivo remain to be established. 
1.4.2 Xanthine oxidase 
Xanthine oxidoreductase (XOR) is a molybdoflavin enzyme that catalyses the oxidation of 
hypoxanthine to xanthine, and xanthine to uric acid in the metabolic pathway of purine 
degradation. It exists in two interconvertible forms, xanthine oxidase (XO) and xanthine 
dehydrogenase (XDH). In vivo most XOR exists in the XDH form but can be converted reversibly 
or irreversibly to XO. XDH is reversibly converted to XO by sulfhydryl oxidation which oxidises 
thiol groups at cysteine residues Cys535 and Cys992 (Berry and Hare, 2004; Nishino, 1994). XDH 
is produced from XO by treatment with thiol compounds. In the presence of proteases (trypsin, 
chymotrypsin, pancreatin) XDH is converted to XO irreversibly by proteolysis (Berry and Hare, 
2004). Significant conformational changes occur around the FAD binding site when XDH is 
converted to XO resulting in different affinities to the electron acceptors NAD
+
 and O2 (Nishino, 
1994). XDH will reduce both NAD
+
 and O2 with a preference for NAD
+
 whereas XO does not 
interact with NAD
+
 and will only reduce O2 leading to the formation of either O2
.-
 or H2O2 (Enroth, 
2000).  
The active form of XDH is a homodimer with catalytically independent subunits each consisting of 
2 iron-sulphur (Fe2-S2) centres at the N-terminal, a FAD domain in the centre and a molybdopterin 
(Mo) binding domain at the C-terminal (Enroth et al., 2000). This enzyme catalyses the oxidation 
of hypoxanthine to xanthine and then xanthine to uric acid, which are the final two stages in the 
purine degradation pathway (see Fig. 5). The mechanism involves donation of electrons from either 
hypoxanthine or xanthine to the Mo cofactor. The electrons are then transferred via the iron-sulphur 
centres onto the FAD domain where reduction of either NAD
+
 or O2 occurs depending on which 
form the enzyme exists in (XDH or XO) (Kelley et al., 2010). The FAD can be divalently oxidised 
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by O2 to produce H2O2 or univalently oxidised in two states to produce 2O2
.-
 (Galbusera et al., 
2006).  
 
 
 
 
 
 
 
 
Ohara and his colleagues (Ohara et al., 1993) showed that oxypurinol (Oxy) can preserve 
endothelium-dependent vascular relaxations to acetylcholine via reducing ROS production in blood 
vessels from hyperlipidaemic rabbits. This is because ROS reduces NO which normally causes the 
relaxation. Their findings suggest that XO contributes to the pathogenesis of endothelial 
dysfunction in presence of hypercholesterolaemia. However, while some clinical studies showed an 
improvement of endothelial dysfunction in hypercholesterolaemic and diabetic patients with 
allopurinol (Butler et al., 2000), which was used due to the fact that inhibits XO, others failed to 
show an effect with allopurinol (O’Driscoll et al., 1999).  
Figure 1.5: Reactions catalysed by xanthine oxidoreductase. 
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1.4.3 Nitric oxide synthase 
Nitric oxide synthase (NOS) is a haeme-containing monooxygenase which produces NO during the 
oxidation of L-arginine to L-citrulline (Förstermann and Münzel, 2006). NOS is functionally active 
as a homodimer and has three isozymes: NOS I (constitutive in neuronal tissue and so termed 
nNOS), NOS II (inducible by cytokines and bacterial endotoxins and so termed iNOS), and NOS 
III (constitutive in vascular endothelial cells and so termed eNOS) (Förstermann et al., 1994). Each 
monomer of NOS contains binding sites for FAD, FMN and NADPH at the reductase domain and 
binding sites for haem (iron protoporphyrin IX), the substrate (L-arginine) and tetrahydrobiopterin 
(BH4) at the oxygenase domain (Sun et al., 2010). Both nNOS and eNOS require calcium ions for 
activation whereas iNOS activation is calcium independent (Knowles and Moncada, 1994). In the 
activation of nNOS and eNOS calcium ions bind to calmodulin which in turn binds to NOS 
activating the transfer of electrons, donated by NADPH, from the reductase domain of one 
monomer to the oxygenase domain of the other monomer allowing oxygenation of the substrate 
(Sun et al., 2010; Govers and Rabelink, 2001). The NOS reaction, is a two-step reaction (see Fig. 
6) which converts L-arginine to L-citrulline and NO via the intermediate species N
ω
-hydroxy-L-
arginine (Huang et al., 2001).  
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Figure 1.6: Nitric oxide synthesis. 
 
When levels of BH4 or L-arginine are low, NOS produces superoxide instead of NO (Bevers et al., 
2006). This is caused by ‘NOS uncoupling’ which is when the reduction of molecular oxygen by 
NADPH becomes uncoupled from L-arginine oxidation and NO synthesis (Fukai, 2007; Katusic, 
2001). BH4 is the major factor for NOS uncoupling as it facilitates electron transfer from the 
reductase domain to the oxidase domain and also helps the enzyme stay in its active form as a 
homodimer (Fukai, 2007). BH4 is easily oxidised to dihydrobiopterin (BH2) which, although binds 
to NOS with equal affinity, will not prevent NOS uncoupling (Crabtree et al., 2008). BH4 is a 
critical regulator of cardiovascular homeostasis. Abnormalities in both absolute levels and 
oxidation state of BH4 are a hallmark of vascular and cardiac dysfunction (Bendall et al., 2014). 
 
1.4.4 NADPH oxidase 
The NADPH oxidase (Nox) family are a class of enzymes involved in the production of superoxide 
from NADPH and oxygen. The NADPH oxidase facilitates electron transfer from the enzyme 
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substrate (NADPH) to molecular oxygen, and was originally found in phagocytes where it rapidly 
produces superoxide as a result of the reactive oxygen burst following bacterial ingestion 
(production of superoxide during phagocytosis is utilised as a microbicidal). However, recent 
investigations have identified the multiple isoforms of the Nox family of enzymes, having a wide 
tissue distribution and expressed in numerous cells and the activation of each requires specific 
stimuli leading to downstream effects (see Table 2). 
Table 2: The cell/tissue distribution and activators of different Nox isoforms. 
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Isoform Whole Body Cardiovascular 
System 
 
Activators References 
Nox1 
 
Colon 
 
Placenta 
 
Prostate 
 
Uterus 
 
Microglia 
  
Neurons 
 
Astrocytes  
 
 
ECs  
 
VSMCs  
 
Adventitial  fibroblasts 
  
Cardiomyocytes  
 
Oxidised LDL  
 
Vascular injury  
 
Oscillatory shear stress  
 
Ang II 
Takac et al., 2012 
 
Lassegue and 
Griendling, 2010 
 
Sorce and Krause, 
2009 
 
Banfi et al., 2000  
 
Suh et al., 1999 
Nox2 
 
Phagocytes 
 
B-lymphocytes 
 
Microglia 
  
Neurons 
 
Astrocytes  
 
ECs  
 
Heart  
 
Cardiac fibroblasts  
 
Adventitial fibroblasts  
 
Cardiomyocytes 
Oxidised LDL  
 
Vascular injury  
 
Ischaemia  
 
IFN-γ  
 
Ang II   
 
Takac et al., 2012 
 
Lassegue and 
Griendling, 2010 
 
Sorce and Krause, 
2009 
 
Meischl and Roos, 
1998 
Nox3 
 
Inner Ear 
 
Foetal Kidney 
 
Brain 
 
Skull  
 
N/A  
 
Palmitate  
 
TNF-α 
Bedard and Krause, 
2007 
 
Banfi et al., 2004  
 
Kikuchi et al., 
2000 
 
Nox4 
 
Kidney  
 
Blood Vessels 
 
Microglia 
  
Neurons 
 
Astrocytes  
 
ECs  
 
VSMCs  
 
Cardiomyocytes  
 
Cardiac fibroblasts  
 
TNF-α  
 
IFN-γ   
 
Hypoxia  
 
Vascular injury  
 
Oscillatory shear stress 
Takac et al., 2012 
 
Lassegue and 
Griendling, 2010 
 
Sorce and Krause, 
2009 
 
Shiose et al., 2001 
 
Geiszt et al., 2000 
 
Nox5 
 
Lymphoid Tissue 
 
Pancreas 
ECs  
 
VSMCs   
Ang II  
 
TNF-α  
Takac et al., 2012 
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Abbreviations: ECs: Endothelial cells; VSMCs: Vascular Smooth Muscle Cells; Ox-LDL: Oxidised low-
density lipoprotein; Ang II: Angiotensin II; IFNγ: Interferon gamma; TNF-α: Tumour Necrosis Factor-α. 
 
1.5 NADPH oxidase – Structure 
NADPH oxidase is a multi-component enzyme consisting of a membrane-bound catalytic core 
called flavocytochrome b558, and a group of cytosolic regulatory subunits (see Fig. 7).  
 
Spleen 
 
Testis 
 
Foetal Tissue 
 
Uterus 
  
Atherosclerosis 
Lassegue and 
Griendling, 2010 
 
Bedard and Krause, 
2007 
 
Bánfi et al., 2001 
 
Cheng et al., 2001 
 
Duox1 
 
Thyroid  
 
Lung 
Testis 
 
Pancreas 
 
Foetal tissue 
 
N/A Ca
2+
 Bedard and Krause, 
2007 
 
De Deken et al., 
2000 
 
Dupuy et al., 1999  
 
Duox2 
 
Thyroid  
 
Colon 
 
Testis 
 
Pancreas 
 
Foetal tissue 
 
 
N/A Ca
2+
 Bedard and Krause, 
2007 
 
Edens et al., 2001 
 
De Deken et al., 
2000 
 
Dupuy et al., 1999 
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Flavocytochrome b558, so called due to the haem maximum absorbance peak at 558 nm in the 
reduced form, consists of gp91
phox
 (β subunit) and p22phox (α subunit) (Rae et al., 1998). The 
gp91
phox
 subunit is a large glycoprotein of 570 amino acids with a molecular mass of 91 kDa in its 
mature form, due to heavy glycosylation and a mass of 65 kDa in its immature form, pre-
glycosylation (Meischl and Roos, 1998). It is encoded by the gene CYBB which is located on the 
short arm of the X chromosome (Patiño et al., 1999). The subunit contains six transmembrane 
helices with two bound haems (in transmembrane helices III and V) in the N-terminal half and in 
the C-terminal region the FAD and NADPH binding domains reside (Takeya and Sumimoto, 
2003). Both COOH and NH2 termini are situated in the cytoplasm (Bedard and Krause, 2007).  
Human p22
phox
 subunit is a small protein of 195 amino acids with a molecular mass of 22 kDa 
(Meischl and Roos, 1998). It is encoded by the gene CYBA which is located in the long arm of 
chromosome 16 (San José et al., 2008). This protein has two transmembrane helices and is the 
Figure 1.7: NADPH oxidase-2 (Nox2) structure. 
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docking site for the cytosolic subunits, containing a proline rich region in the C-terminal 
cytoplasmic tail which is involved in interactions with Src homology 3 (SH3) domains (Keith et al., 
2009).  
The cytosolic subunits of NADPH oxidase are p47
phox
, p67
phox
, p40
phox
 and a small Rho GTPase 
protein (Rac1 or Rac2) (GTP: guanosine triphosphate) explained in detail below. 
Human p47
phox
 subunit is a protein of 390 amino acids with a molecular mass of 47 kDa (Meischl 
and Roos, 1998). It is encoded by the gene NCF1 which is located on chromosome 7 (Chanock et 
al., 2000). The N-terminal region of this subunit contains a PX (phox homology) domain, the 
middle region of the amino acid sequence contains two SH3 domains and the C-terminal is rich in 
serine residues (phosphorylation sites) and has a proline rich region (El-Benna et al., 2009).  
Human p67
phox
 subunit is a protein of 526 amino acids with a molecular mass of 67 kDa (Meischl 
and Roos, 1998). It is encoded by the gene NCF2 which is located on chromosome 1 (Köker et al., 
2009). This subunit contains two SH3 domains, a PB1 (phox and Bem 1) domain and an N-
terminal domain comprising four tetratricopeptide repeats (TPR) motifs (Maehara et al., 2010).  
Human p40
phox
 subunit is a protein of 339 amino acids with a molecular mass of 40 kDa (Meischl 
and Roos, 1998). It is encoded by the gene NCF4 which is located on chromosome 22 (Meischl and 
Roos, 1998). This subunit contains a PX domain at the N-terminus, an SH3 domain and a PB1 
domain (Honbou et al., 2007).  
Human Rac1 subunit is encoded by a gene on chromosome 7, whereas the Rac2 subunit is encoded 
by a gene on chromosome 22 (Matos et al., 2000). Rac1 and Rac2 differ in just 14 of 92 residues 
making them 92% identical. At the N-terminus of these subunits reside two ‘switch’ regions which 
change conformation according to the type of nucleotide (GDP or GTP) which is bound to the 
amino acid residues also present at the N-terminus. At the C-terminus a geranylgeranyl group can 
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be attached by a thioether linkage to a cysteine residue (Vignais, 2002). Rac2 is expressed in 
hematopoietic cells and is the most relevant Rac GTPase for activation of Nox2 in human 
neutrophils. In contrast, Rac1 is ubiquitously expressed and is likely the main Rac GTPase for Nox 
activation in non-hematopoietic cells (Hordijk, 2006).  
1.5.1 NADPH oxidase - Homologues, expression and signalling  
In the last 15 years new homologues of gp91
phox
 have been identified, raising the total number of 
Nox isoforms to seven (see Fig. 8).  Nox1 (Banfi et al., 2000; Suh et al., 1999), Nox3 (Cheng et al., 
2001; Kikuchi et al., 2000), Nox4 (Shiose et al., 2001; Geiszt et al., 2000), Nox5 (Bánfi et al., 
2001; Cheng et al., 2001) and Duox1 and 2 (De Deken et al., 2000; Dupuy et al., 1999) with the 
original gp91
phox
 being renamed Nox2.  
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Figure 1.8: The seven different Nox isoforms and their different subunits promoting their 
activation (a) Nox1, (b) Nox2, (c) Nox3, (d) Nox4, (e) Nox5 and (f) DUOX1/2. 
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Nox1, 3 and 4 share a similar structure with Nox2 and are expressed in a variety of tissues (see 
Table 2). Nox5, also present in a wide variety of tissues, shares the same basic structure with Nox1-
4 but with an additional calmodulin-like Ca
2+
 binding domain at the N-terminus (Bedard and 
Krause, 2007; Dworakowski et al., 2006). The Duox proteins also share the same basic structure 
with Nox1-4 however they also contain a Ca
2+
 binding domain (like Nox5) as well as a peroxidase 
homology domain at the N-terminal (Dworakowski et al., 2006).  
Table 3: Location, length and sequence similarity of Nox isoforms. 
 
In research investigating the cardiovascular system the most relevant and highly expressed Nox 
isoforms are Nox1, Nox2, Nox4 and Nox5 (Santillo et al., 2015). Nox2 expression has been found 
to be increased with obesity in a variety of tissues like the heart, aorta, brain etc. (Chrissobolis et 
al., 2012; Serpillon et al., 2009). This Nox isoform therefore may play an important role in the 
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development of obesity-related diseases such as CVD through its increased expression and 
subsequent increased ROS production and oxidative damage (Sukumar et al., 2013). 
ROS produced by the endothelial Nox is an essential part of redox signalling which governs several 
cellular processes, such as cell growth, apoptosis, migration and extracellular matrix remodelling 
(Li and Shah, 2003). Mitochondria are not only a target for Nox-produced ROS, but also a source 
of ROS which can stimulate Nox in return (Dikalov, 2011). The study of this cross-talk between 
mitochondria and Nox may provide a novel strategy for the treatment of novel pathological 
conditions. In non-phagocytic cells NADPH oxidases have been found to be constitutively 
activated at a basal level and their activity is increased in response to various stimuli such as 
oscillatory mechanical stress, hypoxia, growth factors, cytokines and hormones (Lassègue et al., 
2012). As will be discussed in section 1.6.5, oxidative stress occurs due to the imbalance of ROS 
and antioxidant molecules such as uric acid, vitamin C, vitamin E and enzymes such as SOD and 
catalase. In such situations NADPH oxidase, the major source of superoxide in vessels has been 
implicated to contribute to inflammation, tissue injury and endothelial dysfunction (Paravicini and 
Touyz, 2008).  
In endothelial cells, Nox-derived superoxide affects the local bioavailability of NO (Jung et al., 
2004). Therefore, the effects of Nox enzymes in the endothelial cells might be due to depletion of 
the vasorelaxant NO. NO plays a protective role in the cardiovascular system. It regulates vessel 
dilatation, neuronal transmission, cardiac contraction, immunomodulation, stem cell differentiation 
and proliferation and suppresses platelet aggregation (Lei et al., 2013). Additionally, Nox can 
regulate endothelial cell cycle arrest and apoptosis (Loffredo et al., 2007) an important mechanism 
due to the fact that the abilities of endothelial cells to proliferate, be quiescent in monolayer and 
undergo apoptosis during remodeling are important determinants relating to angiogenesis, wound 
healing, and many diseases, including atherosclerosis (Li et al., 2007). Moreover, the 
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phosphorylation of Nox subunit p47 
phox 
with the activation of Nox is found to be involved in TNF-
α activated redox signalling cascades in microvascular endothelial cells (Li et al., 2005) and in Ang 
II-dependent cellular responses in endothelial cells (Thakur et al., 2010; Li and Shah, 2003). TNF-α 
has been shown to both be secreted by endothelial cells and to induce intracellular ROS formation. 
These observations provide a potential mechanism by which TNF-α may activate and injure 
endothelial cells resulting in endothelial dysfunction (Chen et al., 2008). Angiotensin II not only 
mediates immediate physiological effects of vasoconstriction and blood pressure regulation, but is 
also implicated in inflammation, endothelial dysfunction, atherosclerosis, hypertension, and 
congestive heart failure (Mehta  & Griendling, 2007).  
Nox enzymes are also involved in signalling in vascular smooth muscle cells (VSMC’s). Nox-
derived ROS in VSMC regulate the activity of the signalling proteins, such as p38 mitogen-
activated protein kinase (MAPK) and protein kinase B (Akt) (Brandes and Kreuzer, 2005) and are 
important for Ang II-induced calcium fluxes (Lambrth, 2007). In cardiomyocytes, Nox produces 
the majority of ROS and contributes to the activation of redox-sensitive kinases such as 
extracellular signal-regulated kinase (ERK) 1/2, ERK 5, c-Jun NH2-terminal kinase (JNK) 1/2, and 
p38 MAPK (Lin et al., 2002). Furthermore, Nox-derived ROS interfere with the extracellular 
matrix, influence gene expression and might also take part in cell proliferation and differentiation 
in the vasculature (Amanso and Griendling, 2012). 
Cells also have a defence against over production of ROS including antioxidants such as uric acid, 
vitamin C, vitamin E and antioxidant enzymes such as SOD and catalase. Overproduction and 
accumulation of ROS can lead to oxidative stress and this occurs when the level of ROS production 
increases to a point where the antioxidant capability is outweighed. Several studies have suggested 
that NADPH oxidases are the major source of ROS in the vessel wall, especially in response to 
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various stimuli such as Ang II and TNF-α (Li and Shah, 2003) which are very likely to be linked 
with obesity (Chudek and Wiecek, 2006). 
1.5.2 NADPH oxidase – Mechanism of activation 
NADPH oxidase activity can be increased both acutely and chronically in response to physiological 
and pathological stimuli including 1) G protein-coupled receptor agonists such as Ang II and 
endothelin-1; 2) cytokines such as TNF-α, transforming growth factor beta (TGF-β) and 
interleukin-1 (IL-1); 3) growth factors such as vascular endothelial growth factor (VEGF), insulin 
and thrombin; 4) metabolic factors such as oxidised low-density lipoprotein (ox-LDL), non-
esterified fatty acids (NEFA) and advanced glycation end products (AGE); 5) hypoxia-
reoxygenation and ischaemia-reperfusion; and 6) mechanical stimuli such as oscillatory shear stress 
(Dworakowski et al., 2006; Li and Shah, 2004). In the presence of these stimuli NADPH oxidase is 
activated via a number of mechanistic steps, detailed below, to produce superoxide.  
1.5.2.1 Nox2 activation 
Nox2 is the best characterised family member and its mode of action has been well studied (Bedard 
and Krause, 2007). The Nox2 enzyme is highly expressed in phagocytes (e.g. neutrophils) with 
intermediate expression in cardiomyocytes, endothelial cells and adventitial fibroblasts. The 
activation of Nox2 is tightly regulated to prevent the overabundance of freely circulating 
superoxide in the vasculature. 
The activation of Nox2 requires the recruitment and assembly of a number of proteins in a specific 
order. The proteins involved in the assembly process include: p40
phox
, p22
phox
, p47
phox
, p67
phox
, a 
Rac GTPase and Nox2 itself. Firstly, in a resting/unstimulated state, Nox2 and p22
phox
 exist as a 
membrane complex to form a stable heterodimer also known as cytochrome b558. On the other 
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hand, the other subunits are present in the cytosol as a trimer (p47
phox
 + p67
phox
 + p40
phox
). Upon 
stimulation, phosphorylation of p47
phox
 at multiple serine residues configures the formation of a 
complex with the other cytosolic subunits (Takeya and Sumimoto, 2003). Non-phosphorylated 
p47
phox
 has an autoinhibitory region (AIR) formed by the interaction of the SH3 domains with the 
C-terminal region (El-Benna et al., 2009). Upon phosphorylation the SH3 and PX domains become 
accessible and p47
phox
 translocates to the membrane taking with it p67
phox
 and p40
phox
.  Interactions 
then occur between the SH3 domain of p47
phox
 with the proline rich regions at the C-terminal of 
p22
phox
, between the PX domain of p47
phox
 with membrane phospholipids and between the proline 
rich region of p47
phox
 with the SH3 domain of p67
phox
 (Bedard and Krause, 2007). The small G 
protein Rac, is also involved in the translocation of the cytosolic subunits and has been shown to 
translocate p67
phox
 to the membrane even in the absence of p47
phox
 (Vignais, 2002). In its inactive 
form Rac is bound with the nucleotide GDP with its geranylgeranyl tail bound to GDI (GDP 
dissociation inhibitor) (Brandes and Kreuzer, 2005). Rac is activated by GEF proteins (GDP/GTP 
exchange factors) that catalyse the exchange of GDP for GTP to give the active form of Rac 
(Vignais, 2002). The activated GTP-bound Rac interacts with TPR at the N-terminal of p67
phox
 and 
interacts with the membrane via its prenylated tail. On translocation to the membrane p67phox 
binds with gp91
phox
 (Nox2), via its activation domain, and p47
phox
 acts as an adaptor protein which 
helps to stabilise the interaction (Paravicini and Touyz, 2008; Brandes and Kreuzer, 2005). A 
schematic representation of the Nox2 enzyme activation can be seen in figure 9. 
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Figure 1.9: Schematic representation of the components of the Nox2 enzyme activation. 
Once activated the NADPH oxidase complex can begin to generate superoxide by a series of 
electron transfer reactions. Electrons are first donated by NADPH which becomes reduced 
(NADP
+
) and the electrons are transferred to FAD. In the next step an electron is transferred from 
the reduced FAD (FADH2) to the first haem and then onto the second haem. The second electron 
can only be transferred from the partially reduced FADH to the first haem after the first electron 
has already been transferred to the second haem, as the iron center in the haem can only 
accommodate one electron at a time (Bedard and Krause, 2007). From the second haem the 
electrons are transferred to molecular oxygen producing two molecules of superoxide. The overall 
pathway of electrons is NADPH  FAD  heme1  heme2  O2.  
Nox2 is upregulated in neutrophils after exposure to microbial infection (Ogier-Denis et al., 2008). 
Additional stimuli such as: oxLDL, vascular injury, ischemia, Ang II and TNF- α can also cause 
the upregulation of Nox2. Recent research in mouse models has discovered that aberrant NADPH 
oxidase signalling, in particular Nox 1, 2 and 4, can contribute to the development of 
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atherosclerosis and hypertension (Murdoch et al., 2011). More details on ROS role in metabolic 
syndrome and atherosclerosis will be given in sections 1.8 and 1.9.3 respectivelly. 
1.5.2.2 Nox isoforms activation 
The activation mechanism for Nox1 is similar to that of Nox2 and depends on the expression of 
p22
phox
 to form a stable heterodimer and to allow superoxide production (Ambasta et al., 2004; 
Sumimoto, 2003). Nox1 superoxide generation also relies on the presence of cytosolic subunits 
such as p47
phox
 and p67
phox
; however, these subunits are not found in high quantities in the colon 
where Nox1 is predominantly expressed. Therefore, homologues of these subunits were found and 
identified as Nox organiser1 (NoxO1) for p47
phox
 and Nox activator1 (NoxA1) for p67
phox
, both of 
which are found in high levels in the colon epithelium (Bánfi et al., 2003). It has also been found 
that Rac1 can activate Nox1 as well as Nox2 and that a decreased Rac expression can lead to lower 
Nox1 dependent ROS production (Cheng et al., 2006). Nox3 dependent superoxide generation is 
known to depend on the expression of p22
phox
, and to increase with involvement of the cytosolic 
subunits p47
phox
, NoxO1, p67
phox
, NoxA1, and Rac (Ueyama et al., 2006; Ueno et al., 2005; Cheng 
et al., 2004). Nox4 dependent superoxide generation is known to depend on the expression of 
p22
phox
 (Ambasta et al., 2004) however it does not require any cytosolic subunits or Rac for 
activation but is constitutively active (Martyn et al., 2006). The activation of Nox5 NADPH 
oxidase is quite different from that of Nox1-4, it does not require cytosolic subunits but generates 
superoxide in response to intracellular calcium (Banfi et al., 2004). Duox1 and Duox2 do not 
require cytosolic subunits to be activated but do require maturation factors DuoxA1 and DuoxA2, 
which allow the dual oxidases to undergo maturation to acquire their active conformation. Once 
matured, Duox1 and Duox2 are activated by intracellular calcium (Rigutto et al., 2009) (see Fig. 8).  
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1.6 ROS in health and disease 
ROS are necessary at low concentrations since they act as secondary messengers in myriad of 
extra- and intracellular signalling cascades (redox signalling) regulating neuronal signalling and 
blood pressure (Zhang et al., 2016). ROS are also important in normal physiological function, as 
they regulate vascular tone, cell growth, proliferation and survival as well as oxygen sensing which 
activates certain genes in different concentrations of oxygen (Valko et al., 2007). However, 
abnormally elevated concentrations promote cytotoxicity and damaging of cellular structures and 
organelles, inducing cellular apoptosis and impairing cellular metabolism when detoxifying 
enzymes are out-balanced (Lassègue et al., 2012).  
To maintain homeostasis and regulate redox signalling, ROS are tightly regulated by antioxidant 
systems. Enzymatic antioxidant molecules such as catalase and GPx counteract the damaging 
effects of H2O2 by conversion to water. Furthermore, the enzymes SOD and heme oxygenase 
convert the potent superoxide to the less reactive H2O2. Uric acid, vitamins C and E are non-
enzymatic antioxidant molecules which contribute to lowering the levels of oxygen-damaging 
derivatives (Li & Shah, 2004). However, during times of a specific stress such as an imbalance 
between oxidant and anti-oxidant activity or failure of the antioxidant systems due to exhaustion, 
ROS levels can increase dramatically resulting in oxidative stress. ROS act by oxidative 
modification of nucleic acids, sugars, lipids, and proteins eventually causing disease states in vivo 
(Lau et al., 2008; Thannickal and Fanburg, 2000).  
Furthermore, the presence of nitrogen-containing oxidative molecules like NO which belong to the 
reactive nitrogen species (RNS) family can combine with ROS. The combination of ROS and RNS 
produces peroxynitrite moieties, which are more potent, causing excessive cell damage and injury 
consequently increasing the risk of developing various pathologies. Also NO removal reduces its 
protective effects. NADPH oxidase has been identified as the major source of ROS in the 
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vasculature suggesting that NADPH oxidase is a potential contributor to CVDs (Thakur et al., 
2010; Li & Shah, 2004).  
1.6.1 ROS in host defence 
Phagocytic cells are an essential part of the body’s innate immune system that circulate in the blood 
and can migrate into tissues attracted by invading pathogens, such as bacteria and any other foreign 
particles or cellular debris, engulfing and ultimately destroying them (Blande, 2007). NADPH 
oxidase is a fundamental enzyme present in phagocytes which is required for the ‘respiratory burst’ 
that involves the conversion of molecular oxygen to superoxide which is responsible for destroying 
any invading pathogens (Segal, 2008). Phagocytes lacking NADPH oxidase activity are unable to 
destroy pathogens effectively and chronic granulomatous disease (CGD) is a rare genetic disorder 
where this phenomenon occurs. CGD results from mutations in the genes which encode for the 
protein subunits which constitute NADPH oxidase. Patients with CGD are immunodeficient and 
suffer from chronic and recurrent, often fatal infections and formation of granulomas and 
premature death. There are a number of variations of this disease depending on the defective gene 
but the most common form, affecting approximately 70 % of CGD patients, is mutations in the 
CYBB gene which encodes for the gp91
phox
 subunit (Heyworth et al., 2003). Other less common 
forms include mutations in the CYBA, NCF1 and NCF2 genes which encode for p22
phox
, p47
phox
 
and p67
phox
 respectively (Heyworth et al., 2003). More recently it has been found that mutations in 
a fifth gene, NCF4 which encode for the p40
phox
 subunit, leads to a very rare form of CGD (Matute 
et al., 2009). There is also a mouse model of CGD that has a non-functional allele for the gp91
phox
, 
or Nox2, subunit. These mice are the first animal model for this disease, and the model closely 
resembles patients with CGD since they have absence of respiratory burst activity and have 
increased susceptibility to infection.  
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1.6.2 ROS signalling pathways 
Reactive oxygen species can activate redox-sensitive signalling pathways involving transcription 
factors, kinases and phosphatases (Bolisetty and Jaimes, 2013) by oxidation of cysteine residues on 
proteins.  
The most common down-stream targets of Nox2-derived ROS are MAPKs such as the ERK, JNK 
and p38 MAPK (Teng et al., 2012; Tickner et al., 2011; Fan et al., 2009; Li et al., 2005), Akt (Du 
et al., 2013; Liu et al., 2013; Thakur et al., 2010; Hingtgen et al., 2006), phosphoinositide 3-kinase 
(PI3K) (Bae et al., 2000), nuclear factor kappa B (NF-κB) (Li et al., 2009); TNF-α receptor 
associated factor 4 (Li et al., 2005)  and signalling molecules involved in cell apoptosis such as 
p21
cip1 
and
 
p53 (Li et al., 2007). Activation of these redox sensitive pathways can result in both 
physiological and pathological cellular responses such as oxygen sensing, endothelial dysfunction 
and permeability, migration, proliferation, inflammation, apoptosis and senescence (Frey et al., 
2009; Li and Shah, 2004).  
1.6.3 ROS and regulation of vascular tone 
ROS also play an important physiological role in the regulation of vascular tone. NO is an 
endothelium-derived relaxing factor (EDRF) which plays a vital role in vasodilation of blood 
vessels and reduced bioavailability of NO can lead to hypertension (Hermann et al., 2006). Another 
species of ROS that plays a role in vasodilation is H2O2 which is an endothelium-derived 
hyperpolarising factor (EDHF) that contributes to flow-induced dilation of human coronary 
arterioles (Miura et al., 2003; Thengchaisri and Kuo, 2003) and murine mesenteric arteries (Arora 
et al., 2010). 
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1.6.4 ROS and oxidative damage 
ROS play important roles in mammalian cell biology, as previously mentioned, however excess 
production of ROS results in oxidative stress which involves damage to cellular components such 
as lipids, proteins, and nucleic acids and leads to the loss of biological function. ROS can 
chemically modify polyunsaturated fatty acid residues of phospholipids, resulting in the production 
of carbon-centred radicals which can then react with molecular oxygen to form peroxyl radicals 
(Marnett, 1999). These radicals can go on to produce a variety of compounds including 
malondialdehyde, hydroxynonenal and F2-isoprostanes, which can be used as biomarkers for lipid 
peroxidation and oxidative stress (Gil Del Valle, 2010). Damage to DNA by ROS can cause base 
and nucleotide modifications as well as breaks in the DNA strand (Bennett, 2001). The oxidised 
DNA product 8-hydroxydeoxyguanosine (8-OHdg), produced from ROS attack on guanine, is a 
good biomarker for DNA damage and oxidative stress (Wiseman and Halliwell, 1996). The 
oxidised forms of DNA can cause errors in transcription and translation and lead to the synthesis of 
abnormal proteins, which are more susceptible to oxidation. Protein oxidation can occur at the 
protein polypeptide backbone by attack from the OH
.
, and on the side chains of all amino acid 
residues of proteins of which methionine and cysteine residues are the most vulnerable. The extent 
of protein oxidation by ROS is most commonly determined by the quantity of protein carbonyl 
groups, which are produced in many protein oxidation mechanisms. 
1.6.5 Redox homeostasis and antioxidants 
Redox homeostasis involves maintaining a balance between the rate of production and rate of 
removal of ROS. Optimal ROS levels are critical for normal functioning of physiological processes 
and antioxidants are an important defence mechanism which helps to keep ROS levels in check. 
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There are a wide variety of antioxidants including both antioxidant compounds and antioxidant 
enzymes which are discussed in further detail below.  
Superoxide dismutase which was identified as an antioxidant enzyme in 1969 catalyses the 
dismutation of superoxide to H2O2 and molecular oxygen (McCord & Fridovich, 1969). There are 
two forms of SOD found inside the cell; Cu/Zn-SOD which is found in the cytoplasm and Mn-SOD 
which is found in the inner mitochondrial matrix. The third form of SOD, extracellular-SOD (EC-
SOD) is found in the extracellular matrix (Fukai, 2007).  
Another predominant antioxidant enzyme is GPx which acts in conjunction with the tripeptide 
antioxidant molecule GSH to convert H2O2 and lipid peroxides to water and lipid alcohols 
respectively (Wassmann et al., 2004). During this reaction GSH is oxidised to glutathione 
disulphide (GSSG) but can be regenerated by glutathione reductase (GR) (Nordberg & Arnér, 
2001). The antioxidant catalase, located primarily in cell peroxisomes, reduces H2O2 to water with 
one of the highest turnover rates of all enzymes (Valko et al., 2006).  
Peroxiredoxins (Prx) are a family of antioxidants which can reduce a wide range of organic 
hydroperoxides including H2O2 and ONOO
-
 and there have been at least six isoforms of PRx 
identified in mammalian cells (PrxI-PrxVI) (Wood et al., 2003).  
 Vitamin C (ascorbic acid) is a powerful antioxidant compound which donates an electron to free 
radicals to become the ascorbate radical which is a relatively unreactive free radical that can be 
reduced back to ascorbic acid by enzyme systems (Buettner & Jurkiewicz, 1996).  
α-Tocopherol (most biologically active isoform of vitamin E) is another powerful antioxidant 
compound which can be reduced to the α-tocopherol free radical by donation of a labile hydrogen 
to a lipid or lipid peroxyl free radical (Valko et al., 2006). The relatively innocuous α-tocopherol 
free radical can subsequently be reduced back to α-tocopherol by ascorbic acid (Valko et al., 2006).  
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Uric acid is an antioxidant compound which donates an electron to free radicals to neutralise them 
becoming a radical itself, however the uric acid free radical is much more stable than oxygen based 
radicals and can be easily reduced back to uric acid by ascorbic acid (Becker, 1993). 
1.7 Experimental animal models in obesity, metabolic syndrome and 
endothelial dysfunction 
Currently, several surrogate models for human obesity are available for the investigation of the 
effect of dietary fats on disease establishment. These include murine models for gene deletions (e.g. 
Apolipoprotein E knockout (ApoEKO)), transgenic knock-ins and environmental exposure models 
(Wisse et al., 2007). Importantly these have become invaluable tools for elucidating the interplay of 
western high-fat diets (HFD) and the progression of obesity (Wisse et al., 2007; Flier, 2004). 
Researchers have studied the effects of the expression of Nox2 in mouse models both under normal 
conditions and under diet induced obesity. Mouse models are widely used in research to study 
human genes and diseases because they share many common genes with humans. More 
specifically, 99% of genes in mice have an equivalent in humans making it ideal to study and 
understand changes in the functionality and modification of genes/proteins in type-2 diabetes 
(King, 2012),  CVDs (Zaragoza et al., 2011) and cancer (Cheon and Orsulic, 2011). Although 
species such as non-human primates are more closely related to humans; working with such large 
animals presents increased costs and doesn’t allow genetic manipulation among others. Mice are 
cost-effective, small in size and fast-breeding animals thereby facilitating high scale investigations 
into potential methods of disease progression and medical research.  
The C57BL/6 strain of mice was chosen as they live long and breed well. Additionally, the 
C57BL/6 strain of mice can be used for obesity studies (Noronha et al., 2005; Parekh et al., 1998) 
as many studies report that obesity, insulin resistance and type-2 diabetes, and cardiovascular 
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phenotypes such as atherosclerosis and hypertension develop when fed a HFD in comparison to 
other models (Zucker obese rats, ob/ob mice and db/db mice). The C57BL/6 mice are able to 
mimic these metabolic syndromes more closely than other animal models (Gallou-Kabani et al., 
2007; Carroll & Tyagi, 2005; Petro et al., 2004; Surwit et al., 1988; Surwit et al., 1995). For 
instance, the C57BL/6 mice are more susceptible to atherosclerosis following the induction of a 
HFD. Moreover, it has also been shown that the C57BL/6 is the most efficient mouse model for 
type-2 diabetes, impaired glucose tolerance and hyperglycaemia. The evidence was observed only a 
week on a HFD which highlights that C57BL/6 are the ideal animal model for studying insulin 
resistance and type-2 diabetes (Winzell & Ahrén, 2004).  
Studies in our group showed that HFD wild-type (WT) mice compared to normal chow diet (NCD) 
mice developed obesity, insulin resistance, dyslipidaemia and hypertension. Aortic vessels from 
these mice showed significantly increased Nox2 expression and ROS production, accompanied by 
significantly increased ERK1/2 activation, reduced insulin receptor expression, decreased Akt and 
eNOS phosphorylation and impaired endothelium-dependent vessel relaxation to acetylcholine. All 
these HFD-induced abnormalities (except the hyperinsulinaemia) were absent in apocynin-treated 
WT or Nox2 knockout (Nox2KO) mice given the same HFD (Du et al., 2013). Apocynin is a 
naturally-occurring methoxy-substituted catechol. The metabolically-active compound of apocynin 
inhibits the intracellular assembly of NADPH oxidases (Stolk et al., 1994) and inhibits 
translocation of p47
phox 
to the membrane in monocytes (Barbieri et al., 2004) and vascular cells 
(Kinkade et al., 2013). Also, according to Pepping et al. (2013) study Nox2KO mice on a HFD 
have been shown to be resistant to the detrimental effects of HFD, characterised with attenuated 
visceral adipose pathology and inflammation, preserved adipose function, improved glucose 
tolerance and cerebral homeostasis.  
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ApoE knockout (ApoEKO) mice show impaired clearing of plasma lipoproteins and they develop 
atherosclerosis in a short time. They are able to spontaneously develop atherosclerotic lesions on a 
standard chow diet and are considered to be a particularly popular model for the elucidation of 
factors affecting atherogenesis (Meir and Leitersdorf, 2004). In addition, diets high in fat and 
cholesterol markedly accelerate plaque development in these mice. For justification of the mice and 
their similarities with humans regarding different pathologies refer to Table 4 and 5. 
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Table 4: Mouse models used to study the importance of vascular NADPH oxidases. 
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Table 5: The role of NADPH oxidases and oxidative stress in the ApoEKO mouse model. 
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1.8 Obesity, oxidative stress and metabolic syndrome 
The American Heart Association (2015) defines metabolic syndrome as “a cluster of metabolic risk 
factors, which when they are present together, the chances for future cardiovascular problems are 
greater than any one factor presenting alone”. Historically, Reaven (1988), noticed that there are 
several risk factors clustered together (e.g, dyslipidaemia, hypertension, hyperglycaemia), which he 
called syndrome X and hypothesized they play a pivotal role in the development of coronary heart 
disease and type-2 diabetes, mainly through insulin resistance.  However, whether this syndrome is 
a specific one or a surrogate of combined risk factors that put the individual at particular risk is still 
under debate.  Moreover, there is still no universally accepted pathogenic mechanism or clearly 
defined diagnostic criteria (Kassi et al., 2011). 
The metabolic syndrome seems to have 3 causes (Grundy et al., 2004): (A) obesity and disorders of 
the adipose tissue; (B) insulin resistance and (C) a variety of independent factors (e.g. molecules of 
hepatic, vascular, and immunologic origin). Such factors can be high plasma nonesterified fatty 
acids which overload muscle and liver with lipid and enhance insulin resistance, high C-reactive 
protein (CRP) levels which may be indicative of cytokine excess and proinflammatory state, high 
plasminogen activator inhibitor-1 (PAI-1) levels which signify prothrombotic state and low 
adiponectin levels that accompany obesity and correlate with worsening of metabolic risk factors. 
Independent factors such as aging, hormonal changes, inflammatory state, oxidative stress, renin-
angiotensin-aldosterone system activity among others, have been implicated as well. 
1.8.1 Obesity and hyperlipidaemia 
Obesity is defined as a BMI greater than or equal to 30 and hyperlipidaemia is a condition where 
the concentration of lipids such as cholesterol, triglycerides and fatty acids in the blood are elevated 
(WHO, 2013b). It is well-known that oxidative stress is associated with obesity and 
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hyperlipidaemia which are strong risk factors for the development of atherosclerosis and other 
cardiovascular diseases. In particular, NADPH oxidase is an important source of ROS and 
oxidative stress with obesity, and it was found that increased expression of the Nox2 isoform has 
been linked with increased total cholesterol levels and superoxide production (Judkins et al., 2010) 
and elimination of Nox2 results in reduced levels of superoxide production and attenuated HFD 
induced obesity, hyperlipidaemia, hypertension and endothelial dysfunction (Du et al., 2013). 
1.8.2 Obesity and hypertension 
NO is an important mediator of a various physiological and pathophysiological processes. A 
decrease in endothelial derived NO favours thrombosis, vasoconstriction and inflammation (Imrie 
et al., 2009; Förstermann & Münzel, 2006). Angiotensin II induces the contraction of blood vessels 
and plays a key role in vascular homeostasis along with numerous roles in cell signalling including 
activation of NADPH oxidase (Mehta & Griendling, 2007). 
NADPH oxidase-derived ROS stimulated by Ang II infusion in vivo plays a pivotal role in 
hypertension and both p47
phox
 knockout mice and mice treated with a Nox inhibitor (gp91ds-tat) 
have been shown to be protected against Ang II induced increases in superoxide production and 
hypertension (Landmesser et al., 2002; Rey et al., 2001). The expression of Ang II and angiotensin 
converting enzyme has been shown to be increased with obesity (Cooper et al., 1997) which further 
increases the risk for NADPH oxidase linked hypertension. Angiotensin II induced hypertension 
can also be linked to decreased NO bioavailabilty and increased ONOO
-
 formation due to the 
increased levels of NADPH-derived superoxide present.  
There is also evidence of ROS linked to hypertension regardless of Ang II levels. In spontaneously 
hypertensive rats (SHR) vascular, renal, and cardiac O2
.− 
production is increased compared with 
normotensive control subjects (Zhang et al., 2005; Liu et al., 2003; Zalba et al., 2000).  In stroke-
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prone SHRs, aortic expression of Nox1 and Nox4 is significantly increased (Akasaki et al., 2006). 
In Deoxycorticosterone acetate (DOCA) salt-induced mineralocorticoid hypertension, there is an 
increase in vascular O2
.−
 production involving elevated NADPH oxidase activity and uncoupling of 
endothelial NOS (Landmesser et al., 2003; Somers et al., 2000). This is possibly mediated, at least 
in part, by the endothelin-1/ETA receptor pathway (Callera et al., 2006). 
Based on human studies there is evidence that oxidative stress is increased in hypertensive patients 
(Fortuno et al., 2004; Ward et al., 2004; Lee et al., 2003; Higashi et al., 2002; Lip et al., 2002). 
These findings are based on plasma measurement of lipid peroxidation and oxidative stress 
biomarkers such as thiobarbituric acid reactive substances and 8-epi-isoprostanes. 
Polymorphonuclear leukocyte- and platelet-derived O2
.−
, which also participates in vascular 
oxidative stress and inflammation, is increased in hypertensive patients (Minuz et al., 2004; 
Yasunari et al., 2002). 
1.8.3 Obesity, hyperglycaemia and insulin resistance  
Insulin resistance is defined as a physiological condition in which normal amounts of the hormone 
insulin are inadequate to produce a normal insulin response from fat, muscle and liver cells 
(Semenkovich, 2016). Skeletal muscle and adipose tissue require insulin for effective glucose 
uptake. To this end, insulin resistant individuals develop a compensatory mechanism by secreting 
more insulin from the ß-cells of the pancreas. However, in some instances where this compensation 
doesn’t occur or whereby the ß-cells of the pancreas are exhausted and unable to produce sufficient 
amounts of insulin for maintenance of normal blood sugar levels, insulin resistance leads to type-2 
diabetes (Kahn et al., 2006). Type-2 diabetes increases the risk of coronary heart disease 
approximately three-fold and the development of other secondary pathologies, such as retinopathy 
and neuropathy (Dyck et al., 1993). It is therefore essential to continue to develop novel 
interventions in order to maintain a high quality of life. The primary aetiology for the development 
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of type-2 diabetes is obesity due to individuals’ sedentary lifestyle and unhealthy diet choices. 
Obesity-associated insulin resistance in the past decade has shown a large number of endocrine, 
inflammatory and cell-intrinsic pathways to be dysregulated (Shoelson et al., 2006; Bugianesi et 
al., 2005). The possibility that one of these factors plays a dominant role is still unanswered as 
many of these factors are interdependent, and it is likely that their dynamic interplay underlies the 
pathophysiology of insulin resistance. 
It is well documented that impaired insulin signalling in the vasculature is associated with obesity 
and endothelial dysfunction. The presence of insulin receptors on endothelial cells is well 
documented, and it has been proven that the endothelium is a target tissue for insulin and insulin 
resistance, with insulin-stimulated production of NO a feature of the action of insulin on 
endothelial cells (Symons et al., 2009). However, the signalling pathways linking vascular insulin 
resistance to the pathogenesis of endothelial dysfunction have not yet been fully elucidated. Also, 
high LDL cholesterol and triglyceride levels in WT HFD mice are associated with endothelial 
dysfunction and high blood pressure.  On the other hand, Nox2KO HFD mice showed reverse 
biochemical parameters and preserved vascular function (Du et al., 2013). However, the exact role 
of several components of the metabolic syndrome including impaired glucose homeostasis, 
dyslipidaemia, and hypertension in relation with endothelial dysfunction remains unknown. 
Physiologically, insulin stimulates glucose uptake in insulin-sensitive tissues, such as the skeletal 
muscle and adipose tissue, by causing the translocation of the insulin-responsive glucose 
transporter to the cell surface, which, in turn, allows glucose entrance into the cell. This effect is the 
final result of the binding of insulin to its receptor on the cell membrane followed by activation of 
intracellular pathways that involves the insulin receptor substrate-1 (IRS-1), PI3K and Akt (Saltiel 
& Kahn, 2001). It is known that insulin receptors are present on endothelial cells, where they 
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activate both the PI3K/Akt pathway and the rat-sarcoma (RAS)/MAPKs cascade leading to NO and 
endothelin-1 (ET-1) synthesis respectively (Muniyappa et al., 2008; Zeng et al., 2000). 
Under physiological conditions, the net effect of insulin stimulation on the endothelial cells results 
in NO-mediated vasodilation, which may contribute to the delivery of insulin and glucose to 
metabolically active tissues, thereby increasing insulin sensitivity (Baron & Clark, 1997). In 
contrast, under pathological conditions, such as obesity, insulin-mediated vasodilation is impaired 
and may contribute to the development of insulin resistance and metabolic syndrome (Kim et al., 
2006; Laakso et al., 1990). Figure 10 depicts a schematic representation of the mechanism leading 
to insulin resistance and endothelial dysfunction in hyperglycaemia and hyperlipidaemia. Studies 
have observed a decrease in the expression of insulin receptor (IR) and insulin-like growth factor-1 
(IGF-1) in obese mice in comparison to lean mice (Imrie et al., 2009; Jiang et al., 1999). 
Additionally, Catalano et al. (2002) found a decrease in IRS-1 expression in obese women during 
gestation in comparison to non-pregnant women. 
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Figure 1.10: Mechanisms for insulin resistance and cardiovascular dysfunction. 
Another physiological role of insulin is its ability to increase the available capillary surface area in 
the skeletal muscle circulation, thus augmenting the delivery of insulin itself, glucose and other 
nutrients to the myocytes (Clark et al., 2003). This notion supports a functional coupling between 
the microvascular effects of insulin, muscle perfusion and glucose utilisation. Accordingly, a 
decrease in muscle perfusion may blunt the delivery of insulin and glucose, and lead to impaired 
glucose tolerance, whereas a decrease in lipoprotein lipase, an enzyme which catalyses the 
hydrolysis and therefore reduces circulatory triglyceride levels, may contribute to dyslipidaemia 
(Lind & Lithell, 1993) suggesting that microvascular dysfunction may precede and contribute to 
the development of insulin resistance and the metabolic syndrome. 
Evidence shows that the abnormalities of insulin signalling or homeostasis may impact endothelial 
function via a complementary pathway for eNOS activation involving its phosphorylation 
(Wheatcroft et al., 2004; Zeng et al., 2000). Insulin resistance is characterised by PI3K-dependent 
signalling impairment, whereas other insulin-dependent pathways remain unaffected, including 
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Ras/MAPK or enhanced due to hyperinsulinaemia, leading to an imbalance between PI3K and 
MAPK pathways (Potenza et al., 2005). In endothelium, decreased PI3K signalling and increased 
MAPK signalling in response to insulin may lead to decreased production of NO and increased 
secretion of ET-1 characteristic of endothelial dysfunction (Muniyappa et al., 2007). Moreover an 
elegant study (Vincent et al., 2003) showed that targeted knockout of the insulin receptor in 
endothelial cells resulted in reduction of eNOS expression and alteration of vasoactive mediators 
and therefore insulin may play a role in maintaining vascular tone. Acute hyperglycaemia itself can 
reduce NO (Giugliano et al., 1997) and attenuate endothelium dependent vasodilation in human in 
vivo (Williams et al., 1998). 
1.8.3.1 Nox2 in insulin resistance  
Type-2 diabetes and other numerous metabolic disorders have been closely linked with oxidative 
stress (Ando & Fujita, 2009; Evans et al., 2003). Regarding type-2 diabetes and insulin resistance, 
an increase in ROS generation is one of the earliest events leading to pancreatic ß-cells dysfunction 
(Prentki & Nolan, 2006). Pancreatic ß-cells have been documented to increase ROS production in 
high glucose levels although they possess relatively low levels of oxygen-detoxifying compounds 
(Robertson & Harmon, 2007). This suggests the possibility that ß-cells are sensitive to the actions 
of ROS. Furthermore, the increased interest in the ROS-generating Nox enzymes raises the 
question whether they play an important role in the pathogenesis of type-2 diabetes. As previously 
discussed, obesity results in impaired insulin signalling. Elevation of ROS causes increased 
proteasomal degradation of IRS-1, increased JNK 1-mediated-serine phosphorylation of IRS-1, and 
impaired insulin-stimulated redistribution of IRS-1 and PI3K activity (see Fig. 11). It has been 
proposed that superoxide produced by Nox2 is converted into H2O2 which can inhibit IRS-1 
activation. 
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Figure 1.11: The mechanism of Nox2-derived ROS in obesity and insulin-resistance. 
 
NADPH oxidase activity and expression is associated with insulin resistance (Fortuño et al., 2009) 
and increased Ang II levels resulted in insulin resistance alongside increased expression of rac1, 
p67
phox
, p22
phox
 and Nox2 and increased NADPH oxidase derived ROS (Wei et al., 2007). 
Apocynin, a Nox inhibitor, has been shown to ameliorate hyperglycaemia and insulin resistance in 
mice fed a HFD diet by reducing oxidative stress (Meng et al., 2011). Insulin resistance and Nox2 
activation are strongly related to endothelial dysfunction and in an in vivo model of insulin 
resistance inhibition or knockout of Nox2 resulted in reduced oxidative stress and improved 
endothelial function (Sukumar et al., 2013). Knockout of Nox2 in a HFD mouse model also 
resulted in reduced levels of superoxide production and attenuated HFD induced hyperglycaemia, 
impaired glucose tolerance and endothelial dysfunction (Du et al., 2013).  
Also, increased Nox-dependent superoxide production (specifically from Nox2 and Nox4) has been 
shown to upregulate the JNK-1 pathway causing β-cell damage thus leading to progression from 
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the metabolic syndrome to insulin resistance and type-2 diabetes (Guichard et al., 2008). However, 
further studies need to be undertaken to provide conclusive evidence. 
1.9 Obesity, oxidative stress and vascular dysfunction 
Aside from insulin resistance, obesity has been shown to be closely related to endothelial 
dysfunction. The endothelium is the innermost lining of the blood vessel, which acts as a barrier 
separating circulating blood from VSMCs and underlying tissue. Endothelial dysfunction refers to a 
change, either an increase or decrease, in any chemical messenger involved in its correct 
functioning. Several potential mechanisms may explain the development of endothelial dysfunction 
and vascular abnormalities in obesity induced by a HFD (see Fig. 12). Types of dysfunction include 
abnormal vasoconstriction/vasodilation and increased prothrombotic/procoagulation activity. An 
imbalance in the homeostatic control of the endothelium increases the risk of many undesirable 
changes in the vasculature including vasoconstriction, increased leukocyte adherence, 
inflammation, atherosclerosis, mitogenesis and thrombosis (Grover-Páez  & Zavalza-Gómez, 
2009). 
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Figure 1.12: Documented mechanistic links between obesity and CVD. 
 
1.9.1 Documented mechanistic links between obesity and CVD 
Endothelial dysfunction is recognised as a preceding event in the pathogenesis of many CVDs, 
particularly atherosclerosis and hypertension. This is thought to be the case due to many CVD risk 
factors such as hyperglycaemia, insulin resistance, type-2 diabetes and dyslipidaemia being linked 
to increased production of ROS (Otani, 2013; Bagi et al., 2012; Siekmeier et al., 2008). An 
increase level of ROS is a hallmark of oxidative stress and therefore decreases the bioavailability of 
NO (Muniyappa et al., 2008; Frisbee & Stepp, 2001), one of the key mediators of normal vascular 
homeostasis and major contributor to maintaining adequate dilation of arteries. Atherosclerosis is 
further thought to disrupt endothelial function via its inflammatory state. More specifically, visceral 
adipose tissue generates high circulating levels of pro-inflammatory cytokines which in turn trigger 
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endothelial cell ROS production leading to altered endothelium-dependant vessel function (Grover-
Páez & Zavalza-Gómez, 2009). Also, the role of ROS in the development of atherosclerosis 
supports the close inter-play between atherosclerosis and diabetes, preceded by oxidant-dependent 
inflammatory disorders. While there is an appreciated link between obesity and CVD 
establishment, the precise mechanisms are not fully understood.  
1.9.2 Apolipoprotein E and atherosclerosis 
Atherosclerosis is a chronic inflammatory disease of the arteries that ultimately leads to the 
formation of complex lesions and atherosclerotic plaques which protrude into the arterial lumen. 
These plaques can result in the acute complications of myocardial infarction and stroke following 
rupture (Patterson et al., 2001). In the early atherogenic process, endothelial cells up-regulate the 
levels of adhesion molecules which allows for extravasation of monocytes that subsequently 
differentiate into macrophages and foam cells following lipid accumulation (Hansson & 
Hermansson, 2011). Importantly, the center of an atherosclerotic lesion, foam cells and 
extracellular lipid droplets form a core region that is surrounded by a cap of proliferating smooth 
muscle cells and a collagen-rich matrix (Hansson & Hermansson, 2011). The process of 
atherogenesis can be seen in Figure 13. 
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Figure 1.13: Schematic representation of the atherogenic process. 
 
A widely investigated mouse model of atherosclerosis is the ApoEKO mouse model. ApoE 
deficient mice are considered a severe model of atherosclerosis due to their elevated levels of very 
low density lipoproteins (vLDL), a cholesterol-rich transporter vesicle. ApoE is a glycoprotein 
component of circulating lipoproteins and functions as a transporter protein to facilitate removal of 
atherogenic lipoproteins from the circulation (Curtiss & Boisvert, 2000; Mahley, 1988). 
Homozygous deletion of the ApoE gene, results in a marked increase of plasma LDL and vLDL 
even when animals are maintained on regular chow diet (Plump et al., 1992). ApoE knockout mice 
develop extensive lesions that mimic those of humans in terms of anatomical location and 
development. Early lesions, which resemble fatty streaks, can be detected in the aortic root and 
proximal aorta around 10 weeks of age and develop, over time, into fibrous, complicated plaques 
which are detected throughout the microvasculature in the aorta and arterial branches (d'Uscio et 
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al., 2001; Curtiss & Boisvert, 2000; Osada et al., 2000). Introduction of HFD in the ApoEKO mice 
significantly accelerates this process and further elevates plasma cholesterol.  
Endothelial dysfunction has been considered as a characteristic of the early atherosclerotic plaque 
formation (Quyyum et al., 1997). Even though the underlying mechanisms are not yet fully 
understood, there are indications that increased ROS generation plays an important role in the 
development of atherosclerotic lesion (Li & Shah, 2004). Recent studies showed that in 
hypercholesterolaemia, increased generation of superoxide via activation of NADPH oxidase may 
play a key role in compromised NO function and promote the development of atherosclerosis 
(Kitayama et al., 2007). However, clinical trials evaluating the effects of antioxidants/ROS 
scavengers on the progression of atherosclerosis have been very disappointing (Bleys et al., 2006). 
Thus the identification of the sources of ROS in atherogenesis may pave the way for other therapies 
that combat vascular oxidative stress by abolishing ROS production from the outset.  
1.9.3 Nox2 and atherosclerosis  
As previously mentioned, Nox2 has been implicated as a contributing factor for various disorders 
such as CVDs, endothelial dysfunction, type-2 diabetes, insulin resistance and inflammation. 
Endothelial dysfunction characterised by excessive ROS production from Nox2 activation has been 
discovered to play a pivotal role in the pathogenesis of CVDs such as atherosclerosis. For this 
reason, therapeutic targets to inhibit the up-regulation of Nox2 require immediate action to protect 
the endothelium from ROS damage thus decreasing the risk of developing CVDs. The resulting 
decrease of NO has been shown to be through the increased production of superoxide. 
Additionally, oxidative modification of LDL by ROS such as superoxide also plays a critical role in 
atherosclerosis development (Förstermann & Münzel, 2006).  
Superoxide and NO have opposing effects on vascular tone and both act negatively on one another. 
For example, superoxide generation from Nox2 activation neutralises NO in the endothelium 
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leading to vasoconstriction. There is compelling evidence suggesting that reduced NO 
bioavailability in the endothelium is due to the action of Nox2 in producing superoxide. It has been 
recently shown that Nox2-containing NADPH oxidase is a major source of ROS in endothelial 
cells, where under vascular oxidative stress the cells are damaged and contribute to endothelial 
dysfunction. Nox2 and its regulatory subunits are implicated in the development of endothelial 
dysfunction and hypertension as shown by preclinical and human studies (Drummond et al., 2011). 
For instance, studies in tissues from human patients have correlated endothelial vasodilator 
dysfunction with increased Nox2 expression and activity (Guzik et al., 2000). Nox2 is involved in 
superoxide production and early atherosclerotic plaque formation in ApoE-deficient mice (Judkins 
et al., 2010). Nox2 knockout mice have improved endothelial dysfunction during experimental 
renovascular hypertension (Jung et al., 2004). The above studies suggest that endothelial Nox2 and 
Nox2-generated superoxide are important in mediating dietary obesity-related hyperglycaemia and 
endothelial dysfunction and Nox2 may present a therapeutic target for the prevention and treatment 
of these diseases. 
NADPH oxidases are ROS-generating enzymes that are strongly implicated in atherogenesis, 
however limited studies have examined which Nox isoforms are involved. The role of Nox2 in the 
development of atherosclerosis was investigated for the first time by Judkins and colleagues (2010) 
using a novel mouse model, Nox2/ApoE double knockout (D-KO) mice. This was the first study to 
directly implicate a specific isoform of NADPH oxidase, namely Nox2, in the pathogenesis of 
atherosclerosis. It has been shown that superoxide production by Nox2 is significantly increased in 
aortic endothelial cells as well as in macrophages in ApoEKO mice when compared to WT mice. 
On the other hand, NO bioavailability was significantly decreased in ApoEKO (Judkins et al., 
2010). More importantly, Nox2/ApoE D-KO mice showed 50% reduction in atherosclerotic plaque 
formation in the aorta due to the deletion of Nox2 and NO bioavailability is restored to the level of 
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WT mice (Judkins et al., 2010). However, there was little difference between ApoEKO and 
Nox2/ApoE D-KO as far as serum lipid profiles are concerned.  
Research linking NADPH-oxidase and endothelium dysfunction has also been carried out in knock-
out mice such as p47
phox
 knockout mice which were found to be protected against Ang II induced 
endothelial dysfunction and Nox2KO mice which were protected against HFD induced endothelial 
dysfunction (Du et al., 2013; Li & Shah, 2004). Insulin resistance-induced impairment of 
endothelial function in association with increased superoxide production can also be attenuated by 
knockout of Nox2 (Sukumar et al., 2013). On the other hand in mice with endothelium specific 
overexpression of Nox2, Ang II induced endothelial dysfunction is exacerbated (Murdoch et al., 
2011).  
Similarly, additional reports have demonstrated that there is a negative correlation between Nox2 
expression and NO-mediated endothelium relaxation in isolated aorta sections (Miller et al., 2010; 
Takenouchi et al., 2009). NO is therefore an anti-atherosclerotic signalling molecule. 
Overexpression of eNOS in HFD mice has been demonstrated to prevent obesogenic effects as 
HFD mice were resistant to hyperinsulinaemia and diet-induced obesity. Furthermore, high fat-fed, 
eNOS overexpressing mice showed decreased levels of plasma triglycerides and fatty acids 
(Sansbury et al., 2014). 
The dysregulation of Nox2 due to obesity is of importance due to the direct effects on the activity 
of the NO and obesity-related molecules. Modifications of obesity-related molecules include; 
increased oxLDL levels and pro-inflammatory cytokines such as TNF-α and these changes result in 
the down-regulation of eNOS. Although the exact mechanism isn’t clear, the down-regulation of 
eNOS results from eNOS-derived NO and superoxide reacting avidly to form ONOO
-
. 
Peroxynitrite in turn oxidises BH4, a crucial eNOS cofactor and this leads to eNOS uncoupling and 
enzyme dysfunction (Laursen et al., 2001).  
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On the other hand, several studies have shown that cardiovascular risk factors are associated with 
an increase rather than a decrease in eNOS expression. The increased expression of eNOS in 
vascular disease is likely to be mediated by superoxide through transcriptional or 
posttranscriptional mechanisms. Therefore, it is likely that superoxide is involved in eNOS 
expression regulation in response to other physiological and/or pathophysiological stimuli. 
(Drummond et al., 2000). 
1.10 Obesity-related oxidative stress and adipose tissue 
Human adipose tissue consists of white adipose tissue (WAT), which is responsible for energy 
storage and consists of a variety of cell populations such as adipocytes, pre-adipocytes, adipocyte 
progenitor cells, pericytes, endothelial cells, and leukocytes (mainly macrophages and other 
monocytes) and brown adipose tissue (BAT), which possesses adipocytes rich in uncoupling 
protein 1 (UCP1) the latter being responsible for the tissue’s thermogenic activity (Dulloo et al., 
2010). However, WAT is not only a fat-storage site. Studies have shown the role of WAT as a 
producer of several bioactive substances, collectively known as adipokines or adipocytokines 
which play important roles in the homeostasis of various physiological conditions (Fonseca-Alaniz 
et al., 2007). In addition to WAT and BAT, a third intermediate-type of adipose tissue that is 
termed ‘beige’ has recently been identified. Adipocytes from beige adipose tissue depots resemble 
white adipocytes but possess the classical properties of brown adipocytes. The differences between 
the three types of adipocytes can be seen in Table 4.  
 
Table 6: Morphological features of brown, white and beige adipose tissue. 
  Brown  White Beige (Brown-like) 
 
Location 
 
Interscapular 
 
Inguinal (sWAT)  
 
Within inguinal WAT 
55 
 
 
Perirenal 
 
Axillary 
 
Paravertebral 
 
Mesenteric 
 
Retroperitoneal  
 
Perigonadal 
 
Omental (vWAT) 
 
 
other sWAT? 
 
Morphology 
 
Multilocular 
 
Small lipid droplets 
 
Unilocular 
 
Large lipid droplets 
 
Unilocular  
 
Large/multiple small 
lipid droplets 
 
 
Function 
 
Heat production 
 
Storage of energy as 
triglycerides 
 
 
Adaptive thermogenesis 
 
Mitochondria 
 
(+++) 
 
(+) 
 
Upon stimulation (++) 
 
 
Iron content 
 
Abundant 
 
Low 
 
Upon stimulation 
(Abundant) 
 
 
Correlation with 
insulin resistance 
 
Negative 
 
Positive 
 
Negative 
 
 
 
UCP1 
 
 
(+++) 
 
Nearly undetectable 
 
Upon stimulation (++) 
 
Vascularisation/ 
Capillaries 
 
 
Abundant 
 
Low 
 
Cold stimulation led to 
increase of angiogenesis 
in sWAT 
 
 
α-, β-Adrenergic 
receptors 
 
β3 (+++) 
 
β3 (++), α2 (+) 
 
β3/α2? 
 
 
 
Obesity 
 
Negative effect 
 
Positive effect 
 
Negative effect 
 
 
Enriched markers 
 
UCP1 
 
Eva1 
 
 
Ang II 
 
Resistin 
 
 
Tmem 
 
Tbx1 
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Pdk4 
 
Ebf3 
 
Hspb7 
 
LPL 
 
G3PDH 
 
Shox2 
 
Activators 
 
Cold 
 
Thyroid hormone 
 
Thiazolidinediones 
 
Fgf21 
 
Bmp7 
 
Bmp8b 
 
Natriuretic peptide 
 
 
HFD 
 
Cold 
 
Thiazolidinediones 
 
Natriuretic peptide 
 
Fgf21 
  
Irisin 
 
Catecholamines 
 
β-adrenergic receptor 
agonists 
 
 
 
Abbreviations: UCP1: Uncoupling protein-1, Ang: Angiotensin II; Eva1: Epithelial V-like antigen-1; 
Pdk4: Pyruvate dehydrogenase kinase-4; Ebf3: Early B-cell factor-3; Hspb7: Heat shock protein 
family B member 7; Tmem: Transmembrane; LPL: Lipoprotein lipase; G3PDH: Glyceraldehyde 3-
phosphate dehydrogenase; Tbx1: T-box associated transcription factor-1; Shox2: Short stature 
homeobox 2; Fgf21: Fibroblast growth factor 21; Bmp7/8b: Bone morphogenetic protein 7/8b; HFD: 
High fat diet. 
 
 
 
Multipotent stem cells become adipoblasts and subsequently differentiate into preadipocytes, which 
under appropriate stimulatory conditions are converted into mature adipocytes (Rosen and 
MacDougald, 2006). Those stem cells can be derived from either an adipogenic lineage of Myf5-
negative cells or a myogenic lineage of Myf5-positive cells. Myf5-expressing progenitors give rise 
to skeletal muscle and brown adipocytes. Myf5-negative progenitors are common precursors for 
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both white adipocytes and beige adipocytes. Beige adipocytes can also derive from the trans-
differentiation of WAT in response to certain stimuli (Reddy et al., 2014).  
Growing evidence suggests that oxidative stress plays a crucial role in linking obesity with its 
related co-morbidities. Obesity per se can induce oxidative stress through various biochemical 
mechanisms, such as superoxide generation from NADPH oxidases, oxidative phosphorylation, 
PKC activation, and polyol and hexosamine pathways to name a few (Manna and Jain, 2015). In 
addition, recent studies suggest that adipose tissue plays a critical role in regulating the 
pathophysiological mechanisms of obesity (Hajer et al., 2008). Furthermore, obesity-induced 
inflammation is frequently associated with increased oxidative stress. Specifically, leptin, an 
adipocyte-derived hormone, is elevated in obese individuals and can induce oxidative stress  
(Korda et al., 2008) and plays a key role in mediating a pro-inflammatory state in obesity  
(Wannamethee et al., 2007) indicating that this physiological link may help to explain the 
relationship of obesity, oxidative stress, and inflammation. 
1.10.1 White adipose tissue 
White adipose tissue mostly consists of white adipocytes. White adipocytes contain a single large 
lipid droplet which accounts for >90% of the cell’s volume. Additionally, white adipocytes have a 
peripheral nucleus and few mitochondria which are situated in the narrow space between the 
droplet and the membrane. Traditionally WAT was considered to be solely a fat storage for excess 
energy intake in the form of triacylglycerides. However, after Friedman and colleagues discovered 
the secretion of leptin from WAT this traditional view was changed (Friedman and Halaas, 1998). 
Later the list of protein signals and factors released from white adipocytes has grown, including 
adiponectin, TNF-α, IL-6, plasminogen activator inhibitor-1 to name a few (Trayhurn and Beattie, 
2001). Thus, WAT is now recognised to be a highly active endocrine organ. Some of the 
substances secreted from the WAT organ are mediators in inflammatory processes, giving the 
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adipose tissue an additional role as a regulator of the immune system. In fact, extensive secretion of 
pro-inflammatory cytokines is believed to play a role in the development of several of the 
comorbidities associated with obesity, including insulin resistance (Wieser et al., 2013). These 
cytokines stimulate the production of ROS and RNS by monocytes and macrophages leading to 
oxidative stress (Shoelson et al., 2006).  TNF-α can lead to O2
.- 
generation whereas adipose tissue 
having the capacity to secrete Ang II  can stimulate NADPH oxidase leading to ROS generation in 
adipocytes (Han et al., 2012).  
1.10.2 ROS in obese adipose tissue 
ROS generation in fat cells can derive from: 
1. Mitochondria   
Considered as a main source of superoxide anions predominantly produced at complexes I and III, 
which will be further converted to H2O2 by mitochondrial manganese superoxide dismutase 
(MnSOD). 
2. NADPH oxidases 
The predominant isoform in adipocytes is Nox4. This isoform presents the particularity to primarily 
generate H2O2, whereas other NADPH oxidases would generate superoxide anions later converted 
to H2O2 by endogenous SOD. 
3. Nitric oxide synthase 
The predominant isoforms in adipocytes are eNOS and iNOS. In the absence of cofactors and 
substrates they can be uncoupled to produce superoxide anions. 
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Fukurawa et al. (2004) demonstrated that in nondiabetic human subjects, fat accumulation and 
plasma adiponectin levels closely correlated with the markers of systemic oxidative stress. Using 
several mouse models, they found that oxidative stress in accumulated fat mediates the obesity-
associated development of metabolic syndrome by the following potential mechanisms: (a) 
increased oxidative stress in accumulated fat leads to dysregulated production of adipocytokines, 
and (b) the selective increase in ROS production in accumulated fat leads to elevation of systemic 
oxidative stress  (Furukawa et al., 2004) Studies in C57BL/6 mice have shown that ROS 
production and mitochondrial dysfunction via glutathione S-transferase alpha 4 (GST-A4) down-
regulation may contribute to the development of insulin resistance and type-2 diabetes (Curtis et 
al., 2010). In agreement it was found that ROS production is significantly increased in adipocytes 
from HFD-induced obese and insulin-resistant mice (Talior et al., 2005).  
Whereas it appears that fat accumulation parallels ROS production, contribution of the different 
pathways involved in this elevation of ROS is still debated. The aforementioned studies by 
Furukawa and Curtis (Curtis et al., 2010; Furukawa et al., 2004), pinpointed the importance of 
NADPH-derived ROS in obese adipocytes. However, mitochondrial ROS production in adipocytes 
was found to be increased by high levels of glucose and free fatty acids (Gao et al., 2010). 
Moreover, it was found that ROS levels in 3T3-L1 adipocytes can be reduced significantly with 
pharmacological agents that lower the mitochondrial membrane potential, or by overexpression of 
UCP1 or SOD (Lin et al., 2005). 
However, in obese adipose tissue, ROS production can also be attributed to reduced antioxidant 
defences. Several antioxidant defence systems are present in fat cells, such as SODs, PRXs, GPXs, 
and catalase. In obese states however, these defences malfunction.  For instance, a decrease in 
expression and activities of antioxidant enzymes such as SOD, GPX, or catalase have been reported 
in WAT from obese mice models (Furukawa et al., 2004). Similarly, expression of the antioxidant 
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enzyme glutathione S-transferase alpha 4 (GST-A4) in humans has been found considerably 
reduced in obese insulin-resistant subjects (Curtis et al., 2010). 
1.10.3 Adipocyte-derived ROS and adipose tissue dysfunction  
1.10.3.1 Insulin Resistance 
Acquired resistance to the action of insulin is associated with obesity.  In skeletal muscle, insulin 
resistance can result from high levels of circulating fatty acids that disrupt insulin signalling 
pathways. Adipose dysfunctions in obesity include secretions of abnormal levels of cytokines 
linked to insulin resistance, impairments in triglyceride storage and increases in lipolysis. These 
abnormalities in turn can contribute to increased fatty acids in the circulation through inflammatory 
mediators and lead to an overload of fatty acids in tissues not suited for lipid storage, such as heart, 
skeletal muscle, pancreas and liver. Such increases in fatty acids in these compartments are likely 
to cause decreased responsiveness to insulin in these tissues in obesity (Guilherme et al., 2008). 
Specifically in the liver, this leads to a spectrum of non-alcoholic fatty liver diseases, which can 
evolve towards cirrhosis (Fromenty et al., 2004).  Nox enzymes in the liver are widely distributed. 
Nox2 has been found in Kupffer cells (hepatic resident macrophages) (Ding and Nathan, 1988), in 
rat hepatocytes (Diaz-Cruz et al., 2011) and in endothelial cells (Jones et al., 1996). Under 
physiological conditions Nox4 ROS production increases glucose uptake from hepatocytes. In non-
alcoholic fatty liver diseases several pathways are involved in insulin resistance. Nox2/Nox4 may 
activate JNK pathway, IRS phosphorylation and activation of transcription factors leading to 
insulin resistance. Inflammatory cytokines such as CD95L and TNF-α may increase 
Nox1/Nox2/Nox4 expression and promote endoplasmic reticulum (ER) stress and hepatocyte 
apoptosis. Nox2/Nox4 may increase TGF-β1 production and fibrosis and Nox2 in macrophages and 
neutrophils may contribute to inflammation by producing more inflammatory cytokines (see Fig. 
15) (Guichard et al., 2008). 
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Figure 1.14: Nox signalling in healthy and diseased (NASH - Nonalcoholic steatohepatitis) 
liver.  
 
1.10.3.2 Adipocyte differentiation 
Adipose tissue demonstrates remarkable malleability in functional adaptation and remodelling in 
response to the nutritional status of the body. As adipocytes continue storing lipids, they can 
increase in the size of fat cells (hypertrophy) or increase in the numbers of fat cells linked to 
differentiation of adipocyte precursors (hyperplasia).  Primary human mesenchymal stem cells 
undergoing differentiation into adipocytes display an early increase in mitochondrial metabolism, 
biogenesis and ROS generation which are not simply a consequence of this process but are a causal 
factor in promoting adipocyte differentiation (Tormos et al., 2011). Conversely, scavenging of 
ROS production inhibits adipogenesis process (Kanda et al., 2011). Therefore, excessive or 
inappropriate redox balance will detrimentally affect adipocyte precursor conversion and favour 
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adipocyte hypertrophy. Hypertrophied adipocytes will concomitantly impair adipose tissue function 
by inducing local inflammation, mechanical stress, and altered metabolism due to dysregulated 
adipokine secretion. Thus, impairment of adipocyte differentiation due to high levels of ROS could 
cause adipose tissue inflammation and other related metabolic dysfunctions (Murdolo et al., 2013). 
1.10.3.3 Inflammation 
Obese adipose tissue is associated with increased infiltration of various innate and adaptive 
immune cells. Thus, adipocytes and infiltrating immune cells secrete pro-inflammatory adipokines 
and cytokines providing an inflammatory environment. Accumulation of B and T cells in adipose 
tissue precedes macrophage infiltration causing a chronic low-grade inflammation (Catalán et al., 
2013).  
Studies have shown that adipocytes exposed to ROS, upregulate the expression of certain 
proinflammatory cytokines (Furukawa et al., 2004). Also it was found that in 3T3-L1 adipocytes 
oxidative stress decreased adiponectin secretion (Soares et al., 2005). Therefore, ROS production 
by obese adipocytes could lead to proinflammatory cytokine or adipokine dysfunction. 
Additionally, it was found that ROS are downstream products of TNF-α signalling in mitochondria 
(Chandel et al., 2001) and that oxidative stress by-products, found in obese adipose tissue are 
potent macrophage activators (Frohnert et al., 2013). 
Altogether, adipocytes might initiate an inflammatory state in WAT establishing a systematic 
feedback-loop between inflammation and oxidative stress in obese adipose tissue concurring to 
WAT dysfunction.  
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1.10.3.4 Endothelial dysfunction 
Most blood vessels are surrounded by adipose tissue known as perivascular adipose (PVAT). 
PVAT can induce vasodilation and vasoconstriction by releasing adipocyte-derived relaxing factor 
(ADRF) and adipocyte-derived constricting factor (ADCF), respectively (Ouwens et al., 2010). 
ADRF open the potassium channels on VSMCs inhibiting various vasoconstrictor molecules, 
whereas ADCF exerts its effects through ROS and is blocked by NADPH oxidase inhibitors (Rey 
et al., 2002).   In obesity, vascular dysfunction is mediated by impaired production of ADRF and 
elevated release of ADCF (Gao, 2007). Studies in diet-induced obese C57BL/6 mice have 
demonstrated that PVAT promotes endothelial dysfunction via NADPH oxidase derived ROS and 
increased inflammatory cytokines (Ketonen et al., 2010). 
1.10.4 Browning in white adipose tissue 
Brown adipose tissue’s main function is thermogenesis. Brown adipocytes are packed with 
mitochondria that contain UCP1 which stimulates respiratory chain activity through ATP synthesis. 
However, within the WAT, clusters of adipocytes expressing UCP1 can also be found after 
exposure to certain stimuli (e.g. cold). These adipocytes have been named beige and although they 
are morphologically similar to brown adipocytes (multilocular lipid droplets, high mitochondrial 
content and brown fat–specific gene expression), they have many distinguishable characteristics 
and should be considered as a separate cell type. Beige cells derive from a different embryonic 
progenitor cell, they have different gene signatures (Wu et al., 2012) and express UCP1 protein 
only under stimulation in contrast to brown cells that express UCP1 and other thermogenic genes 
constitutively and in high levels (see Table 5). Beige adipocytes lose UCP1 expression after the 
stimulus ceases to exist (Rosenwald, 2013).  
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Table 7: Differences between brown and beige adipocytes. 
 
Recently Jeanson et al. (2015) demonstrated the role of redox metabolites, such as lactate in the 
browning process. They found that lactate-induced browning occurs through a change in the 
intracellular redox state (NADH/NAD) which in turn triggers the expression of browning genes. 
The subsequent increase in oxidative metabolism causes thermogenesis and oxidises reduced 
equivalents such as NADPH.  
 Several studies have shown that obesity-resistant strains of mice, such as A/J and Sv129 mice, 
have higher amounts of “beige” adipocytes in white fat (Harms and Seale, 2013). Furthermore, 
transgenic mice with increased amounts of UCP1-postive adipocytes in WAT are protected from 
HFD-induced obesity (Takahashi et al., 2015).  Interestingly, the multilocular cells previously 
observed in humans are found to be more similar to “beige” fat cells rather than classical brown fat 
cells (Dempersmier and Sul, 2015).  
 Consequently, manipulation of inducible brown adipocytes in humans may be a potential target in 
the treatment and prevention of obesity and its related diseases.  
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1.11 Understanding and ameliorating obesity-related oxidative stress 
The role that antioxidants play on cardiovascular risk and mortality has been examined through 
various clinical trials and there have been varied responses resulting in studies showing no effects, 
beneficial effects and even adverse effects (Kris-Etherton et al., 2004). Although the majority of 
studies have not shown beneficial effects, the use of antioxidants as a therapy to reduce oxidative 
stress and CVD risk can still not be justified due to the risk of possible adverse effects. Possibly, a 
better alternative would be the targeting of the enzymes which are responsible for the production of 
ROS such as NADPH oxidase, resulting in the understanding and improvement of obesity-related 
oxidative stress. Regarding this, numerous inhibitors of NADPH oxidase have been established 
with only few shown to be specific for NADPH oxidase such as the peptide inhibitor gp91ds-tat 
(Rey et al., 2001) and the small molecule inhibitors VAS2870 and VAS3947 (Tegtmeier et al., 
2005).  However, even these superior inhibitors do not appear to be isoform specific (Wind et al., 
2010; Brandes, 2003), which is challenging considering the high-degree of homology between the 
7 Nox isoforms. In order to help further understand the mechanisms behind obesity-related 
oxidative stress would help to use the knockout mouse models such as Nox2 and p47
phox
.  
1.12 Aim and Hypothesis 
It is well-known that cardiovascular functions are tightly regulated by redox homeostasis. 
Physiological levels of ROS are required for redox signalling involved in maintaining normal 
cardiovascular function. However, enhanced redox-signalling together with decreased NO 
production causes endothelial injury and cardiovascular damage. Oxidative stress is recognised as a 
dominant mechanism proposed to be involved in obesity-associated CVDs.  HFD is associated with 
obesity, hyperglycaemia, hyperlipidaemia and risks for the development of cardiovascular diseases. 
Obesity also results in impaired insulin signalling. It has been proposed that ROS produced by 
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Nox2 is converted into H2O2 which can inhibit IRS-1 activation. Nox2 activity and expression is 
associated with insulin resistance (Fortuño et al., 2009) and increased Ang II levels resulted in 
insulin resistance. In addition, recent studies suggest that adipose tissue plays a critical role in 
regulating the pathophysiological mechanisms of obesity (Hajer et al., 2008). Furthermore, obesity-
induced inflammation is frequently associated with increased oxidative stress. 
Despite there being several studies and data that indicate the contributions of Nox2 in ApoEKO 
mouse model in the pathogenesis of insulin resistance, endothelial dysfunction, inflammation and 
adipose tissue dysfunction, there has been only one study (Judkins et al., 2010) conducted that 
specifically investigates the effects of Nox2 deletion. However, in this study was investigated the 
role of Nox2 in ApoEKO mouse model regarding atherosclerosis. Since it has been clearly shown 
that Nox2 plays a crucial role in these deleterious processes, it is implied that complete removal or 
inhibition of Nox2 would have a protective effect. Because this has not been tested directly, this 
project was set out to determine if in fact complete deletion of Nox2 in ApoEKO mouse model in 
the context of HFD-induced obesity would preserve endothelial function, prevented metabolic 
syndrome, inflammation and adipose tissue dysfunction. 
Objectives 
The first objective of this project was designed to elucidate the effects of Nox2 deletion in 
ApoEKO mouse model on whole body in the context of HFD. This was done in order to examine if 
deletion of Nox2 would provide protection against metabolic impairments. The second objective 
was to elucidate the effects of Nox2 deletion in ApoEKO mouse model in the context of 
hyperglycaemia and hyperinsulinaemia using mouse aorta, a well-established and mostly used 
organ for studying metabolic-related large vessel dysfunction. The third objective was to 
investigate the effects of Nox2 deletion in ApoEKO mouse adipose tissue in the context of HFD. 
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Specific Aims 
Firstly, ApoEKO mouse model was utilised with a global knockout of Nox2 which was then 
evaluated on a HFD along with the ApoEKO counterparts. More specifically, the effect of obesity 
and Nox2-induced ROS production in respect to metabolic parameters, vascular dysfunction and 
insulin resistance was explored. Also, Nox2 intracellular cascades were examined. This is 
necessary in order to validate that Nox2 deletion does indeed offer protection in the face of HFD-
induced obesity. The hypothesis of this thesis is that Nox2 activation and expression plays an 
important role in HFD associated metabolic syndrome, organ dysfunction and a key role in the 
accumulation of oxidative stress leading to CVDs and Nox2/ApoE D-KO mice will be protected 
from the HFD as compared to ApoEKO mice. 
Next, the role of Nox2 in insulin-resistance (hyperglycaemia and hyperinsulinaemia) was 
investigated in respect to Nox2-induced ROS production, vascular function and IR function. 
Finally, the relationship of Nox2-induced ROS due to obesity and adipose tissue dysfunction was 
examined. Nox2 expression and intracellular pathways such as ERK and p38, insulin resistance by 
IR expression and eNOS phosphorylation, macrophage infiltration and ICAM-1 expression and 
UCP1 protein levels were determined. 
The mechanism of HFD-induced vascular dysfunction remains unclear. Therefore, the overall aim 
of this PhD research project is to investigate the role of a Nox2-containing NADPH oxidase in 
HFD (45% kcal fat)-induced metabolic disorders using Nox2/ApoE D-KO mice in comparison to 
age-matched ApoEKO mice on the C57BL/6 background.  
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Chapter 2 
Materials and Methodology 
For a comprehensive list of materials and reagents used in this study please see Table 2.15. All 
equipment used is detailed in the text including, where appropriate, the company and model.  
2.1 Animals and dietary treatment  
The animals were bred on a C57BL/6J background and they were individually housed in clear, 
sterile standard containers in specific pathogen free conditions in an animal vivarium maintained on 
a 12-hour-light/-dark cycle (lights on at 7:00a.m.), at constant temperature (18-23°C) and humidity 
(45-55%). Food and water were provided ad-libitum except for fasting glucose measurements 
where only water was provided ad-libitum. Foods were irradiated and drinking water was 
autoclaved to prevent exposure of mice to any infectious agents. They were euthanised by 
intraperitoneal injection of sodium pentobarbital (100mg/kg body weight), their organs harvested 
and used immediately in further experiments. 
The C57BL/6 strain of mice was chosen as they are long lived and breed well. All mice, except 
Nox2/ApoE D-KO mice, were originally obtained from the Jackson Laboratory and were 
subsequently bred at the University of Surrey Experimental Biology Unit (EBU). Nox2KO mice 
were originally generated by Pollock et al. by insertion of a neomycin resistant gene (Cybb
tm1Din
) 
into exon 3 of the CYBB (Nox2) gene which encodes the 91 kD subunit of the oxidase cytochrome 
b (Pollock et al., 1995). Male Nox2KO hemizygous and female Nox2 heterozygous mice were 
mated to produce male WT and Nox2KO littermates which were genotyped by polymerase chain 
reaction (PCR) amplification of tail lysates followed by gel electrophoresis separation (see section 
2.3). Nox2KO mice were also routinely outcrossed with WT to keep the colony healthy. The 
Nox2/ApoE D-KO mice were generated as described below (see section 2.2).  
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The effects of HFD on ApoEKO and Nox2/ApoE D-KO mice were studied. Nox2/ApoE D-KO 
mice were initially fed a NCD purchased from LabDiet Ltd, UK (5LF5: 25.9% protein, 9.3% fat, 
64.8% carbohydrates). Subsequently, Nox2/ApoE D-KO mice at 6 weeks of age were randomly 
divided into 2 groups (n=9) and placed on either the NCD or the HFD purchased from Special 
Diets Services, UK (SDS: 20% protein, 45% fat, 35% carbohydrates) for 10 weeks of dietary 
intervention. All animal studies and procedures were conducted in accordance with the Guidance 
on the Operation of the Animals (Scientific Procedures) Act, 1986 (UK Home Office). All our 
experiments were carried out in male mice. 
In Chapter 5, transgenic mice with endothelial-targeted overexpression of Nox2 (Nox2-Tg) were 
used. These mice were bred by Professor Channon’s Lab and our group acquired adipose tissue for 
analysis. They were generated utilising a tie 2 promoter/enhancer construct (Douglas et al., 2012) 
containing the full length human Nox2 cDNA sequence. 
2.2 Generation of Nox2/ApoE double knockout mice 
Female Nox2KO mice were crossed with male ApoEKO mice on the C57BL/6 background to 
produce littermates of Nox2/ApoE heterozygote mice as shown in figure 2.1. From this generation, 
female Nox2/ApoE heterozygote mice were crossed with male Nox2/ApoE heterozygote mice. The 
resulting generation consisted of twelve different genotypes (female or male) of WT, Nox2KO, 
ApoEKO, Nox2/ApoE D-KO and heterozygote mice. After 3 generations of cross mating 
Nox2/ApoE D-KO mice were generated. 
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Figure 2.1: Diagrammatic description of Nox2/ApoE double knockout mouse mating and breeding 
‘Nox2 gene and its mutant gene (Nox2 knockout) are located on X-chromosome and ApoE gene and its 
mutant gene (ApoE knockout) are located on chromosome 19. Male and female littermates of 
Nox2/ApoE double knockout mice can be obtained by mating male ApoE knockout mice with female 
Nox2 knockout mice’. 
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2.3 Genotyping 
2.3.1 Nox2 knockout mice 
Genotyping was performed using PCR on tail genomic DNA, with primers specific for the gene-
targeting cassette. Genotyping was carried out on 10-15 day old mice by PCR and gel 
electrophoresis to identify Nox2KO, ApoEKO
 
and Nox2/ApoE
 
D-KO hemizygous male mice for 
scientific use. Each mouse was tail marked with permanent marker for later identification and a 
tail-tip (2-3mm) was cut from the end of the tail of each mouse with clean, autoclaved sharp 
scissors and placed in a pre-labelled DNase-free 1.5ml microcentrifuge tube. Each tail-tip tissue 
was digested overnight (5pm-9am) with 150µl digestion mix containing tail lysis buffer (see table 
2.1) and proteinase K (200μg/ml) in a water bath (Clifton shaking water bath, Nickel Electro Ltd, 
UK) at 55
o
C with gentle agitation. 
 
 
 
 
 
 
 
 
Reagent  Concentration 
MgCl2 1.5mM 
KCl 50mM 
Tris HCl (pH 7.5) 10mM 
Nonidet P-40 0.45% 
Gelatin 0.01% 
Tween-20 0.45% 
Proteinase K 200μg/ml 
Table 2.1 Tail Lysis Buffer 
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The next morning, the PCR mixture was prepared. A common primer (forward), a WT reverse 
primer, and a mutant (Nox2 knockout) reverse primer, designed to identify the genotype of mice, 
were synthesised by Eurofins MWG Operon (Germany), and the sequence information was 
obtained from the Jackson Laboratory (see table 2.2). 
  
 
 
 
 
After the preparation of PCR mix (see table 2.3) the samples were heated at 95°C for 5 minutes to 
inactivate proteinase K. The samples were then briefly mixed by a vortex mixer before being 
centrifuged at 13000g for 5 minutes to pellet the debris. The supernatant containing genomic DNA 
was used for PCR analysis. The PCR mix (10μl) was added to PCR tubes with 2μl of DNA sample 
and PCR was run on a PCR thermal cycler (Applied Biosystems, USA) according to the thermal 
cycling parameters in table 2.4.  
 
 
 
 
Primer Sequence 5′ to 3′ 
Common Forward 5′-AAG AGA AAC TCC TCT GCT GTG AA-3′ 
Wild-type Reverse  5′-CGC ACT GGA ACC CCT GAG AAA GG-3′ 
Mutant Reverse 5′-GTT CTA ATT CCA TCA GAA GCT TAT CG-3′ 
Table 2.2 Primer sequences used to identify Nox2 genotypes 
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Table 2.3 Nox2 PCR mix 
Reagent  Concentration 
GoTaq Flexi Buffer  1x 
MgCl2 2.5mM 
dNTP mix 0.2mM 
Common Forward Primer 1μM 
Wild-type Reverse Primer 1μM 
Mutant Reverse Primer  1μM 
GoTaq Hot Start Polymerase 0.3 Units 
Table 2.4 Thermal cycling parameters of Nox2 PCR 
Step Temperature Time Comments 
1 94°C 3min  
2 94°C 20sec  
3 64°C 30sec -0.5°C per cycle 
4 72°C 35sec Repeat steps 2-4 for 12 cycles 
5 94°C 20sec  
6 58°C 30sec  
7 72°C 35sec Repeat steps 5-7 for 25 cycles 
8 72°C 2min  
9 10°C  Hold 
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After DNA amplification via PCR DNA fragments were separated by length, to estimate the size of 
the fragments by applying an electric field. The negatively charged nucleic acid molecules migrate 
through an agarose gel. Shorter molecules move faster through the agarose matrix than longer once. 
A 3% agarose gel was made up in a glass duran bottle by adding 3g of agarose to 100ml 1X Tris-
acetate-EDTA (TAE) buffer, composed of 40mM Tris-acetate and 1mM ethylenediaminetetraacetic 
acid (EDTA), and heated in a microwave oven with lid loose until totally dissolved. Then, 5μl 
ethidium bromide (10mg/ml) was added into 100ml agarose solution before it was poured into a gel 
rack. The samples (12μl) and a 100bp DNA ladder (5μl) were loaded onto the agarose gel and 
electrophoresis (Electrophoresis system FB300, Fisher Scientific, UK) was carried out at 120V for 
around 45 minutes to separate negatively charged DNA which migrated from the cathode (-) to the 
anode (+). The bands were visualised by exposing the gel on a UV transilluminator (Genegenius, 
Syngene Ltd, UK) and captured using GeneSnap software. The presence of a 240 base pair (bp) 
band in the gel represents the WT allele and a 195bp band represents the mutated (Nox2) allele. 
Heterozygote mice were identified by the presence of both bands (see figure 2.2). 
2.3.2 ApoE knockout mice 
Tail samples were collected and prepared (see table 2.5-2.7) as previously described for Nox2KO 
mice. PCR was done as described previously (section 2.3.1). Primer sequences for ApoE genotypes, 
ApoE PCR mix and thermal cycling parameters for ApoE PCR are described in tables 2.5, 2.6 and 
2.7 respectively. To detect bands, a 1.5% agarose gel with ethidium bromide (10mg/ml; 5μl) was 
made up with 1X TAE buffer (100ml). The samples (12μl) and a DNA ladder (5μl) were loaded 
onto the gel and electrophoresis was carried out at 120V for around 45 minutes. The bands were 
visualised and captured using GeneSnap software. The ApoE WT gene (+/+) is 155bp and the ApoE 
knockout gene (-/-) is 245bp (see figure 2.2). 
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Table 2.6 ApoE PCR mix 
Reagent Concentration 
GoTaq Flexi Buffer 1x 
MgCl2 2mM 
dNTP mix 0.2mM 
Common Forward Primer 0.5μM 
Wild-type Reverse Primer 0.5μM 
Mutant Reverse Primer 0.5μM 
GoTaq Hot Start Polymerase 0.3 Units 
 
Table 2.7 Thermal cycling parameters of ApoE PCR 
 
 
 
 
 
Table 2.5 Primer sequences used to identify ApoE genotypes 
Primer Sequence 5′ to 3′ 
Common Forward 5′-GCC TAG CCG AGG GAG AGC CG-3′ 
Wild-type Reverse 5′-TGT GAC TTG GGA GCT CTG CAG C-3′ 
Mutant Reverse 5′-GCC GCC CCG ACT GCA TCT-3′ 
Step Temperature Time Comments 
1 94°C 3min  
2 94°C 30sec  
3 68°C 40sec -0.5°C per cycle 
4 72°C 1min Repeat steps 2-4 for 35 cycles 
5 72°C 2min  
6 10°C  Hold 
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Figure 2.2: Representative PCR gels showing the PCR products of the genotyping reaction 
for Nox2 and ApoE gene separated by gel electrophoresis. 
 (A) Representative gel electrophoresis result for detection of WT or Nox2KO animals. Digested 
tail tips from crossed Nox2 and ApoE knockout offspring were genotyped for expression of WT or 
Nox2 knockout genes followed by gel electrophoresis and visualisation by UV detection using 
ethidium bromide. Lane 5 shows a single band representing the wild-type gene with 240bp. The 
bands in lanes 1,3,4,6 and 7 represent the Nox2 knockout gene with 195bp. The double bands in 
lane 2, one of which is at 240bp and another at 195bp, stand for heterozygote.  
(B) Representative gel electrophoresis result for detection of WT or ApoEKO animals. Digested 
tail tips were genotyped for expression of WT or ApoE genes followed by gel electrophoresis and 
visualisation by UV detection using ethidium. Lanes 1,3,6,7 shows a single band representing the 
wild-type gene with155bp. The bands in lanes 4 and 5 represent the ApoE knockout gene with 
245bp. The double bands in lane 2, one of which is at 245bp and another at 155bp, stand for 
heterozygote. 
Therefore, Nox2/ApoE D-KO mice were generated (lane 4) with Nox2KO (lane 1,3,6,7), ApoEKO 
(lane 5) and Nox2/ApoE double heterozygote (lane 2) mice. 
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2.4 Food Intake and Body Weight Measurements 
Food intake and body weight measurements were determined in Nox2/ApoE D-KO NCD and HFD 
male littermates at the beginning (6 weeks old) and end of the study (16 weeks old). Mice were 
individually housed in standard cages when food intake measurements were carried out. The food 
was weighed every 24 hours using a 1 decimal place balance for at least 3 days/week and the 
average weekly intake per mouse was calculated. The bodyweight of each mouse was measured 
with the same way as food intake measurement. 
2.5 In Vivo Blood Pressure Measurement  
A typical characteristic of endothelial dysfunction corresponds to alterations in blood pressure 
(BP). Systolic and diastolic BP was measured using a computer controlled non-invasive tail-cuff 
plethysmography BP system (Kent Scientific Corporation, USA) on conscious, restrained mice at 
an ambient temperature of 24-26°C between 9am and noon. BP measurement was determined in 
Nox2/ApoE D-KO NCD and HFD male littermates every 2 weeks from the beginning up to the end 
of the study. 
This system works by inflation of the volume-pressure recording (VPR) cuff to remove blood to the 
tail, the occlusion cuff then inflates to prevent blood flow back into the tail and then gradually 
deflates. The systolic BP is taken as the pressure at which the blood volume in the tail increases 
after deflation of the occlusion cuff and the diastolic BP is the pressure at which the blood flow into 
and out of the tail equalises (Feng et al., 2008). Animals were habituated to the restraining 
apparatus on a heated platform for 5 days (15min/day), and tail cuff inflation on three occasions 
before measurements were taken. Mice were handled gently to minimise stress and were not forced 
to enter the restrainer. Once in the restrainer the tail of the mouse was threaded through the 
occlusion cuff and VPR cuff (see figure 2.3). The body temperature of the mice was also recorded 
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with an infra-red thermometer (La Crosse Technology, USA) to ensure that the body temperature 
remained stable. At a high temperature the mice overheat and become stressed and at a low 
temperature blood flow to the tail is impaired. On the day of measurement mice were habituated in 
the restrainer with both cuffs on the tail for 5-10 minutes until they remained calm. The 
measurements were recorded by the CODA-6TM program and V2.5 software and the mean of a 
minimum of 5 recordings on each occasion was taken, and mean data were compared between 
groups.  
The only disadvantages of this method include the under or over-estimation of arterial pressure due 
to mouse being placed into plastic holders, pre-warming to a high temperature and the pressure of 
tail cuffs and noise (Whitesall et al., 2004). Therefore, these potential stress-induced impacts on the 
behaviour of the mouse have been minimised by a period of pre-training of the mice, and ensuring 
that the measurements taken in a semi-dark and peaceful environment.  
2.6 Fasting Blood Glucose Measurement and Intraperitoneal Glucose and 
Insulin Tolerance Test  
Measurement of fasting glucose is a simple screening method for detecting alterations in glucose 
metabolism. Fasting blood glucose measurement was determined in ApoEKO and Nox2/ApoE D-
KO NCD and HFD male littermates at the beginning (6 weeks old) and end of the study (16 weeks 
old). Mice were placed into a new standard cage containing only wood shavings to remove all 
potential food sources. Fresh water was provided ad libidum to the mice during the fast period. 
They were fasted overnight for 8 hours (from 12 midnight to 8am). The following day, the mice 
were restrained in the restraining device with the tail exposed and the tip of the tail was cut using a 
sterilised scalpel blade. Plasma glucose was measured by glucose meter (Contour Accu-Check, 
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Bayer Health Care, UK) and the reading was recorded. The experiments were conducted at 
approximately the same time of the day (~ 8-9am).  
Intraperitoneal glucose tolerance test (IPGTT) was performed in conscious, overnight fasted mice 
(same mice as above – only Nox2/ApoE D-KO; for HFD study IPGTT was performed only at the 
end of the study). Firstly, the mice were weighed and a 20% glucose solution was made up with 
sterile saline (0.9% NaCl; 1g in 5ml). Secondly, syringes were prepared with 10µl of glucose 
solution per gram of bodyweight for each mouse. Glucose was injected intraperitoneally (2g/kg 
body weight in 0.9% NaCl) and blood glucose levels were measured immediately before (fasting 
glucose 0 time) and at 15, 30, 60 and 120-min post-administration from a small drop of blood from 
the mouse tail using a blood glucose meter. 
Intraperitoneal insulin tolerance test (IPITT) was performed in conscious, 4 hours fasted HFD 
ApoEKO and Nox2/ApoE D-KO mice (same mice as above – for HFD study IPITT was performed 
only at the end of the study). Firstly, the mice were weighed and and human insulin (0.75 unit/kg) 
was injected intraperitoneally and blood glucose levels were measured immediately before (fasting 
glucose 0 time) and at 15, 30, 60, 90 and 120-min post-administration from a small drop of blood 
from the mouse tail using a blood glucose meter. 
2.7 Euthanasia and Tissue Collection 
Mice were euthanised by an intraperitoneal injection of sodium pentobarbital (100mg/kg) and the 
body was sprayed with 70% ethanol to disinfect the skin and fur. Using forceps the skin below the 
ribs was lifted and a small cut was made through the skin with scissors. Closed scissors were 
inserted into the cut made and then opened and this was repeated until the skin was separated from 
the abdominal and thoracic cavities. The skin was then cut along the midline of the body up to the 
neck and down towards the hind legs. The abdominal cavity was cut open along the midline and 
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across the body below the ribs to open up the abdominal region. The intestines were gently pushed 
to the left side and the liver forward until the inferior vena cava (between the kidneys) was clearly 
visible. A 25 gauge needle was carefully inserted into the vein and blood was slowly drawn into 
1ml syringe and transferred to a 1.5ml centrifuge tube with no anticoagulant. The blood was left to 
clot at 4
o
C until ready for serum collection (see section 2.9). After blood collection the stomach and 
intestines were removed and the epididymal fat pads, pancreas, spleen, liver and kidneys were 
collected. The rib cage was then removed by cutting along the sternum towards the head, through 
the ribs down to the diaphragm and through the diaphragm to give access to the heart and lungs 
which were collected. The aorta was then collected from the heart down to the iliac bifurcation, by 
cutting the connective tissue underneath the vessel. The brain was collected by cutting and peeling 
away the skull and then gently lifting out with a thin spatula. The muscle from around the legs was 
collected by cutting through the femur close to the pelvis and then pulling the leg free allowing the 
muscle to be easily removed. All organs not used for physiological experiments were fixed or 
frozen for future use by the research group. The aortas used for physiological experiments were 
collected and prepared as described in section 2.10. The weight of all the organs was measured 
using a 4 decimal place balance. 
2.8 Preparation of aorta for sectioning  
Freshly excised aortas of WT, Nox2KO, ApoEKO and Nox2/ApoE D-KO mice were cleaned of 
any connective tissue and adherent fat and were cut into 2-3mm long rings. Aorta rings were 
arranged upright in optimum cutting temperature (OCT) compound on cork discs with 3 rings per 
disc. Isopentane was cooled by liquid nitrogen until the edges of the solution began to turn into a 
white solid. The OCT embedded aorta sample was slowly immersed in the cold isopentane until the 
OCT solidified. The sample was stored at -80
o
C until ready for sectioning. 
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2.9 Tissue dehydration, clearing and impregnation with wax 
Following fixation (10% formalin), all tissues were placed overnight in an automatic tissue 
processor (Shandon Citadel, Thermo Electron Corporation, UK). Samples underwent dehydration 
(70% alcohol 1 hour → 90% alcohol 1 hour → 100% alcohol 1 hour → 100% alcohol 2 hours → 
100% alcohol 2 hours), clearing (toluene 1 hour → toluene 1.5 hours → toluene 1.5 hours), and 
impregnation in wax (paraffin wax 2 hours → paraffin wax 3 hours) according to a pre-set 
programme. Samples were then placed in appropriate-sized blocks and embedded in wax using an 
embedding station (Raymond Lamb Blockmaster II). 20μm sections of wax-embedded epididymal 
fat of NCD and HFD WT, Nox2KO, ApoEKO and Nox2/ApoE D-KO mice were cut using a 
microtome (Reichert 2040 Microtome, Leica, Germany) and placed on superfrost plus slides 
(VWR, UK). 
2.10 Aortic Vasomotor Function 
The aorta was excised as described in section 2.8 and immersed in ice cold Krebs-Henseleit buffer 
(composition in mmol/L: NaCl 118.0, KCl 4.7, KH2PO4 1.2, NAHCO3 25.0, MgSO4 1.2, CaCl2 
2.5, and glucose 12.0; pH 7.4). The aorta was pinned at either end in a Petri dish filled with ice cold 
Krebs-Henseleit buffer. Connective tissue and fat were carefully removed under a dissection 
microscope (GT Vision, UK) with fine scissors and forceps. 
Vasomotor function was assessed in ex vivo thoracic aortic rings (3-4mm) of NCD and HFD 
ApoEKO and Nox2/ApoE D-KO mice mounted in an organ bath (ML0146/C-V, AD Instrument 
Ltd, UK) containing 10ml Krebs Henseleit buffer  gassed with 95% O2/5% CO2. The aortic rings 
were each mounted on 2 parallel horizontal hooks, made of stainless steel wire (150µm diameter), 
in a water-jacketed organ bath chamber (figure 2.4) and maintained at 37
o
C. The upper hook was 
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attached to an isometric force displacement transducer and the lower hook was fixed to a support 
leg attached to the organ bath.  
 
 
 
 
 
 
 
 
The isometric force was measured digitally on a computer with the software programme PowerLab 
Chart 5.0 (AD Instruments, UK). Rings were equilibrated with no tension for 45 minutes with the 
buffer being replenished every 15 minutes. Gradually the tension was manually increased until a 
passive tension of 0.3g was reached and was left for 15 minutes (Russell and Watts, 2000). All 
subsequent measurements throughout the experiment represent tension generated above this 
baseline. After 15 minutes the tension was checked and adjusted if necessary to ensure it was at 
0.3g. To ensure integrity of the contractile apparatus of the aortic ring, rings were exposed to 2M 
KCl (250µl; 50mM final concentration in 10ml) for 10 minutes, and any rings which did not 
contract were rejected at this point.  
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Figure 2.3: Diagram showing aortic isometric force measurement. 
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Figure 2.4: Representative image of the response of an aortic ring to KCl followed by a 
series of washes. 
 
Following washing and re-equilibration, the cumulative dose response to the constrictor 
phenylephrine (PE; 1nmol/L to 10μmol/L) was first assessed. PE is a α1-adrenergic receptor 
agonist which causes smooth muscle cell contraction by releasing intracellular calcium.  
 
 
 
Figure 2.5: Representative image of the response of an aortic ring to increasing 
concentrations of phenylephrine (PE; 1nmol/L to 10μmol/L).  
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After washing and re-equilibration, relaxation responses to the endothelium-dependent vasodilator 
acetylcholine (ACh; 1nmol/L to 10μmol/L), to insulin (1nmol/L to 1μmol/L) or endothelium-
independent vasodilator sodium nitroprusside (SNP; 0.1nmol/L to 1μmol/L) were assessed in rings 
pre-constricted to 70-80% of their maximal PE-induced tension. ACh binds to muscarinic receptors 
on the endothelium to stimulate the production of NO by eNOS which causes smooth muscle cell 
relaxation and SNP is a nitric oxide donor. Relaxation was expressed as the percentage of pre-
constricted tension. 
 
 
 
 
Figure 2.6: Representative images of the response of an aortic ring to increasing 
concentrations of ACh or SNP after pre-contraction with phenylephrine (PE). 
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Experiments were also carried out in the presence of tiron (a non-enzymatic superoxide anion 
scavenger; 10mM). Rings were incubated with tiron for 15 minutes before endothelial relaxation by 
acetylcholine, as described above, was assessed.  
To assess the effect of glucose (30mM) and insulin (1.2nM) on vascular function, maximal PE 
constriction responses (Emax) were assessed in a separate cohort of aortic rings following incubation 
with glucose and insulin for 2 hours. Experiments were also carried out in the presence of 100µM 
Nω-Nitro-L-arginine methyl ester (L-NAME). The results were analysed manually on the 
PowerLab Chart 5.0 (AD Instruments, UK) software by taking the plateau tension reading after 
each addition of either PE, ACh or SNP. All dose response curves were generated in GraphPad 
Prism 6.0 software using four parameter variable slope nonlinear regression curve fitting and the 
EC50 and Emax were determined. The PE contraction results were expressed in grams of tension 
and the ACh and SNP relaxation results were expressed as a percentage of the pre-contraction to 
PE. 
2.11 Measurements of fasting plasma lipids and insulin 
Plasma triglyceride, NEFA, total cholesterol and HDL levels from fasted NCD and HFD 
Nox2/ApoE double knockout mice (16 weeks old) were determined by using enzymatic 
colorimetric kits using the ILab 650 Chemistry Systems. Low density lipoprotein levels were 
calculated as LDL=TC-HDL-(TG/2.17) based on Friedewald equation (Friedewald et al., 1972). 
Insulin levels were measured in NCD and HFD ApoEKO and Nox2/ApoE D-KO mice. Insulin 
resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-
IR) by multiplying fasting insulin (μg/L) with fasting glucose (mmol/L) and then dividing by the 
constant 22.5. For measurement of plasma insulin, the supernatant plasma was subjected to the 
mouse insulin enzyme-linked immunosorbent assay kit (ELISA) (Mercodia Developing Diagnostic, 
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Sweden). The blood that was collected for these metabolic measurements was spun at 6000 rpm in 
a microcentrifuge for 15 minutes at 4°C and then the mouse serum was collected and transferred 
into 1.5 ml eppendorf tubes and kept at -80
o
C until required for analysis.  
2.11.1 Insulin ELISA 
The kit uses a direct sandwich technique where two monoclonal antibodies are directed against 
separate antigenic determinants on the insulin molecule. Insulin in the mouse serum sample reacts 
with anti-insulin antibodies bound to the bottom of the microplate wells and with peroxidase-
conjugated anti-insulin antibodies. The insulin bound peroxidase-conjugate is detected by reaction 
with its substrate 3,3’,5,5’-tetramethylbenzidine (TMB) which produces a blue reaction product. 
The reaction is then stopped by adding acid which gives a colorimetric endpoint with a yellow 
reaction product that can be measured by spectrophotometry at 450nm.  
Calibrators and samples (10µl) were added in duplicate to a 96 well plate coated with anti-insulin 
antibodies and 100µl of enzyme conjugate solution was added to each well. The plate was 
incubated at room temperature for 2 hours with orbital shaking (800rpm). The plate was then 
washed 6 times with 300µl of wash buffer before 200µl of the substrate TMB was added to each 
well. The plate was incubated for 15minutes at room temperature and then 50µl of stop solution 
containing 0.5M H2SO4 was added. The plate was briefly placed back on a shaker to ensure mixing 
before the optical density was measured at 450nm using a spectrophotometer (MBA 2000, Perkin 
Elmer). The concentration of insulin was calculated in GraphPad Prism 6.0 using cubic spline 
regression. 
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2.12 Griess Assay 
Griess assay (Tsikas, 2007) (Tsikas D, 2007) is the most commonly used indirect method for 
measuring NO. Nitric oxide has a half-life of less than 30 seconds, and reacts rapidly with free 
oxygen, oxygen radicals, redox metals, sulphydryls, disulfides and oxygenated haemoglobin. The 
stable degradation products of NO, nitrite (NO2
-
) and nitrate (NO3
-
) accumulate in solution can be 
measured using the Griess reaction. The detection range of the technique is in the micromolar area 
(1-100μM) and the concentrations of nitrite and nitrate can be assessed as an index of NO 
production. The Griess reaction is based on the two-step diazotization reaction in which acidified 
NO2
-
 produces a nitrosating agent which reacts with sulfanilic acid to produce the diazonium anion. 
This ion is then coupled to N-(1-naphthyl) ethylenediamine to form the chromophoric azo-
derivative which absorbs light at 540nm.   
The Greiss reagent kit (Molecular Probes, Eugene, OR) for nitrite determination was used to 
determine the NO levels in Nox2/ApoE D-KO NCD and HFD fasting serum samples respectively 
(16 weeks old). Also, NO has been measured in WT, Nox2KO, ApoEKO and Nox2/ApoE double 
knockout supernatants stimulated with high glucose and insulin (see Chapter 4). The concentrations 
of nitrite were determined by comparison to a standard curve, constructed using sodium nitrite 
ranging from 0-100μM. Briefly, 20μl of Griess reagent with 150μl of supernatants or serum 
samples (25μl of serum sample diluted in 125μl of deionised water) and 130μl of deionised water 
were added to a 96 well plate. Serial dilutions were performed to create 10 sodium nitrite standards 
ranging from 0-100μM. The plate was then incubated for 30 minutes at room temperature before 
the absorbance was measured at 540nm using a spectrophotometer (MBA 2000, Perkin Elmer). The 
concentration of nitrite (nitric oxide) in serum samples was calculated from the standard curve.  
88 
 
2.13 Homogenisation 
In the result section, for the HFD study of Nox2/ApoE D-KO mice, tissues were frozen in liquid 
nitrogen and ground to a fine powder by the use of a chilled mortar and pestle.  Next the tissue was 
suspended in pre-cooled Hank’s Balanced Salt Solution (HBSS; 200μl) containing 50mM sodium 
fluoride and 1X concentration protease inhibitor cocktail (1:500; Sigma) to protect proteins from 
proteolysis during purification from animal tissues. The suspension was homogenised with an 
ergonomic handheld homogeniser (Polytron, Kinematica Ltd, UK) on ice (3x/1min) to prevent 
protein denaturation. The homogenate was inspected at the end of the homogenisation and if intact 
tissue was still apparent, an additional 1-2 round of re-homogenisation was applied.  
2.15 Sonication 
To disrupt the cell membrane and release cellular components an ultrasonic processor (VC130PB, 
Sonics & Materials Inc, USA) at half of maximal amplitude was used. Cells are disrupted by high-
frequency sound waves via a probe inserted in the sample. The sound waves generate a region of 
low pressure, causing disruption of the membrane of cells in the vicinity of the probe tip. Cells 
suspensions were sonicated in short bursts to avoid heating and samples were cooled on ice 
between bursts. Sonication was performed 2 times for 20 seconds bursts with 1 minute intervals on 
ice in a cold room (4°C).  
2.16 Total Protein Concentration Measurement using Bradford Protein 
Assay 
The protein concentrations were determined by the Bradford Protein Assay Kit (Bio-Rad) which 
uses the colorimetric assay principle. This assay is based on changes in absorbance produced by the 
reaction between Coomassie Brilliant Blue G-250 dye and it’s binding to proteins, which shifts its 
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colour from red to blue, depending on protein concentration. This change in colour occurs during 
the formation of a complex between the dye and the protein. The Bradford reagent passes a free 
proton to the ionic groups found in proteins, which opens their tertiary structure. This positions the 
positive amine groups of the proteins in proximity to the negative charge of the dye. These changes 
in protein charge increase the ionic interaction, which stabilises the blue form of Coomassie 
Brilliant Blue G-250, so that the intensity of the colour can be used to measure protein 
concentration in a linear fashion by reading absorbance. The absorbance peak of Coomassie 
Brilliant Blue G-250 solution shifts from 470nm to 595nm when dye protein binding occurs under 
acidic conditions. The change of absorbance at 595nm is proportional to the amount of the dye-
protein complex, and thus to the amount of protein present in the solution. The more intense is the 
blue colour, the higher is the protein concentration (Bradford, 1976). Under strongly acidic 
conditions, the dye is most stable in its double protonated form (red). Upon binding to protein, 
however, it is most stable in an unprotonated form (blue). 
The tissue homogenates were diluted with HBSS if the volume did not lay in the standard curve 
values. A 1:5 dilution of the Bio-Rad protein assay dye reagent (200μl) was prepared by mixing 
with Milli-Q water (800μl) in a total volume of 1ml. 2μl of tissue homogenate was then added to 
the mixture and thoroughly mixed using a vortex. The protein concentration (μg/ml) of each sample 
was measured at 595nm wavelength by the use of spectrophotometer (Perkin Elmer, UK). The 
protein concentration was calculated from the absorbance value using a standard curve created 
using known concentrations of bovine serum albumin (BSA). Tissue homogenates were then used 
for lucigenin chemiluminescence (section 2.17) and for western blotting (section 2.19). 
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2.17 Lucigenin-enhanced chemiluminescence assay for detection of 
superoxide 
Lucigenin (5μmol/L)-enhanced chemiluminescence (BMG Lumistar, Germany) was used to assess 
NADPH-dependent superoxide production (O2
.-
) in organ homogenates (heart, aorta, lung, liver, 
kidney, spleen, pancreas, epididymal fat, muscle and brain tissues) in a 96-well microplate 
luminometer. The monitor system consists of a lightproof box, a photon multiplier, and a photon 
counter. Lucigenin, an acridylium dinitrate compound that emits light on reduction and interaction 
with superoxide anion, was used to measure the production of superoxide. The relevant reactions of 
the assay are as follows (O2
.-
 Superoxide Anion; LC Lucigenin; LCO2 Lucigenin Dioxetane): 
 
O2
.-
 + LC
.2+
 → LC.+ + O2 
LC
.+
 + O2
.-
 → LCO2 
LCO2 → 2N-methylacridone + h (light) 
Lucigenin (bis-N-methylacridinium) is first reduced by one electron to produce the lucigenin cation 
radical. Superoxide then reduces this cation radical to produce lucigenin dioxetane, which 
decomposes creating two molecules of N-methylacridone, one of which is in the excited state and 
emits light as it relaxes to its ground state (Guzik and Channon, 2005).  
The flux of photons (h) emitted is measured in terms of lucigenin-enhanced chemiluminescence 
intensity and taken as superoxide anion levels.  
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2.17.1 NADPH Activity Measurement 
The lucigenin-enhanced chemiluminescence assay was used to determine the NADPH oxidase 
activity in organ homogenates as previously described (Li et al., 2007). After homogenisation, 
sonication and measurement of the protein concentration a 96-well microplate was prepared. The 
appropriate volume of organ homogenates containing 50μg total protein was added to each well of 
a 96-well microplate and made up to 140μl with lucigenin buffer. The 96-well plate was 
immediately placed in the luminometer to allow the auto-dispenser to add 40μl of lucigenin 
solution (5μM of lucigenin solution was made using lucigenin buffer). It has been suggested that 
lucigenin itself, especially at high concentrations (50μM), may act as a source for superoxide via 
redox cycling (Munzel et al., 2002). Lower lucigenin concentrations (5μM) do not participate in 
redox cycling to an important extent in intact tissues and, therefore, provide an accurate assessment 
of the rate of superoxide production in such samples (Munzel et al., 2002). To obtain a basal 
reading, omitted light was recorded for 10 cycles with 3 seconds intervals per well.  Then 20μl of 
NADPH solution (1mM of NADPH solution was made using lucigenin buffer) was added manually 
to each well using an auto-pipette. The total reaction volume was 200μl with final concentration of 
5μM of lucigenin and 100μM of NADPH. NADPH dependent superoxide production 
measurements were taken at 37°C every 3 seconds intervals per well and a total of 21 cycle 
readings were recorded. Light emission was recorded in a tube luminometer and expressed as mean 
arbitrary light units/min (MLU/min). All measurements were made in duplicate. The specificity of 
O2
.-
 was also confirmed by the addition of tiron (10mmol/L), which is a non-enzymatic O2
.-
 
scavenger. 
To investigate the enzymatic sources of superoxide utilising NADPH as a substrate, 50µg of total 
protein from tissue homogenates was incubated in a 96 well plate with the following inhibitors: 
50µM mitochondria inhibitor rotenone, 100µM xanthine oxidase inhibitor oxypurinol, 100µM 
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NOS inhibitor L-NAME, 20µM flavoprotein inhibitor diphenyleneiodonium (DPI), 10mM 
superoxide scavenger tiron and 100µM Nox2 inhibitor apocynin. After a 10 minute incubation 
period lucigenin chemiluminescence was performed as described above. The concentrations of the 
inhibitors that have been used in this thesis have been determined from dose response curves from 
our group. The dose response curves created by placing incremental concentrations of these 
inhibitors were compared using the I50 parameter, which is the concentration resulting in a 50% 
reduction. 
2.18 In Situ Dihydroethidium (DHE) Staining  
Dihydroethidium (DHE; also called hydroethidine) is a cell-permeable compound that has been 
used for the detection and imaging of intracellular superoxide levels in several studies. DHE itself 
its blue fluorescent in cell cytoplasm while the oxidised form ethidium is red fluorescent upon 
DNA intercalation. Upon entering the cells DHE interacts with O2 
.-
 to form 2-hydroxyethidium 
which in turn interacts with nucleic acids (DNA) to emit a bright red colour detectable by 
fluorescent microscopy. Frozen samples of ApoEKO and Nox2/ApoE D-KO NCD and HFD aorta 
or WT, Nox2KO, ApoEKO and Nox2/ApoE D-KO aortas stimulated with high glucose and insulin 
were prepared as in section 2.8 and 10μm cryosections were cut on a cryostat (Bright Instrument 
Company, UK) and thaw mounted onto superfrost plus slides (VWR, UK). The slides were washed 
with pre-warmed 37
o
C DHE buffer (HBSS with 50µM MgCl2) 100μl/section and dried by tapping 
off the excess buffer and wiping edges with tissue. Then 20µl of DHE buffer was added to each 
section and the slide was incubated in a humidified chamber at 37
o
C for 10-15 minutes. Finally, 
10µl of DHE stain (0.5µM in DHE buffer) was added to each section and was incubated at 37
o
C for 
5 minutes in the dark. Sections were immediately viewed under an Olympus BX61 fluorescent 
microscope (Olympus, UK) (excitation 530-560nm and emission 575-650nm) and images were 
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taken at 20x magnification. Images were quantified using Simple PCI imaging software 
(Hamamatsu, USA).  
2.19 Detection of ROS Production by DHE Fluorescence Microplate 
The detection of HFD-induced ROS production in epididymal fat pads of WT, Nox2KO, ApoEKO 
and Nox2/ApoE D-KO mice fed with NCD and HFD or WT and Nox2-Tg mice at the age of 3-4 
month and 15-17 month was assessed by DHE fluorescence in a microplate assay (Fernandez et al., 
2007). The Nox2-Tg epididymal fat pads were kindly given from Professor Channon’s group 
(Oxford University). DHE reacts with superoxide to form the highly fluorescent 2-OH-E, which 
can be detected by fluorescence using a black 96-well plate, in a similar way to lucigenin 
chemiluminescence. Epididymal fat pads were homogenised as described in section 2.14. The 
appropriate volume containing 50μg protein was added to each well and the volume adjusted to 
140μl with lucigenin buffer. Prior to beginning the assay, NADPH (100μΜ) and DHE (10μM) 
were added followed by incubation in the dark for 30 minutes at room temperature. To measure 
DHE ROS production, the fluorescence (excitation at 495nm and emission at 580nm) was 
measured using a fluorescence adapted microplate reader (Victor 3; Perkin-Elmer). The resultant 
fluorescent intensities were exported to Microsoft Excel and results expressed as mean 
fluorescence intensity (MFI) over 30 minutes, following correction for DHE only blank readings. 
2.20 Immunoblotting  
Immunoblotting, also known as western blotting, is a well-established and widely used technique 
for the detection and analysis of proteins expression and investigation of signalling pathways 
activation. For western blotting, aorta and epididymal fat tissue homogenates were prepared by 
homogenisation and sonication as previously described (see section 2.12 and 2.13), with total 
protein concentration of each sample determined using the Bradford assay (see section 2.16). 
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Samples containing equal protein concentration (30-40μg) were prepared by adding 3x sample 
buffer containing 2-mercaptoethanol (2-ME) and diluting in an appropriate volume of assay buffer, 
followed by boiling at 95°C for 5 minutes (see table 2.8).  
Table 2.8: Sample Buffer 
 
 
 
 
 
 
Add 60µl 2-Mercaptoethanol (2-ME) to 940µl buffer before use. 
To prepare samples for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
separation, Mini-Gels were prepared using the Bio-Rad Mini-protein II
TM
 (Bio-Rad, UK) apparatus 
according to the manufacturer’s instructions. The SDS-PAGE relied on two-phases, a resolving gel 
of 10% acrylamide overlaid with a stacking gel of 5% acrylamide (see table 2.9).  
 
 
 
 
Reagent  Volume/Weight 
1M Tris-HCl pH 6.8 30ml 
SDS 6g 
100 % Glycerol 30ml 
H2O 40ml 
Bromophenol blue 50mg 
Vt 300ml 
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Table 2 9: Gel and buffer recipes 
 
Table 2.9.1 10% Resolving/Separating Gel 
 
 
 
 
 
 
 
 
Abbreviations: APS: Ammonium Persulfate; TEMED: Tetramethylethylenediamine. 
Table 2.9.2 5% Stacking Gel 
 
 
 
 
 
 
 
 
 
Abbreviations: APS: Ammonium Persulfate; TEMED: Tetramethylethylenediamine 
 
 
Reagent  Volume for 2 gels 
H2O 4.8ml 
1.5M Tris pH 8.8 2.5ml 
10% SDS  100µl 
40% Acrylamide 2.5ml 
10% APS 100µl 
TEMED 4µl 
Reagent   Volume for 2 gels 
H2O 3.64ml 
1M Tris pH 6.8 630µl  
10% SDS  50µl 
40% Acrylamide 625µl 
10% APS 50µl 
TEMED 5µl 
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30-40μg of total protein from prepared samples were loaded into each well in a total volume of 10-
12μl. 5μl of rainbow molecular marker (Lonza) was used as well to monitor electrophoretic 
mobility and calculate the molecular weight of target-proteins  The gels were run at 90V for 30 
minutes followed by 120V for 90 minutes in ice cold 1X SDS running buffer until the loading dye 
(blue front on the gel) was near to running off (see table 2.10).  
Table 2.10 Running Buffer 
 
 
 
 
 
The SDS-PAGE separated samples within the gel were next prepared for membrane transfer and 
western blot. The separated proteins were transferred from the gel onto a Millipore Immobilon-P 
Polyvinylidene Difluoride (PVDF) membrane using a Bio-Rad Semi-Dry Transfer Cell (Bio-Rad, 
UK). Filter papers (Whatman, UK) were soaked in transfer buffer (see table 2.11) for 10-15 
minutes and the PVDF membrane was soaked in methanol for 30 seconds then in water for 2 
minutes and finally in transfer buffer with no SDS for 10 minutes.  
 
 
 
Reagent  Volume/Weight 
Tris-Base 6g 
Glycine 29g 
10% SDS 10ml 
Vt Up to 1L with H2O 
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Table 2.11 Transfer Buffer 
Reagent  Volume/Weight 
Tris-Base 3.75g 
Glycine 18g 
10% SDS 0.01% (0.1g/L; for filter paper only) 
98% Methanol 250ml 
Vt Up to 1L with H2O 
 
The transfer ‘sandwich’ was prepared by stacking the PVDF membrane with the resolving gel on 
top between two layers of rectangular filter papers (five either side). The semi-dry transfer process 
was run at 15V for 1 hour. After transfer of proteins to the PVDF membrane, non-specific protein 
binding was blocked with 5% non-fat milk in TBST buffer (1X TBS (see table 2.12) with 0.1% 
Tween 20) for 1 hour at room temperature with orbital shaking.  
Table 2. 12: 10X Tris-Buffered Saline (TBS) with or without Tween-20 
 
 
 
 
 
 
Reagent  Weight 
Tris/Base  30g 
NaCl 88g 
KCl 2g 
Tween-20  1ml (for TBST) 
Vt Up to 1L with H2O  (pH to 7.4) 
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The membrane was then incubated with primary antibody diluted to its optimal concentration with 
2.5% non-fat milk in 1X PBS (see table 2.13) at 4
o
C overnight with orbital shaking.  
Table 2.13: 10X Phosphate Buffered Saline (PBS) 
 
 
 
 
 
 
The following day the membrane was left shaking at room temperature for 1 hour before being 
washed with 1X TBST for 10 minutes then 1X TBS for 10 minutes and finally 1X PBS for 10 
minutes. After washing, the membrane was incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody diluted to its with 2.5% non-fat milk in 1X PBS for 120 minutes at 
room temperature with orbital shaking. Following another set of 10 minute washes with TBST, 
TBS and PBS the membrane was exposed to Clarity Western Enhanced Chemiluminescence Plus 
ECL
plus Substrate (GE Healthcare) made up following the manufacturer’s instructions (1:1 
dilution). The images were captured digitally using a BioSpectrum AC imaging system (UVP, 
Cambridge, UK), and the optical densities of the protein bands were normalised to the loading 
control α-tubulin and quantified. Sixty images were captured in 20 min of exposure. 
Reagent  Weight 
NaCl  80g 
Na2HPO4 14.4g 
KH2PO4 2.4g 
KCl 2g 
Vt Up to 1L with H2O (pH to 7.4) 
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Figure 2.7: Representative western blot image of C57BL/6 WT and Nox2-Tg mouse 
epididymal fat pad homogenates stained with p-p38 antibody. 
 
2.21 Immunofluorescence Microscopy 
The relative expression and cellular location of proteins of interest were investigated by indirect 
antibody labelling immunofluorescence.  
Frozen samples of ApoEKO and Nox2/ApoE D-KO NCD and HFD aorta were prepared (see 
Chapter 3) as in section 2.8 and sections of aorta (10µm) were cut on a cryostat (Bright Instrument 
Company, UK) and thaw mounted onto superfrost plus slides. Frozen samples of WT, Nox2KO, 
ApoEKO and Nox2/ApoE D-KO aortas stimulated with high glucose and insulin were also 
prepared and cut (see Chapter 4). The sections were fixed in chilled 50% methanol/50% acetone 
solution for 9 minutes at room temperature and then fan dried for 10-15 minutes before being 
stored at -80
o
C until ready for further use. Slides were removed from the -80
o
C freezer and were 
fan dried at room temperature for 10-15 minutes.  
15-17
month
15-17
month
3-4 
month
PM 3-4
month
Nox2-TgWT
250
150
100
50
75
37
25
20
15
100 
 
For Chapter 5 the paraffin sections (20μm) of the fixed WT, Nox2KO, ApoEKO and Nox2/ApoE 
D-KO NCD and HFD epididymal fat tissue were transferred to superfrost plus slides. After 
deparaffinisation and rehydration to buffer in a graded series of alcohol (100, 70 and 50% 
respectively), the sections were prepared for immunofluorescence.  
Sections (either frozen or paraffin) were then washed in ice cold 1X PBS (see table 2.13) prior to 
blocking. Blocking of nonspecific binding was performed with 2% BSA and 0.5% Triton X-100 
diluted in 1X PBS (50µl per section) for 30 minutes at room temperature in a humidified dark box. 
After blocking, the sections were washed twice in ice cold 1X PBS for 5 minutes each. Primary 
antibodies (1:100 dilution; 30µl per section) diluted in 0.2% BSA/1X PBS were incubated with the 
sections in a humidified chamber for 1 hour at room temperature. The antibody was drained from 
the slides which were then rinsed and washed three times/ 5 minutes each in ice cold 1X PBS. 
Biotin-conjugated anti-goat or anti-rabbit IgG (1:250 dilution; 30µl per section) diluted in 
BSA/PBS under the conditions reported above were used as secondary antibodies. Sections were 
incubated for 30 minutes at room temperature. Then, the sections were washed once again in the 
same way as above and specific binding was detected by streptavidin-Cy3 (Carbocyanine 3) or 
extravidin-FITC (fluorescein isothiocyanate) diluted (1:500 dilution; 30µl per section) in PBS/BSA 
(this part and the rest of the experiment was carried out in the dark). Sections were incubated for 30 
minutes at room temperature. In the last 5 minutes of the extravidin-FITC incubation 10µl of 1X 
DAPI (4',6-diamidino-2-phenylindole) was added to each section and incubated for the remaining 5 
minutes. The extravidin-FITC and DAPI was drained from the slides which were then rinsed and 
washed 3 times in ice cold 1X PBS. Slides were then briefly immersed in distilled water to wash 
away any salt. Then 50µl antifade solution (9:1 Mowiol: 0.1% p-phenylenediamine) was added to 
each section and a coverslip was gently placed over the top. Slides were stored at 4
o
C overnight 
and images were taken the next day.  
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Images were acquired with an Olympus BX61 fluorescent microscope (Olympus, UK) equipped 
with an argon UV lamp to investigate Cy3 (streptavidin; excitation/emission: 530-560/575-650nm), 
FITC (extravidin; excitation/emission: 470-495/510-550nm) and DAPI (excitation/emission: 360-
370/420-460nm) localisation. Images were captured at 20x magnification and exported as 48-bit 
overlaid Tiff image with pseudo colour from the Simple PCI imaging software (Hamamatsu, USA). 
Imaging exposure was kept constant throughout the capturing process between samples. Images 
were imported into Adobe
TM
 Photoshop (CS9, Adobe, UK) and analysed for fluorescent intensities 
and investigation of cellular location.  
2.22 Immunohistochemistry 
WT, Nox2KO, ApoEKO and Nox2/ApoE D-KO epididymal fat tissues were fixed in 10% formalin 
for 3 hours at room temperature. They were then processed for paraffin embedding, and cut into 
20μm sections using a microtome (see section 2.9). Firstly, antigen retrieval was performed in 1X 
proteinase working solution for 10 minutes. After incubation, the sections were washed once for 10 
minutes in 1X PBS. Then the epididymal fat sections were incubated with 3% hydrogen peroxide 
in methanol for 10 minutes to block endogenous peroxidase activity and then washed once for 10 
minutes in 1X PBS. After inactivation of endogenous peroxidase blocking was performed with 5% 
bovine serum albumin containing 1% triton X-100 for blocking nonspecific binding of antibodies. 
The sections were incubated with goat anti-UCP1 polyclonal antibody, and this was diluted 1:100 
in 1X PBS. The sections were incubated overnight at 4°C. After three washes in 1X PBS (10 
minutes each), the sections were incubated with horseradish peroxidase-conjugated secondary 
antibodies anti-goat/ (1:250) for 45 minutes at room temperature. The sections were washed three 
times in 1X PBS (10 minutes each) and then incubated with NovaRed substrate for 8 minutes. The 
sections were finally dehydrated, cleared, counterstained with haematoxylin, and cover slipped. 
Images were taken using an EVOS microscope. 
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2.23 Oil Red O Staining 
Oil Red O is a lysochrome diazo dye used for histological visualisation of neutral lipids in tissue. 
Oil Red O was used to stain frozen liver sections of NCD and HFD WT, Nox2KO, ApoEKO and 
Nox2/ApoE D-KO mice to identify accumulation of lipids. Working solution of Oil Red O was 
prepared by mixing 5% Oil Red O dye into isopropanol with distilled water. Quantifying stained 
liver tissue area using Image J. 
2.24 Haematoxylin and Eosin Staining  
Haematoxylin and Eosin (H&E) staining is a widely-used staining method used to investigate the 
structure of biological tissues. H&E was used for analyses of epididymal fat tissues. Haematoxylin 
gives a purplish blue stain to basophilic structures, such as nuclei, ribosomes and rough 
endoplasmic reticulum due to their content of DNA and RNA, respectively. Staining with 
haematoxylin was done in conjunction with the use of eosin/azophloxin which is an acidic dye that 
stains eosinophilic structures, such as most cytoplasmic proteins, pinkish red.  
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Table 2.14 Haematoxylin and Eosin Staining Protocol 
 
Solution Time Comments 
Xylene 3min De-wax 
Xylene 1min De-wax 
100% alcohol 1min Rehydration 
70% alcohol 1min Rehydration 
50% alcohol 1min Rehydration 
d-H2O 1min Rehydration 
Haematoxylin 15min Nuclear Stain (solution is soluble and coloured red) 
Running tap water 1min Rinse 
1% acid alcohol 5-10sec Differentiation (decreases haematoxylin binding) 
Running tap water 8min Alkaline hard water ‘blues’ the haematoxylin stain 
1% eosin 2min Cytoplasmic Stain 
Tap water Rinse Rinse 
85% alcohol 0.5min Dehydrate 
100% alcohol 0.5min Dehydrate 
100% alcohol 0.5min Dehydrate 
Xylene 0.5min Clearing  
Xylene 3min Clearing 
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2.25 Statistical Analysis 
Comparisons were made by either a one-way or two-way ANOVA followed by a Bonferroni post-
hoc test (compare more than two means), or by an unpaired Student’s t-test (compare two means) 
where appropriate using GraphPad Prism 6.0 software. Data are expressed as mean ± SEM with 
p<0.05 denoting statistical significance. Sample size and details of which statistical method was 
used are presented in the figure legends of each figure.  
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Table 2.15 Appendix table I: Details of materials and reagents 
 
Reagent Supplier Catalogue 
Number 
100bp DNA ladder G2101 Promega 
2-Mercaptoethanol M7154 Sigma 
Acetone A/0606/17 Fisher Scientific 
Acetylcholine A6625 Sigma 
Acrylamide BPE1410-1 Fisher Scientific 
Agarose BP1356-500 Fisher Scientific 
Ammonium Persulfate (APS) A9164 Sigma 
Bio-Rad Protein Assay Reagent 500-0006 Bio-Rad 
Bovine Serum Albumin A2153 Sigma 
Bromophenol blue 161-0404 Bio-Rad 
CaCl2 C5670 Sigma 
Clarity Western ECL Substrate 170-5061 Bio-Rad 
D (+) Glucose G-7021 Sigma 
DAPI D9542 Sigma 
Dihydroethidium (DHE) D11347 Invitrogen 
Diphenyleneiodonium Chloride 
DMEM (Normal Glucose) 
D2926 
D5546 
Sigma 
Sigma 
dNTP mix (dATP, dGTP, dCTP, dTTP) 
ECL
PLUS
 Reagent 
U120A, U121A, U122A, U123A 
N/A 
Promega 
GE Healthcare 
EDTA D/0700/53 Fisher Scientific 
ELISA Kit 10-1247-01 Mercodia 
Ethanol E/0650DF/17 Fisher Scientific 
Ethidium Bromide E8751 Sigma 
Extravidin-FITC E2761 Sigma 
Gelatin G1393 Sigma 
Glycerol G5516 Sigma 
Glycine G/0800/60 Fisher Scientific 
GoTaq Green Flexi Buffer M891A Promega 
GoTaq Hot Start Polymerase M500A Promega 
Griess Assay Kit G-7921 Invitrogen 
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Haematoxylin H9627 Sigma 
HBSS Buffer 14175-137 Invitrogen 
Isopentane P/1030/17 Fisher Scientific 
KCl P3911 Sigma 
KH2PO4 P/4800/53 Fisher Scientific 
L-NAME N5751 Sigma 
Lucigenin B49203 Sigma 
Methanol M/4056/17 Fisher Scientific 
MgCl2 M8266 Sigma 
MgSO4 M7506 Sigma 
PVDF membrane P2813 Sigma 
Mowiol 4-88 81381 Sigma 
Na2HPO4 S/4520/53 Fisher Scientific 
NaCl S/3120/65 Fisher Scientific 
NADPH N7785 Sigma 
NaF S7920 Sigma 
NaH2PO4 71500 Sigma 
NaHCO3 S5761 Sigma 
Non-fat milk - Marvel 
Nonidet P-40 - Sigma 
OCT Compound KMA-0100-00A CellPath 
Oxypurinol O4502 Sigma 
Paraformaldehyde P6148 Sigma 
Phenylephrine Hydrochloride P6126 Sigma 
P-phenylenediamine P6001 Sigma 
Protease Inhibitor Cocktail P8340 Sigma 
Protein marker 161-0374 Bio-Rad 
Proteinase K 03 115 836 001 Roche 
Rotenone R8875 Sigma 
Sodium dodecyl sulphate (SDS) 71725 Sigma 
Sodium nitroprussidedihydrate S/5720/48 Fisher Scientific 
Pentoject (Sodium pentobarbital) 57-33-0 Animalcare 
Sodium Thiosulphate 72049 Sigma 
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Streptavidin-CY3 S6402 Sigma 
TEMED 87689 Sigma 
Tiron 89460 Sigma 
Tris Acetate T1258 Sigma 
Tris Base T/3710/60 Fisher Scientific 
TrisHCl T5941 Sigma 
Triton X-100 X100 Sigma 
Tween-20 BPE337 Fisher Scientific 
Xylene 534056 Sigma 
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CHAPTER 3 
Effects of Nox2 on Vascular and Metabolic Phenotype in 
Nutritional Obesity and Hypercholesterolaemia 
3.1 Introduction 
In this chapter the effect of obesity and Nox2-induced ROS production in respect to metabolic 
parameters, vascular dysfunction and insulin resistance was explored. In addition to this, Nox2 
intracellular cascades were also examined. More specifically MAPK and Akt/eNOS pathway 
activation, IR expression, endothelial cell activation and macrophage recruitment were determined.  
Increased production of ROS in the vascular wall is a hallmark of vascular disease states including 
type-2 diabetes, hypertension and atherosclerosis (Cai and Harrison, 2000). Excessive generation of 
ROS, particularly superoxide, is thought to be an important mediator of atherosclerotic initiation by 
causing increased oxidative stress, recruitment of inflammatory cells, and endothelial dysfunction. 
It has been also shown that the superoxide anion is mainly released by the endothelium at the early 
stages of hypercholesterolaemia, and then contributes to the early atherosclerotic process (Collin et 
al., 2007). Nox2-derived ROS has an important role in vascular disease pathogenesis. It has been 
strongly associated with experimental hypertension, cardiac hypertrophy, thrombosis, restenosis 
and atherosclerosis (Vendrov et al., 2007). Both Nox2 and Nox4 have been shown to be localised 
within the plaque of diseased human coronary arteries (Lassègue and Griendling, 2010; Sorescu et 
al., 2002). However, only Nox2 has been shown to be up-regulated during atherosclerosis (Judkins 
et al., 2010; Guzik et al., 2006). 
It is well-known that Nox2 is mostly expressed in the endothelium and adventitia (Du et al., 2013; 
Görlach et al., 2000), although Nox2 was also detected in intima VSMCs of human aorta, and the 
proportion of these cells that expressed Nox2 increased from 28 to 68% according to the severity of 
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the atherotic lesions (Kalinina et al., 2002). However, Nox2 was not up-regulated during the early 
stage (Szöcs et al., 2002) of the disease as might be expected, since the early development of 
vascular lesions is characterised by proliferation of cells related to VSMCs, which do not express 
Nox2 in either culture or arterial media (Kalinina et al., 2002). Barry-Lane et al. (2001) provided 
evidence that p47
phox
 (a regulatory subunit necessary for the activation of both Nox1 and Nox2) is 
required for VSMC proliferation in ApoEKO mouse aorta, which is an important event in the 
atherosclerotic lesion formation. Therefore, Nox2 may have a role in lesion development because 
ROS formation in the endothelium has been implicated in expression of chemotactic and adhesion 
molecules, leading to recruitment of monocytes from the circulation. Also, extracellular release of 
ROS by the adventitia may enhance smooth muscle proliferation via a paracrine effect and 
inactivate NO (Stenmark et al., 2011).  
Furthermore, it has been demonstrated that p22
phox
 is associated with coronary risk. This peptide is 
known to complex with gp91
phox
 to form cytochrome b558, a key component of phagocytic Nox2; 
p22
phox
 is highly expressed by endothelial cells, VSMCs, and macrophages associated with 
complex coronary atherosclerotic lesions, with little or no expression by SMCs of normal coronary 
arteries (Kalinina et al., 2002). Inoue et al. (1998) and Cahilly et al. (2000) have shown that 
polymorphism of the gene p22
phox
 (C242T), which is involved in maintaining the redox state in the 
vessel wall, is associated with risk of coronary atherosclerosis and Azumi et al. (1999) have 
demonstrated elevations in the expression of p22
phox
 within severe human coronary lesions. 
Previous studies investigating the role of Nox2 in the development of atherosclerosis have 
produced mixed results with initial studies of global Nox2 (Kirk et al., 2000) and p47phox (Hsich 
et al., 2000) knockout mice showing no difference in atherosclerosis in the aortic sinus. Kirk et al. 
(2000) using Chronic Granulomatous Disease (CGD)/ApoE D-KO mice – which lack both the 
gp91
phox
 subunit and apolipoprotein E -  showed that ROS generated by phagocyte Nox2 does not 
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promote atherosclerosis in mice with either diet-induced or genetic forms of 
hypercholesterolaemia. Also, Hsich et al. (2000) and Vendrov et al. (2007) showed using 
p47
phox
/ApoE D-KO mice that the absence of p47
phox
 does not significantly affect the progression 
of atherosclerosis in the standard mouse ApoEKO model. However, other studies have shown that 
global knockout of p47
phox
 in ApoEKO mouse model results in a significant decrease in aortic 
lesion formation in the descending aorta in both NCD and HFD animals without altering serum 
lipid content (Barry-Lane et al., 2001), and that global Nox2 deletion results in a significant 
decrease in descending aortic lesion burden in hyperlipidaemic mice (Judkins et al., 2010). 
Moreover, in animal models of surgical vascular injury or high cholesterol diet, Nox2 is 
significantly up-regulated, at least during the chronic phase of the disease, even in the absence of 
inflammation (Collin et al., 2007; Lassègue and Clempus, 2003). Similarly, in human vessels Nox2 
expression is correlated with lesion severity (Guzik et al., 2006; Lassègue and Clempus, 2003), 
although part of the effect derives from macrophage infiltration in advanced lesions. Overall, these 
results favour a causal role of Nox2 in atherosclerosis. 
 MAPK activation, in particular ERK1/2 phosphorylation has been reported in the vasculature of 
animals suffering from dietary obesity and insulin resistance (Kim et al., 2008) as well as in 
endothelial cells isolated from patients with type-2 diabetes (Gogg et al., 2009). ROS promote the 
phosphorylation and activation of various kinases such as ERK1/2 and p38 (Markou et al., 2011). 
In respect to ERK1/2 it was found that ROS production caused ET-1 increase through ERK1/2 up-
regulation (Kubin et al., 2011). In addition oxidative modification of Ras, a major component of 
the ERK1/2 pathway, activates Ras and the whole (MAPK/ERK) cascade (Lander et al., 1997). 
Since MEK1/2 (MAPK/ERK kinase 1/2) inhibitors can suppress ROS-mediated ERK1/2 activation 
(McCubrey et al., 2007) ROS might act indirectly at the level of MEK1/2 or by inhibiting 
phosphatases like mitogen-activated protein kinase phosphatase (MKP3). Evans et al. (2002) 
demonstrated that hyperglycemia and FFA-induced activation of p38 and MAPK play a key role in 
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causing late complications in type-1 and type-2 diabetes, along with insulin resistance and impaired 
insulin secretion in type-2 diabetes. 
As far as insulin receptor is concerned, it was found that IR expression was decreased in tissues 
that are involved in energy homeostasis (liver, skeletal muscle, and adipose tissue) and has been 
shown to correlate with insulin resistance (Boden et al., 1994), whereas Wigand and Blackard 
(1979) demonstrated reduced IR expression in obese men. In a previous study using HFD WT and 
Nox2KO mice it was demonstrated that obesity reduced significantly the expression of IR in the 
aortas of WT mice. Reduced IR expression was due to Nox2-derived oxidative stress and insulin 
resistance because inhibition of Nox2 by apocynin or Nox2KO improved insulin sensitivity and 
restored aortic IR expression. We also found that reduced IR expression was accompanied by 
decreased Akt activity in HFD WT mice (Du et al., 2013).  
The IRS proteins are immediate substrates for the tyrosine kinase activity of the IR upon insulin 
binding, which constitutes a critical step in the insulin signal transduction cascades. The most 
frequently described consequences of IRS Ser phosphorylation are a decrease in its capacity to 
undergo tyrosine phosphorylation, and enhanced degradation (Zick, 2005). The functional 
consequence of oxidant-mediated IRS Ser/Thr phosphorylation due to ERK1/2 activation is 
enhanced degradation and impaired insulin-induced tyrosine phosphorylation. IRS proteins activate 
the PI3K/Akt/eNOS pathway. Therefore, deficits in IRS tyrosine phosphorylation due to ROS 
cause decreased Akt/eNOS pathway activation. Reports suggest that serine phosphorylation of IRS-
1 inhibits its ability to associate with the IR and to serve as a substrate for tyrosine phosphorylation 
(De Fea and Roth, 1997). The increased phosphorylation of ERK1/2 in diabetes may be an 
important reason for the decreased IRS-1 protein expression, since MAPK phosphorylate IRS-1 
leading to increased degradation (Aguirre et al., 2002). Interestingly, basal ERK1/2 
phosphorylation is also increased in adipose cells in type-2 diabetes (Carlson et al., 2003) and IRS-
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1 protein is also decreased (Rondinone et al., 1997). In a previous study, (Du et al., 2013), we 
found a close relationship between ERK1/2 activation, impaired Akt/eNOS phosphorylation and 
endothelial dysfunction in HFD WT aortas, but not in aortas of apocynin-treated or HFD-Nox2KO 
mice. Ex vivo experiments further confirmed that U0126 - an inhibitor of ERK1/2 activation - 
preserved eNOS phosphorylation, following high glucose and insulin stimulation. Animal studies 
have also shown that in the vasculature of obese Zucker rats, insulin resistance affects the PI3K 
pathway but not other pathways of insulin signalling including the MAPK pathway (Jiang et al., 
1999).  
In segments of human saphenous veins obtained from patients undergoing routine coronary artery 
bypass surgery, Guzik et al. (2000) reported that both diabetes and hypercholesterolaemia are 
associated with increased Nox2-dependent ROS production and that increased vascular Nox2 
activity is associated with impaired NO-mediated endothelial function (Cai and Harrison, 2000). 
D’Uscio et al. (2001) and his colleagues showed that the impairment of endothelial function in 
ApoE-deficient mice on a western-type fat diet is caused by increased production of ROS and 
reduced eNOS activity. It has been also shown that eNOS/ApoE D-KO mice fed with western-type 
diet increase atherosclerosis and suffer from cardiovascular complications like aortic aneurysm and 
dissection showing the importance of eNOS in atherosclerosis (Kuhlencordt et al., 2001). 
Therefore, ROS induced NO reduction is a key mechanism responsible for endothelial dysfunction 
in aortas of atherosclerotic ApoE-deficient mice (d’ Uscio et al., 2001). 
The role of NO as a second messenger or a positive modulator of insulin signalling was 
demonstrated in various systems. In isolated rat heart muscles and in cultured human VSMCs, 
insulin-stimulated glucose transport and GLUT4 recruitment were blocked by an inhibitor of NO 
synthesis (Li et al., 2004). Moreover, using in vivo models, intravenous administration of N
G
-
monomethyl-l-arginine (l-NMMA), a competitive inhibitor of all NOS isoforms, acutely induced 
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insulin resistance in rats (Baron et al., 1995). In addition, eNOS knockout mice were shown to be 
insulin resistant at the level of the liver and peripheral tissues, whereas the nNOS knockout mice 
displayed insulin resistance in peripheral tissues, but excluding the liver (Shankar et al., 2000). 
Taken together, these results indicate that insulin-induced NO production is necessary for 
successful propagation of the metabolic actions of insulin. 
Obesity is considered a low grade inflammatory state and involves complex interactions between 
inflammatory cells (neutrophils, lymphocytes, and monocytes/macrophages) and vascular cells 
(endothelial cells and SMCs). Vascular cells regulate the inflammatory process through the 
expression of adhesion molecules, cytokines, chemokines, and growth factors (Tedgui and Mallat, 
2001). Endothelial cell adhesion molecules (ECAMs), such as E-selectin, vascular cell adhesion 
molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1), are up-regulated in the 
vascular endothelium in response to inflammatory stimuli, which in turn mediates leukocyte 
recruitment and adherence to the endothelium at the early stages of vascular inflammation, 
ultimately leading to the progression of numerous vascular diseases (Blankenberg et al., 2003). 
Kim et al., (2008) studied a visceral adipokine known as visfatin in human microvascular 
endothelial cells (HMECs). Visfatin is involved in obesity related vascular disorders. Kim et al., 
(2008) showed that visfatin accelerates monocyte adhesion to endothelial cells by up-regulating 
adhesion molecules like VCAM in vascular endothelial cells and also up-regulates cytokine 
production via the p38MAPK pathway. VCAM-1 along with selectins, eNOS and NO represent an 
important group of genes implicated in the pathogenesis of atherosclerosis, for which regulation is 
associated with oxidative stress through redox-sensitive signals and transcriptional factors 
(Holmlund et al., 2002). Expression of VCAM-1 occurs particularly in the vascular endothelium 
and is strongly associated with increased intimal leukocyte accumulation (Brevetti et al., 2001). As 
far as insulin resistance is concerned, it was found that PI3K/Akt activity is inhibited thus limiting 
eNOS phosphorylation and NO release through PKC activation. At the same time PKC mediated 
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overexpression of adhesion molecules like ICAM-1, VCAM-1 and E-selectin and enhanced 
vascular contractility by increasing ET-1 release (Sheetz and King, 2002).  
Accumulating evidence suggests that Nox2 in resident endothelial cells and adventitial fibroblasts 
as well as recruited macrophages promotes inflammation and atherosclerosis (Csányi et al., 2009; 
Maiellaro and Taylor, 2007; Siow and Churchman, 2007; Haurani and Pagano, 2007). Du et al. 
(2013) showed that Nox2-derived ROS played a key role in damaging IR and endothelial function 
in dietary obesity after middle age and Pepping et al. (2013) raised the possibility that inhibition of 
Nox2 just within visceral adipose may be sufficient to prevent the pattern of macrophage 
accumulation and inflammation that precipitates metabolic decline.  Also, it has been shown that 
Nox2 mRNA, superoxide anion production, and monocyte binding are increased by oscillatory 
shear stress in endothelial cells (Hwang et al., 2003). Vendrov et al. (2007) showed that attenuation 
of Nox2-dependent ROS production in monocyte/macrophages or vessel wall cells decreases 
atherosclerosis in ApoEKO mice. It can therefore be seen that multiple pathways can contribute to 
accelerated atherosclerosis in diabetics and nondiabetics, including increased oxidative stress and 
inflammatory burden. 
Dietary obesity is often associated with progressive oxidative stress in multiple organs. Although 
the redox-signalling pathways underlying dietary obesity remain unclear, it is possible that Nox2 
signalling through ERK1/2 is involved in dietary obesity-associated deterioration of endothelial 
function. In this chapter, littermates of age-matched ApoEKO and Nox2/ApoE D-KO mice were 
used to investigate the mechanisms (or factors) of dietary obesity-associated Nox2 activation and 
global oxidative stress. The hypothesis tested in this chapter is that Nox2 activation and ROS 
generation in HFD can induce endothelial dysfunction and metabolic disorders. Despite there being 
several studies that indicate the contributions of Nox2 in ApoEKO mouse model in the 
pathogenesis of insulin resistance, endothelial dysfunction and inflammation at present, there is 
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only one experimental study (Judkins et al., 2010) showing the effects of Nox2 deletion in 
ApoEKO mouse model. However, in this study the role of Nox2 in ApoEKO mouse model has 
been examined only in relation to nitric oxide and atherosclerosis. In this study will be examined if 
complete deletion of Nox2 in ApoEKO mouse model, in the context of HFD-induced obesity, 
would preserve endothelial function, prevent metabolic syndrome and inflammation. 
3.2 Methods 
The critical role of metabolic disorder in Nox2 activation and endothelial dysfunction was 
examined using a model of HFD-induced obesity and insulin resistance in ApoEKO and 
Nox2/ApoE D-KO mice. In particular, the relationship between the levels of HFD-related glucose 
metabolic disorders and endothelial Nox2 activation in aorta inflammation, stress signalling 
pathways, decline of Akt expression and endothelial dysfunction was examined. To assess this 
hypothesis Nox2/ApoE D-KO mice were generated by crossing Nox2KO mice with ApoEKO 
mice. Littermates of ApoEKO and Nox2/ApoE D-KO mice on the C57BL/6 background (6 weeks 
old, n=9) were fed with HFD (45% kcal fat, 20% kcal protein and 35% kcal carbohydrate) or 
normal chow diet (NCD, 9.3% kcal fat, 25.9% kcal protein and 64.8% kcal carbohydrate) for 10 
weeks. The parameters that were measured were: 
1. Metabolic phenotype by measuring body weight, food and energy intake, lipid profile and blood 
pressure (see 2.4, 2.5 and 2.11). Weight gain/obesity in response to HFD in ApoEKO mice has 
already been reported and was not repeated here. 
2. Hepatic steatosis and insulin resistance by Oil red O staining of liver sections, fasting glucose, 
insulin levels, IPGTT and IPITT assays and NO measurement by Griess Assay (2.6, 2.11, 2.12 and 
2.23). 
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3. Vascular function by SMC contraction (PE), Endothelial Dependent Relaxation (ACh), 
Endothelial Independent Relaxation (SNP) and Insulin Relaxation (see 2.10). 
4. ROS production by chemiluminescence (see 2.17). 
5. Oxidative stress by in situ DHE fluorescence (see 2.18). 
6. Nox2 exprssion and MAPK activation by western blot (see 2.20). 
7. Endothelial activation and macrophage recruitment by VCAM-1 and F4/80 immunofluorescent 
detection (see 2.21). 
8. Akt phosphorylation by western blot and immunofluorescence (see 2.21). 
3.3 Results 
3.3.1 The effects of Nox2/ApoE D-KO on HFD-induced obesity and 
metabolic syndrome 
3.3.1.1 The effects of HFD on body weight, food/energy intake, lipid profile, 
blood pressure and epididymal fat in Nox2/ApoE D-KO mice 
Before diet intervention, there was no significant difference in body weight and food intake 
between NCD Nox2/ApoE D-KO and HFD Nox2/ApoE D-KO mice at 6 weeks of age (see Table 
3.1.1). After 10 weeks of diet intervention (at 16 weeks of age), there was no significant difference 
in body weight and energy intake between both groups but the HFD mice were eating less food 
(equal energy intake) than the NCD controls (see Table 3.1.1). Also, there were no significant 
differences in the levels of fasting serum triglycerides, non-esterified fatty acids (NEFA), total, 
HDL and LDL cholesterol and blood pressure between NCD and HFD Nox2/ApoE D-KO mice 
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Parameter 10weeks diet NCD HFD
Body weight (g) Before 24.0  0.4 24.1  0.5
After 27.9  0.4 28.1  0.3
Food Intake (g/day) Before 3.68  0.04 3.66  0.06
After 3.56  0.09 2.62  0.03 *
Energy Intake (kcal/day) Before 11.67  0.12 11.59  0.19
After 11.27  0.30 11.88  0.13
Triglycerides (mmol/L) After 1.15 ± 0.20 1.10 ± 0.11
NEFA (mmol/L) After 0.97  0.02 1.05  0.09
Total cholesterol (mmol/L) After 12.90 ± 0.89 13.09 ± 1.15
HDL(mmol/L) After 1.22  0.12 1.28  0.12
LDL(mmol/L) After 11.46  0.79 11.25  1.09
Systolic BP (mmHg) Before 117.4  1.3 116.5  1.8
After 117.6  1.4 118.1  1.9
Diastolic BP (mmHg) Before 92.4  1.5 92.6  1.7
After 92.5  1.7 93.6  1.6
(see Table 3.1.1). ApoEKO mice showed significant increases of epididymal fat pad (EPF) weight 
(NCD 0.823 ± 0.070 versus HFD 1.945 ± 0.031 g * p<0.05) compared to Nox2/ApoE D-KO mice 
(NCD 0.280 ± 0.017 versus HFD 0.314 ± 0.001 g p>0.05). 
Table 3.1.1 Metabolic and biochemical measurements before and after diet intervention in 
Nox2/ApoE D-KO mice. Data are expressed as mean ± SEM with a number of 9 mice per 
group. Comparisons were made by the Student’s unpaired t-test * p<0.05 significantly 
different from NCD values. 
 
 
 
 
 
 
 
 
 
 
 
3.3.1.2 The effects of HFD on fasting glucose, glucose clearance and insulin 
sensitivity in Nox2/ApoE D-KO mice 
The fasting glucose and insulin levels were measured in the ApoEKO and Nox2/ApoE D-KO mice 
to investigate possible insulin resistance with HFD. ApoEKO mice under HFD had significantly 
higher levels of fasting serum glucose (Fig. 3.1.2A NCD 6.28 ± 0.11 versus HFD 7.77 ± 0.19 
mmol/L * p<0.05) and insulin (Fig. 3.1.2C NCD 0.770 ± 0.091 versus HFD 1.969 ± 0.142 ug/L * 
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p<0.05) with high scores of HOMA-IR (NCD 0.23 ± 0.03 versus HFD 0.71 ± 0.07 Units * p<0.05) 
indicating insulin resistance. Interestingly, Nox2/ApoE D-KO mice under HFD had significantly 
reduced serum levels of fasting glucose (Fig. 3.1.2A NCD 5.89 ± 0.20 versus HFD 5.98 ± 0.19 
mmol/L p>0.05) and insulin (Fig. 3.1.2C NCD 0.532 ± 0.125 versus HFD 0.639 ± 0.128 ug/L 
p>0.05) with low levels of HOMA-IR (NCD 0.13 ± 0.03 versus HFD 0.16 ± 0.03 Units p>0.05) 
compared with the HFD ApoEKO mice. Also, glucose tolerance was well preserved in Nox2/ApoE 
D-KO HFD mice. Glucose tolerance in the Nox2/ApoE D-KO mice was not significantly different 
between both groups at any time point (Fig. 3.1.2B). Improved insulin sensitivity was further 
confirmed by the IPITT assays. This test was significantly impaired in the HFD ApoEKO mice 
compared to HFD Nox2/ApoE D-KO mice (Fig. 3.1.2D). Serum concentration of nitrite (a final 
product of NO breakdown) was also measured as an index of systemic NO production. There was 
no significant difference between NCD Nox2/ApoE D-KO and HFD Nox2/ApoE D-KO mice 
(NCD 22.70 ± 1.39 versus HFD 21.39 ± 1.55 μM p>0.05).  
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Figure 3.1.2: The effects of HFD in the levels of fasting serum (A) glucose, (B) 
intraperitoneal glucose tolerance test (IPGTT), (C) insulin and (D) intraperitoneal insulin 
tolerance test (IPITT) in Nox2/ApoE D-KO mice. Data are expressed as mean ± SEM with a 
number of 6-9 mice per group. Comparisons were made by two-way ANOVA with bonferroni 
post-hoc test and with Students unpaired t-test * p<0.05 significantly different from NCD 
values; * significantly different from ApoEKO values. 
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3.3.2 HFD-induced hepatic steatosis  
Obesity is usually correlated with ectopic fat deposition in the liver. To examine whether HFD 
caused hepatic steatosis in WT, ApoEKO, Nox2KO and Nox2/ApoE D-KO mice, Oil-red O 
staining on liver sections was performed (Fig. 3.2). HFD-induced hepatic steatosis in WT (Fig. 
3.2A NCD 1.62 ± 0.09 versus HFD 35.61 ± 1.20 % * p<0.05) and ApoEKO (Fig. 3.2B NCD 2.27 ± 
0.12 versus HFD 51.43 ± 1.26 % * p<0.05) mice but not in Nox2KO (Fig. 3.2A NCD 0.49 ± 0.04 
versus HFD 0.62 ± 0.04 % p>0.05) and Nox2/ApoE D-KO (Fig. 3.2B NCD 0.60 ± 0.05 versus 
HFD 0.73 ± 0.08 % p>0.05) mice. 
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Figure 3.2: Representative sections and quantification (% of positive stained area) of Oil 
Red O histological staining, as marker of fat accumulation in the liver in (A) WT and 
Nox2KO and (B) ApoEKO and Nox2/ApoE D-KO mice fed with NCD and HFD. Data are 
expressed as mean ± SEM with a number of 4-6 mice per group. Comparisons were made by 
two-way ANOVA with Bonferroni post-hoc test * p<0.05 significantly different from NCD 
values; * p<0.05 significantly different from WT/ApoEKO values. 
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3.3.3 The effects of HFD on vascular function in ApoEKO and Nox2/ApoE 
D-KO mice 
3.3.3.1 The effects of HFD on phenelephrine contractions in ApoEKO and 
Nox2/ApoE D-KO mice 
Firstly, the smooth muscle contraction to phenylephrine (PE) was assessed (Fig. 3.3.1) and no 
significant difference was seen in the maximum contraction (Emax) between the NCD ApoEKO 
and HFD ApoEKO mice (Fig. 3.3.1A NCD 0.260 ± 0.026 versus HFD 0.262 ± 0.025 g p>0.05) or 
the NCD Nox2/ApoE D-KO and HFD Nox2/ApoE D-KO mice (Fig. 3.3.1B NCD 0.249 ± 0.029 
versus HFD 0.253 ±0.022 g p>0.05). Also, there was no significant difference in the maximum 
contraction (Emax) between the HFD ApoEKO and Nox2/ApoE D-KO mice (ApoEKO 0.262 ± 
0.025 versus D-KO 0.253 ±0.022 g p>0.05). 
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Figure 3.3.1: Smooth muscle contraction of an aortic ring was assessed by adding 
cumulative concentrations (1nM to 10μΜ) of phenylephrine (PE) in NCD and HFD (A) 
ApoEKO and (B) D-KO aortas. Data are expressed as mean ± SEM with a number of 9 mice 
per group. Comparisons of Emax were made by the Student’s unpaired t-test p>0.05. 
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3.3.3.2 The effects of HFD on endothelium relaxations in ApoEKO and 
Nox2/ApoE D-KO mice 
Secondly, the endothelium-dependent relaxation was assessed by acetylcholine (ACh) which 
stimulates the endothelium to produce nitric oxide (Fig. 3.3.2). Compared to NCD ApoEKO 
controls, the endothelium-dependent relaxation of aortic rings to ACh was attenuated in HFD 
ApoEKO aortas (Fig. 3.3.2A NCD 82.03 ± 2.23 versus HFD 65.16 ± 2.89 % * p<0.05), and this 
was prevented by Nox2/ApoE D-KO mice (Fig. 3.3.2B NCD 82.97 ± 1.53 versus HFD 82.54 ± 
1.77 % p>0.05). Also, there was a significant decrease in the maximum vessel relaxation (Emax) to 
ACh, calculated as a percentage of the total PE contraction, between the HFD ApoEKO and 
Nox2/ApoE D-KO mice (ApoEKO 65.16 ± 2.89 versus D-KO 82.54 ± 1.77 % * p<0.05). There 
was also a significant difference in the ACh logEC50 value between the NCD and HFD ApoEKO 
mice (7.55 ± 0.06 versus 7.16 ± 0.10 * p<0.05). There was no significant difference in the ACh 
logEC50 value between the NCD and HFD Nox2/ApoE D-KO mice (NCD 7.29 ± 0.10 versus 7.28 
±0.14 p>0.05). 
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Figure 3.3.2: Endothelium-dependent relaxation was assessed by adding cumulative 
concentrations (1nM to 10μΜ) of acetylcholine (ACh) in NCD and HFD (A) ApoEKO and 
(B) D-KO aortas. Data are expressed as mean ± SEM with a number of 9 mice per group. 
EC50 values were derived from a non-linear dose response curve fit for NCD (open bar) and 
HFD (filled bar) aortic rings. Comparisons of Emax were made by the Student’s unpaired t-
test * p<0.05 significantly different from NCD values. 
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3.3.3.3 The effects of HFD on relaxations in response to tiron in ApoEKO 
mice 
The impairment of endothelium-dependent relaxation to ACh in HFD ApoEKO aortas was 
inhibited by tiron which further confirmed the role of ROS in mediating HFD-induced endothelial 
dysfunction (Fig. 3.3.3 NCD ApoEKO+Tiron 89.97 ± 3.94 versus HFD ApoEKO+Tiron 87.54 ± 
4.37 % p>0.05).  
 
Figure 3.3.3: Relaxant–response curves to (1nM to 10μΜ) ACh in NCD and HFD ApoEKO 
aortas in the presence of tiron. Data are expressed as mean ± SEM with a number of 8-9 
mice per group. Comparisons of Emax were made by the Student’s unpaired t-test p>0.05. 
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3.3.3.4 The effects of HFD on endothelium independent relaxations in 
ApoEKO and Nox2/ApoE D-KO mice 
The smooth muscle relaxation (endothelium independent) was assessed by the nitric oxide donor 
sodium nitroprusside (SNP) (Fig. 3.3.4). No significant difference was seen in the maximum vessel 
relaxation (Emax) to SNP between the NCD ApoEKO and HFD ApoEKO mice (Fig. 3.3.4A NCD 
99.41 ± 2.20 versus HFD 96.37 ± 1.90 % p>0.05) or the NCD Nox2/ApoE D-KO and HFD 
Nox2/ApoE D-KO mice (Fig. 3.3.4B NCD 100.73 ± 4.77 versus HFD 100.43 ± 5.02 % p>0.05). 
Also, there was no significant difference in the maximum vessel relaxation (Emax) to SNP, 
calculated as a percentage of the total PE contraction, between the HFD ApoEKO and Nox2/ApoE 
D-KO mice (ApoEKO 96.37 ± 1.90 versus Nox2/ApoE D-KO 100.43 ± 5.02 % p>0.05). 
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Figure 3.3.4: Endothelium-independent relaxation was assessed by adding cumulative 
concentrations (0.1 nM to 1μΜ) of sodium nitroprusside (SNP) in NCD and HFD (A) 
ApoEKO and (B) D-KO aortas. Data are expressed as mean ± SEM with a number of 9 mice 
per group. Comparisons of Emax were made by the Student’s unpaired t-test p>0.05. 
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3.3.4 Relaxation of aortic rings in response to insulin  
In order to confirm that the relaxant effects of insulin were indeed reduced in HFD-treated mice 
insulin was assessed after pre-contraction with PE (Fig. 3.4). There was a significant decrease in 
the maximum vessel relaxation (Emax) to insulin, calculated as a percentage of the total PE 
contraction, between the HFD ApoEKO and Nox2/ApoE D-KO mice (Fig. 3.4A; ApoEKO 18.95 ± 
1.17 versus Nox2/ApoE D-KO 36.39 ± 2.20 % * p<0.05). Also, there was a significant decrease in 
the maximum vessel relaxation (Emax) to insulin between the HFD ApoEKO and HFD 
ApoEKO+Apocynin aortas (Fig. 3.4B ApoEKO 18.95 ± 1.17 versus ApoEKO+Apocynin 34.47 ± 
1.73 % * p<0.05). 
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Figure 3.4: The effects of Nox2 in insulin-induced aorta relaxation. (A) Concentration–
response curves to insulin in aorta from HFD ApoEKO and Nox2/ApoE D-KO mice. (B) 
Relaxant–response curves to insulin in HFD ApoEKO mice in the presence of Apocynin. 
Data are expressed as mean ± SEM with a number of 5-6 mice per group. Comparisons of 
Emax were made by the Student’s unpaired t-test * p<0.05 significantly different from 
ApoEKO mice; * p<0.05 significantly different from HFD values. 
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3.3.5 The effects of HFD on ROS production detected by lucigenin 
chemiluminescence 
3.3.5.1 The effects of HFD on aorta ROS production in ApoEKO and 
Nox2/ApoE D-KO mice 
HFD ApoEKO aortas had significantly higher levels of NADPH-dependent O2
.−
 production 
compared to NCD ApoEKO aortas (Fig. 3.5.1A) (NCD 58.17 ± 1.17 versus HFD 115.20 ± 9.03 
MLU * p<0.05). In contrast, in Nox2/ApoE D-KO aortas, the levels of NADPH-dependent 
O2
.−
 production were very low in both NCD and HFD mice, without significant differences (Fig. 
3.5.1A NCD 29.57 ± 2.07 versus HFD 35.13 ± 1.50 MLU p>0.05). However, HFD ApoEKO aortas 
had significantly higher levels of NADPH-dependent O2
.−
 production compared to HFD WT aortas 
(Fig. 3.5.1A ApoEKO 115.20 ± 9.03 versus WT 77.43 ± 4.99 MLU * p<0.05). The enzymatic 
sources of O2
.−
production in HFD ApoEKO aortas were further examined using different enzyme 
inhibitors (Fig. 3.5.1B). The production of this ROS was inhibited significantly by DPI (a flavo-
protein inhibitor; HFD 161.59 ± 6.25 versus DPI 16.00 ± 2.31 MLU * p<0.05) and apocynin (Nox2 
inhibitor; 161.59 ± 6.25 versus Apo 40.34 ± 3.76 MLU * p<0.05), but not by rotenone 
(mitochondria complex 1 enzyme inhibitor; 161.59 ± 6.25 versus Rot 166.72 ± 13.37 MLU 
p>0.05), oxypurinol (xanthine oxidase inhibitor; 161.59 ± 6.25 versus Oxy 169.23 ± 9.99 MLU 
p>0.05) or L-NAME (NOS inhibitor; 161.59 ± 6.25 versus L-NAME 135.63 ± 8.83 MLU p>0.05) 
further supporting Nox2 as a major enzymatic source of the HFD-induced vascular O2
.−
 production. 
Tiron was also used to confirm the detection of O2
.− 
(161.59 ± 6.25 versus Tiron 33.44 ± 4.21 MLU 
* p<0.05). 
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Figure 3.5.1: (A) Tiron-inhibitable ROS production was detected in aorta homogenates by 
NADPH-dependant lucigenin (5μM) chemiluminescence. (B) The effect of different enzyme 
inhibitors on O2 
.-
 production by HFD ApoEKO aorta  homogenates. Data are expressed as 
mean ± SEM with a number of 9 mice. Comparisons were made by two-way ANOVA with 
Bonferroni post-hoc test * p<0.05 versus NCD values; † p<0.05 versus WT/ApoEKO values; 
* p<0.05 versus HFD values 
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3.3.5.2 The effects of HFD on heart and lung ROS production in ApoEKO 
and Nox2/ApoE D-KO mice 
HFD ApoEKO hearts had significantly higher levels of NADPH-dependent O2
.−
 production 
compared to NCD ApoEKO hearts. (Fig. 3.5.2A) (NCD 44.67 ± 3.49 versus HFD 54.70 ± 1.48 
MLU * p<0.05). In contrast, in Nox2/ApoE D-KO hearts, the levels of NADPH-dependent 
O2
.−
 production were very low in both NCD and HFD mice, without significant differences 
(Fig. 3.5.2A NCD 20.14 ± 2.28 versus HFD 24.73 ± 2.72 MLU p>0.05). HFD C57BL/6 WT hearts 
had significantly higher levels of NADPH-dependent O2
.−
 production compared to the ApoEKO 
(Fig. 3.5.2A WT 132.15 ± 6.68 versus ApoEKO 54.70 ± 1.48 MLU * p<0.05). HFD ApoEKO 
lungs had significantly higher levels of NADPH-dependent O2
.−
 production compared to NCD 
ApoEKO lungs (Fig. 3.5.2B) (NCD 449.42 ± 23.63 versus HFD 714.29 ± 38.31 MLU * p<0.05). In 
contrast, in Nox2/ApoE D-KO lungs, the levels of NADPH-dependent O2
.−
 production were very 
low in both NCD and HFD mice, without significant differences (Fig. 3.5.2B NCD 224.29 ± 21.96 
versus HFD 239.35 ± 16.31 MLU p>0.05). HFD ApoEKO lungs had significantly higher levels of 
NADPH-dependent O2
.−
 production compared to the C57BL/6 WT (Fig. 3.5.2B ApoEKO 714.29 ± 
38.31 versus WT 555.20 ± 27.92 MLU * p<0.05).  
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Figure 3.5.2: Tiron-inhibitable ROS production was detected in (A) heart and (B) lung 
homogenates by NADPH-dependant lucigenin (5μM) chemiluminescence. Data are expressed 
as mean ± SEM with a number of 6 mice. Comparisons were made by two-way ANOVA with 
Bonferroni post-hoc test * p<0.05 versus NCD values; † p<0.05 versus WT/ApoEKO values. 
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3.3.5.3 The effects of HFD on kidney and spleen ROS production in 
ApoEKO and Nox2/ApoE D-KO mice 
HFD ApoEKO kidneys had significantly higher levels of NADPH-dependent O2
.−
 production 
compared to NCD ApoEKO kidneys (Fig. 3.5.3A) (NCD 122.78 ± 3.51 versus HFD 265.65 ± 
13.51 MLU * p<0.05). In contrast, in Nox2/ApoE D-KO kidneys, the levels of NADPH-dependent 
O2
.−
 production were very low in both NCD and HFD mice, without significant differences 
(Fig. 3.5.3A NCD 43.59 ± 2.53 versus HFD 46.55 ± 4.12 MLU p>0.05). HFD ApoEKO kidneys 
had also significantly higher levels of NADPH-dependent O2
.−
 production compared to the 
C57BL/6 WT (Fig. 3.5.3A ApoEKO 265.65 ± 13.51 versus WT 127.56 ± 3.95 MLU * p<0.05). 
HFD ApoEKO spleens had significantly higher levels of NADPH-dependent O2
.−
 production 
compared to NCD ApoEKO spleens (Fig. 3.5.3B) (NCD 22.15 ± 2.40 versus HFD 43.63 ± 2.57 
MLU * p<0.05). In contrast, in Nox2/ApoE D-KO spleens, the levels of NADPH-dependent 
O2
.−
 production were very low in both NCD and HFD mice, without significant differences 
(Fig. 3.5.3B NCD 4.78 ± 0.34 versus HFD 5.58 ± 0.67 MLU p>0.05). HFD ApoEKO spleens had 
also significantly higher levels of NADPH-dependent O2
.−
 production compared to the C57BL/6 
WT (Fig. 3.5.3B ApoEKO 43.63 ± 2.57 versus WT 17.57 ± 1.27 MLU * p<0.05).  
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Figure 3.5.3: Tiron-inhibitable ROS production was detected in (A) kidney and (B) spleen 
homogenates by NADPH-dependant lucigenin (5μM) chemiluminescence. Data are expressed 
as mean ± SEM with a number of 6-7 mice. Comparisons were made by two-way ANOVA 
with Bonferroni post-hoc test * p<0.05 versus NCD values; † p<0.05 versus WT/ApoEKO 
values. 
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3.3.5.4 The effects of HFD on epididymal fat pad ROS production in 
ApoEKO and Nox2/ApoE D-KO mice 
HFD ApoEKO epididymal fat pads had significantly higher levels of NADPH-dependent 
O2
.−
 production compared to NCD ApoEKO epididymal fat pads (Fig. 3.5.4A) (NCD 100.50 ± 2.54 
versus HFD 193.36 ± 12.62 MLU * p<0.05). In contrast, in Nox2/ApoE D-KO epididymal fat pads, 
the levels of NADPH-dependent O2
.−
 production were very low in both NCD and HFD mice, 
without significant differences (Fig. 3.5.4A NCD 36.46 ± 4.57 versus HFD 39.86 ± 2.59 MLU 
p>0.05). HFD ApoEKO epididymal fat pads had also significantly higher levels of NADPH-
dependent O2
.−
 production compared to the C57BL/6 WT (Fig. 3.5.4A ApoEKO 193.36 ± 12.62 
versus WT 80.63 ± 4.64 MLU * p<0.05). The enzymatic sources of O2
.−
production in HFD 
ApoEKO aortas were further examined using different enzyme inhibitors (Fig. 3.5.4B). The 
production of this ROS was inhibited significantly by DPI (a flavo-protein inhibitor; HFD 292.78 ± 
30.01 versus DPI 16.51 ± 2.91 MLU * p<0.05) and apocynin (Nox2 inhibitor; 292.78 ± 30.01 
versus Apo 25.20 ± 2.20 MLU * p<0.05), but not by rotenone (mitochondria complex 1 enzyme 
inhibitor; 292.78 ± 30.01 versus Rot 354.68 ± 10.12 MLU p>0.05), oxypurinol (xanthine oxidase 
inhibitor; 292.78 ± 30.01 versus Oxy 355.31 ± 28.13 MLU p>0.05) or L-NAME (NOS inhibitor; 
292.78 ± 30.01 versus L-NAME 231.18 ± 3.20 MLU p>0.05) further supporting Nox2 as a major 
enzymatic source of the HFD-induced vascular O2
.−
 production. Tiron was also used to confirm the 
detection of O2
.− 
(292.78 ± 30.01 versus Tiron 35.46 ± 5.46 MLU * p<0.05). 
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Figure 3.5.4: (A) Tiron-inhibitable ROS production was detected in epididymal fat 
homogenates by NADPH-dependant lucigenin (5μM) chemiluminescence. (B) The effect of 
different enzyme inhibitors on O2 
.-
 production by HFD ApoEKO epididymal fat 
homogenates. Data are expressed as mean ± SEM with a number of 5-9 mice. Comparisons 
were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 versus NCD values; † 
p<0.05 versus WT/ApoEKO values; * p<0.05 versus HFD values. 
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3.3.6 Oxidative stress detected by in situ DHE fluorescence 
In situ O2
.−
 production by vessel sections, using DHE fluorescence was examined (Fig. 3.6). 
Experiments were performed in the presence or absence of tiron (an O2
.−
 scavenger), and tiron-
inhibitable O2
.−
 production was quantified. HFD ApoEKO aortas had significantly more 
O2
.−
 production than the NCD ApoEKO controls (NCD 40.49 ± 1.61 versus HFD 65.41 ± 6.39 
Fluorescence Intensity * p<0.05). In contrast, HFD failed to increase O2
.−
 production by 
Nox2/ApoE D-KO aortas (NCD 27.75 ± 2.54 versus HFD 30.79 ± 2.26 Fluorescence Intensity 
p>0.05). 
 
Figure 3.6: Tiron-inhibitable ROS production detected by DHE fluorescence microscope on aorta 
sections. The fluorescence intensity was quantified and calculated for the tiron-inhibitable O2 
.-
 
production. Data are expressed as mean ± SEM with a number of 6 mice. Comparisons were made 
by two-way ANOVA with Bonferroni post-hoc test * p<0.05 significantly different from NCD 
values; * p<0.05 significantly different from ApoEKO values. 
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3.3.7 HFD-induced oxidative stress and redox-sensitive MAPK activation 
3.3.7.1 Nox Expression in ApoEKO and Nox2/ApoE D-KO mice 
To define a role of Nox2 in HFD-induced vascular oxidative stress and dysfunction, in extracts of 
aorta, the protein expression of Nox2, p22
phox
 and the regulatory subunits of Nox2 that are p47
phox 
and Rac-1 were examined by immunoblotting (Fig. 3.7.1). Compared to NCD ApoEKO controls, 
HFD ApoEKO aortas had significantly higher levels of Nox2 (Fig. 3.7.1A NCD 0.136 ± 0.006 
versus HFD 0.196 ± 0.006 OD Units * p<0.05), p47
phox
 (Fig. 3.7.1B NCD 0.619 ± 0.046 versus 
HFD 0.958 ± 0.109 OD Units * p<0.05), p22
phox 
(Fig. 3.7.1C NCD 0.267 ± 0.022 versus HFD 
0.387 ± 0.014 OD Units * p<0.05)
 
and Rac-1 (Fig. 3.7.1D NCD 0.925 ± 0.032 versus HFD 1.475 ± 
0.070 OD Units * p<0.05). There was no effect on p47
phox
 (Fig. 3.7.1B NCD 0.440 ± 0.042 versus 
HFD 0.437 ± 0.059 OD Units p>0.05), p22
phox
 (Fig. 3.7.1C NCD 0.152 ± 0.002 versus HFD 0.161 
± 0.006 OD Units p>0.05) and Rac-1 (Fig. 3.7.1D NCD 0.579 ± 0.100 versus HFD 0.741 ± 0.060 
OD Units p>0.05) protein expression between NCD and HFD Nox2/ApoE D-KO mice.  
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Figure 3.7.1: Nox expression assayed by Western blot. Levels of protein expression of (A) 
Nox2, (B) p47phox, (C) p22phox and (D) Rac1. α-tubulin detected in the same sample was 
used as a loading control. The optical densities (OD) of Nox subunits bands were quantified 
digitally and normalised to the α-tubulin levels. Data are expressed as mean ± SEM with a 
number of 9 mice. Comparisons were made by two-way ANOVA with Bonferroni post-hoc 
test * p<0.05 significantly different from NCD values; * p<0.05 significantly different from 
ApoEKO values. 
 
3.3.7.2 MAPK phosphorylation and NF-kB activation in ApoEKO and 
Nox2/ApoE D-KO mice 
HFD-induced MAPK activation was examined using monoclonal antibodies against p-ERK and p-
p38MAPK (Fig. 3.7.2). HFD-induced significant increases in ERK1/2 (Fig. 3.7.2A NCD 0.260 ± 
0.023 versus HFD 1.072 ± 0.132 OD Units * p<0.05) and p38MAPK (Fig. 3.7.2B NCD 0.440 ± 
0.031 versus HFD 0.842 ± 0.032 OD Units * p<0.05) phosphorylation in ApoEKO aortas, but not 
in HFD Nox2/ApoE D-KO aortas (Fig. 3.7.2A p-ERK NCD 0.171 ± 0.015 versus HFD 0.185 ± 
0.013 OD Units p>0.05; Fig. 3.7.2B p-p38 NCD 0.309 ± 0.014 versus HFD 0.361 ± 0.018 OD 
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Units p>0.05). Also HFD-induced aorta NF-kB was measured in both ApoEKO and Nox2/ApoE 
D-KO aortas via NF-kB expression using immunoblotting (Fig. 3.7.2C). HFD significantly 
increased NF-kB (NCD 1.034 ± 0.053 versus HFD 1.942 ± 0.142 OD Units * p<0.05) in ApoEKO 
aortas but not in HFD Nox2/ApoE D-KO aortas (Fig. 3.7.2C NCD 0.586 ± 0.108 versus HFD 
0.685 ± 0.055 OD Units p>0.05).  
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Figure 3.7.2: MAPK phosphorylation assayed by Western blot. Phosphorylation of (A) 
ERK1/2 and (B) p-38MAPK and (C) NF-kB activation in aorta homogenates. The optical 
densities (OD) of the phospho-protein bands were quantified and normalised to the total 
protein levels of the same kinase detected in the same samples. For NF-kB a-tubulin was used 
as a loading control. Data are expressed as mean ± SEM with a number of 9 mice. 
Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from NCD values; * p<0.05 significantly different from ApoEKO 
values. 
Figure 3.3.8 The effects of increased Nox2 expression on endothelial cell activation and 
macrophage recruitment in HFD ApoEKO aortas  
Figure 3.3.8.1 Increased VCAM-1 expression in HFD ApoEKO aortas   
Compared to NCD ApoEKO controls, HFD ApoEKO aortas had significantly higher levels of 
Nox2 (Fig. 3.8.1 NCD 458.51 ± 13.56 versus HFD 534.09 ± 21.20 Fluorescence Intensity * 
p<0.05). Compared to NCD ApoEKO controls, HFD ApoEKO aortas had significantly higher 
levels of VCAM-1 (Fig. 3.8.1 NCD 421.71 ± 4.95 versus HFD 464.65 ± 9.96 Fluorescence 
Intensity * p<0.05) but not in HFD Nox2/ApoE D-KO aortas (Fig. 3.8.1 NCD 385.78 ± 7.22 versus 
HFD 384.71 ± 1.78 Fluorescence Intensity p>0.05). 
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Figure 3.8.1: (A) Immunofluorescence images of HFD ApoEKO and Nox2/ApoE D-KO 
mouse aorta sections stained with Nox2/CD31 and VCAM-1. Nox2/CD31 was labelled by 
Cy3 (red) and VCAM-1 was labelled by FITC (green) and nuclei was labelled by DAPI 
(blue). (B) The fluorescent intensity of individual molecule was quantified. Data are 
expressed as mean ± SEM with a number of 6 mice. Comparisons were made by two-way 
ANOVA with Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * 
p<0.05 significantly different from ApoEKO values. 
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Figure 3.3.8.2 Increased F4/80 expression in HFD ApoEKO aortas   
Compared to NCD ApoEKO controls, HFD ApoEKO aortas had significantly higher levels of 
Nox2 (Fig. 3.8.2 NCD 465.73 ± 4.63 versus HFD 506.90 ± 1.63 Fluorescence Intensity * p<0.05). 
Compared to NCD ApoEKO controls, HFD ApoEKO aortas had significantly higher levels of 
F4/80 (Fig. 3.8.2 NCD 430.23 ± 4.78 versus HFD 513.35 ± 8.73 Fluorescence Intensity * p<0.05) 
but not in HFD Nox2/ApoE D-KO aortas (Fig. 3.8.2 NCD 400.27 ± 4.19 versus HFD 408.80 ± 
5.78 Fluorescence Intensity p>0.05). 
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Figure 3.8.2: (A) Immunofluorescence images of HFD ApoEKO and Nox2/ApoE D-KO 
mouse aorta sections stained with Nox2/CD31 and F4/80.  Nox2/CD31 was labelled by Cy3 
(red) and F4/80 was labelled by FITC (green) and nuclei was labelled by DAPI (blue). (B) 
The fluorescent intensity of individual molecule was quantified. Data are expressed as mean 
± SEM with a number of 6 mice. Comparisons were made by two-way ANOVA with 
Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * p<0.05 
significantly different from ApoEKO values. 
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Figure 3.3.9 The effects of increased Nox2 expression on Akt phosphorylation in HFD 
ApoEKO aortas 
The effect of HFD in Akt phosphorylation was also examined using antibodies against 
phosphorylated Akt in ApoEKO and Nox2/ApoE D-KO aortic homogenates by using both 
immunoblotting (Fig. 3.9A) and immunofluorescence (Fig. 3.9B). HFD significantly decreased 
phosphorylated Akt (Fig. 3.9A NCD 0.537 ± 0.034 versus HFD 0.128 ± 0.028 OD Units * p<0.05) 
protein levels in ApoEKO animal model. However, it had no effect on Nox2/ApoE D-KO (Fig. 
3.9A NCD 0.711 ± 0.041 versus HFD 0.656 ± 0.035 OD Units p>0.05). Band intensities were 
normalised against total Akt.Compared to NCD ApoEKO controls, HFD ApoEKO aortas had 
significantly higher levels of Nox2 (Fig. 3.9B NCD 454.71 ± 3.56 versus HFD 497.90 ± 0.87 
Fluorescence Intensity * p<0.05). Compared to NCD ApoEKO controls, HFD ApoEKO aortas had 
significantly lower levels of p-Akt (Fig. 3.9B NCD 424.74 ± 3.24 versus HFD 395.59 ± 1.75 
Fluorescence Intensity * p<0.05) but not in HFD Nox2/ApoE D-KO aortas (Fig. 3.9B NCD 486.30 
± 2.21 versus HFD 485.18 ± 2.21 Fluorescence Intensity p>0.05). 
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Figure 3.9.1: (A) Phosphorylation of Akt in aorta homogenates. The optical densities (OD) of 
the phospho-protein bands were quantified and normalised to the total protein levels of the 
Akt detected in the same samples. (B) Immunofluorescence images of HFD ApoEKO and 
Nox2/ApoE D-KO mouse aorta sections stained with Nox2/CD31 and p-Akt. Nox2/CD31 was 
labelled by Cy3 (red) and p-Akt was labelled by FITC (green) and nuclei was labelled by 
DAPI (blue). The fluorescence intensity of individual molecule was quantified.  Data are 
expressed as mean ± SEM with a number of 6-9 mice. Comparisons were made by two-way 
ANOVA with Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * 
p<0.05 significantly different from ApoEKO values. 
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3.4 Discussion 
In this chapter, the effect of obesity-induced Nox2-dependent ROS production on endothelial 
dysfunction, metabolic disorders and vascular function was investigated using ApoEKO and 
Nox2/ApoE D-KO mice. Also, Nox2-dependent intracellular cascades were investigated in 
respect to p38, ERK1/2 and Akt phosphorylation levels, macrophage recruitment and 
endothelial cell activation (VCAM expression). The novelty of this study is the role of global 
Nox2-containing NADPH oxidase activation (not restricted in the endothelium) in response 
to dietary obesity-associated metabolic disorders (in particular hyperglycaemia and 
hyperinsulinaemia secondary to insulin resistance) in mediating systemic oxidative stress in 
ApoEKO mice and oxidative damage of endothelial function and vascular inflammation. 
Knockout of Nox2 in ApoEKO mouse model preserves endothelial function and delays 
vascular dysfunction. 
Another important discovery in ths study is the reduced IR signalling (Akt phosphorylation) 
in HFD aortas together with inflammation and oxidative damage of endothelial function. 
Using two independent techniques, lucigenin chemiluminescence and in situ DHE 
fluorescence, it has been demonstrated that HFD ApoEKO aortas produced about twice as 
much ROS as the NCD controls and this was accompanied by profound endothelial 
dysfunction, characterised by impaired endothelial dependent vessel relaxation. The impaired 
vascular relaxation was related to oxidative stress because addition of superoxide scavenger 
(tiron) in the organ bath restored the endothelial function. Furthermore, knockout of Nox2 in 
ApoEKO mouse model abolished HFD-induced vascular ROS production and restored IR 
signalling in dietary obesity.  
It was found that HFD increased glucose and insulin levels in ApoEKO mice indicating insulin 
resistance. Moreover, HFD induced vascular dysfunction and at the same time HFD ApoEKO mice 
exhibited increase ROS production in various organs. More specifically aorta, heart, lung, kidney, 
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spleen and epididymal fat from HFD ApoEKO mice were found to have increased ROS levels. All 
of the above parameters were attenuated in Nox2/ApoE D-KO mice demonstrating the importance 
of Nox2-derived ROS production in the pathogenesis of CVDs-associated metabolic disorders. 
Vascular disease states, including atherosclerosis, are associated with a net increase in ROS, to 
which Nox in general, and Nox2 in particular, are important contributors (Drummond et al., 2011).  
HFD mice have been widely used as a tool for studying diabetes and atherosclerosis. They have 
been found to exhibit increased body weight gain, hyperglycaemia and hyperinsulinaemia 
indicating insulin resistance (Winzell and Ahrén, 2004).  ApoEKO mice on HFD exhibit 
hypercholesterolaemia and atherosclerotic plaque formation (Nakashima et al., 1994). Phillips et al. 
(2003) demonstrated that HFD ApoEKO mice develop hypercholesterolaemia with a metabolic 
profile of hyperinsulinaemia and hyperglycaemia with an insulin release profile consistent with 
type-2 diabetes. Sharma et al. (2011) studied HFD ApoEKO mice and they found elevated glucose 
and insulin levels, triglycerides and cholesterol as well as atherosclerotic plaque formation. In their 
study they correlated ROS production with insulin resistance and atherosclerotic burden. This 
finding was also shown in human studies where high levels of a specific lipid peroxidase biomarker 
(N-linoleoyl tyrosine) reflect oxidative stress in the diabetic population (Szuchman et al., 2008). In 
humans there is a positive correlation between oxidative stress, hyperglycaemia and 
hyperlipidaemia. In obese subjects advanced oxidation protein products positively correlate with 
obesity, triglycerides and insulin and negatively with glucose to insulin ratio and HDL suggesting 
increased metabolic risk (Codoner-Franch et al., 2012). Studies have implicated oxidative stress in 
metabolic syndrome development (Bryan et al., 2013) and more specifically Nox (Furukawa et al., 
2004) since its inhibition in mice reduces diabetes, adipokine dysregulation and hepatic steatosis. In 
a previous study (Du et al., 2013) we demonstrated that HFD WT aortas produced about twice as 
much ROS as the NCD controls and this was accompanied by profound endothelial dysfunction, 
characterised by reduced eNOS phosphorylation and NO production, and impaired endothelium 
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function. Furthermore, the mice were hypertensive. Treating mice with apocynin abolished HFD-
induced vascular ROS production, preserved the eNOS and endothelial function and mice were 
normotensive. In agreement with this, studies in patients with coronary artery disease and animals 
with experimentally induced hypertension, diabetes or atherosclerosis suggest that Nox2 promotes 
endothelial dysfunction, inflammation and apoptosis (Drummond and Sobey, 2014).  It is well 
known that Nox2 is crucial for phagocytic ROS production and macrophage-mediated adipose 
inflammation plays a key role in the increased adipocyte size and body mass induced by HFD (Lee 
et al., 2011; Weisberg et al., 2003). Nox2 deficiency attenuates HFD-induced adipose deposits, 
adipocyte hypertrophy and adipose macrophage infiltration. Endothelial oxidative stress associated 
with Nox2 activation, preceded the pathogenesis of hypertension and atherosclerosis, two of the 
most common cardiovascular complications suffered by obese and diabetic patients (Gupta et al., 
2012). 
Therefore, we can state as a conclusion that in obesity free fatty acids, insulin resistance, oxidative 
stress, endothelial dysfunction and NO dysregulation are key pathogenic factors for CVD (Standl, 
2012). Endothelial NO regulates vascular function; however, in the presence of oxidative stress its 
function is impaired and atherosclerosis will develop. Progression of vascular disease is further 
enhanced by obesity and hypertension that up-regulate Nox-derived ROS, renin-angiotensin system 
and cytokine release, thus generating a continuous vicious circle. ROS production can induce 
endothelial cell apoptosis and monocyte/macrophage activation thus contributing to vascular 
inflammation and injury (Abhijit et al., 2013). Nox2 deletion had a positive effect on vascular 
function, insulin resistance and metabolic parameters indicating that Nox2 inhibition might be a 
therapeutic target for obesity-related diseases.  
A close relationship between the levels of endothelial oxidative stress and the degree of insulin 
resistance and cardiovascular disorders demonstrated in both experimental animals and 
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humans (Sukumar et al., 2013; Li and Shah, 2004). With respect to Nox2, expression was 
upregulated both in human aortic endothelial cells and in the aorta of diabetic mice. Also, 
transgenic mice with endothelial-specific Nox2 overexpression had high levels of ROS production 
and ERK1/2 activation in the endothelium. While the ApoEKO mouse model has been established 
as an excellent model of atherosclerosis, the lack of ApoE is extremely rare in the human 
population. However, its lesion development, plaque composition and its ability to model human-
like plaques-associated endothelial dysfunction, establish it as an excellent animal model for 
studying the pathogenesis of atherosclerosis and metabolic diseases. Humans lacking apoE are 
reported to have elevated remnant cholesterol in plasma. Similar to these individuals, ApoEKO 
mice accumulate cholesterol-rich remnant particles with plasma cholesterol levels reaching 400 
mg/dl, even when fed a regular low-fat, low-cholesterol diet (Pendse et al., 2009). 
Next, intracellular cascades concerning obesity related Nox2 expression and ROS production were 
investigated in respect to p38 and ERK1/2 and Akt phosphorylation.  
Initially it was found that HFD increased Nox2 expression and ROS production in ApoEKO aortas. 
It is well-known that Nox2 is mainly expressed in the endothelium and adventitia and is the 
predominant isoform up-regulated in obesity and HFD-induced vascular oxidative stress (Furukawa 
et al., 2004). In this study, it has been shown that HFD significantly increased Nox2 expression in 
aortas of ApoEKO mice, mainly in the endothelium and adventitia. It is also possible that increased 
adventitial Nox2 expression may also come from inflammatory cell infiltration. ROS are known to 
be able to activate the ERK and MAPK cascades and ERK inhibitors are known to suppress ROS 
mediated ERK1/2 activation (McCubrey et al., 2007). A number of cellular stimuli that induce 
ROS production also in parallel can activate MAPK pathways in multiple cell types (Torres and 
Forman, 2003). The prevention of ROS accumulation by antioxidants blocks MAPK activation 
after cell stimulation with cellular stimuli (McCubrey et al., 2006) indicating the involvement of 
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ROS in activation of MAPK pathways. Moreover, direct exposure of cells to exogenous H2O2, to 
mimic oxidative stress, leads to activation of MAPK pathways (Ruffels et al., 2004). Redox-
sensitive MAPKs are important signalling pathways for both insulin and Nox2-derived ROS. 
MAPK activation, in particular p38 and ERK1/2 phosphorylation has been reported in the 
vasculature of animals suffering from dietary obesity and insulin resistance (Symons et al., 2009; 
Kim et al., 2008), as well as in endothelial cells isolated from patients with type-2 diabetes (Gogg 
et al., 2009). ERK pathway activation in obesity and insulin resistance was first demonstrated by 
Bost et al., (2005) in ERK1-deficient mice that were protected against obesity when fed a HFD, 
because of a decrease in adipogenesis and an increase in postprandial energy expenditure. The lack 
of obesity was associated with a better glucose and insulin tolerance compared to WT mice. 
Treatment of ApoEKO mice with a p38 inhibitor reduces atherosclerosis progression (Seeger et al., 
2010). Therefore, p38/ERK pathways are activated in both insulin resistance and atherosclerosis. 
Likewise, Zucker rats, another model of obesity and insulin resistance were found to have 
increased p38 and ERK1/2 expression (Xu et al., 2005). In the current study, it has been 
demonstrated that in HFD there is a direct relationship between Nox2-induced ROS and p38-
ERK1/2 activation.  
The other intracellular pathway that was studied was the one involving PI3K/Akt/eNOS. It was 
found that in HFD ApoEKO mice Akt phosphorylation was decreased indicating a dysfunction of 
the pathway which ultimately leads to NO production. A key pathogenic step in atherogenesis is 
the development of endothelial cell dysfunction, manifested by a reduction in bioavailability of the 
antiatherosclerotic signalling molecule NO (Ross, 1999). Insulin binding to the IR activates the 
PI3K/Akt signalling pathway, resulting in eNOS activation and NO release and vasodilation 
(Muniyappa and Quon, 2007). Insulin resistance is considered a primary defect in vascular 
dysfunction and obesity is often associated with resistance to vascular actions of insulin (Fulton, 
2009). Studies have shown that impaired NO-dependent vasodilatation is a predictor of future 
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cardiac events and atherosclerosis development (Schachinger et al., 2000) and insulin resistance 
has been associated with endothelial dysfunction (Steinberg et al., 1996). Insulin through its 
receptors, IRα and IRβ, promotes vasodilation and plays an important role in regulating blood 
pressure and vascular metabolism. Mice heterozygous for knockout of IR are hypertensive 
(Wheatcroft et al., 2004), and mice with targeted vascular endothelial IR deficiency had reduced 
levels of eNOS expression (Sato et al., 2005). Duncan et al. (2008) studied a transgenic mouse with 
endothelium-targeted overexpression of a dominant-negative mutant human insulin receptor 
(ESMIRO). They found that disruptive insulin signalling leads to endothelial dysfunction, 
increased ROS production and decreased NO bioavailability. Da Costa et al., (2016) demonstrated 
that HFD induces vascular insulin resistance via increased tumor-suppressor phosphatase and 
tensin homologue (PTEN) activity and impaired Akt/eNOS signalling. It has been suggested that in 
insulin-resistant states, there might be a shift from the antiatherosclerotic PI3K-Akt-eNOS pathway 
to a proatherosclerotic ERK pathway, which governs the biological effects not only of insulin but 
also of other molecules that activate these signalling pathways, including ET-1 a known 
atherogenic molecule. In aggregate, recent research shows that several molecules act to inhibit 
PI3K-Akt-eNOS pathway in insulin resistant endothelial cells and that endothelial insulin 
resistance is likely to promote atherosclerosis (Kanter and Bornfeldt, 2013; Li et al., 2013). In 
relation to Akt/eNOS pathway inactivation, this study demonstrated that HFD ApoEKO mice had 
decreased Akt expression. Studies in human subjects have demonstrated that obesity is linked 
to decreased numbers of IR due to expression downregulation (Wigand and Blackard, 1979). In 
obesity and obesity induced diabetes, there is a decrease in insulin binding due to IR 
downregulation as well as defects in signalling by the IR associated with alteration in the 
phosphorylation state of post-receptor substrates. These data are in agreement with previous 
published results from our group where it has been shown that this high ROS production in HFD 
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WT mice was accompanied by profound endothelial dysfunction, characterised by endothelial 
dysfunction, reduced NO production and reduced eNOS phosphorylation (Du et al., 2013). 
Finally, endothelial cell activation and macrophage recruitment were examined in HFD ApoEKO 
mice. Recently, it has been demonstrated that increases in Nox2-derived ROS production -
specifically in ApoEKO endothelial cells- is sufficient to cause increases in vascular ROS 
production resulting in markedly increased endothelial cell activation and enhanced macrophage 
recruitment. However, this increase in recruitment of macrophages to fatty streaks within the 
vasculature did not result in increased plaque progression suggesting that Nox-mediated ROS 
signalling has important cell-specific and distinct temporal roles in the initiation and progression of 
atherosclerosis (Douglas et al., 2012).  
Also, these data (Douglas et al., 2012) suggests that Nox2 may not play a critical role in 
atherosclerosis as increased vascular superoxide in Nox2-Tg ApoEKO mice was still observed at 
24 weeks of age but alternative endothelial sources of ROS such as uncoupled eNOS, lipid 
peroxides, or an alternative Nox-derived source of ROS such as Nox4 may play a greater role. 
Nox4 has a greater relative abundance in the vasculature compared to Nox2 (Douglas et al., 2012). 
Unlike Nox2, Nox4 is now considered to be a H2O2, not a superoxide-producing enzyme (Nisimoto 
et al., 2014) and studies in ApoEKO mice have shown a role for H2O2 in the pathology of 
atherosclerosis (Yang et al., 2004). Furthermore, previous studies in human pulmonary endothelial 
cells have shown that knock-down of Nox2 using siRNA resulted in a compensatory increase in 
Nox4 mRNA expression (Pendyala et al., 2009). On the other hand Douglas et al. (2012) found no 
evidence for a compensatory change in the expression of either native Nox2 or Nox4 in whole 
aortas.  
Also, previous studies have shown that, in ApoEKO mice, fatty streaks consisting of lipid-laden 
macrophages start to appear from 9 weeks of age. Fatty streaks are initially observed to form a 
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single row in the sub-endothelial space, later growing in size as the macrophages aggregate into 
large groups (Coleman et al., 2006). In this thesis, it has been shown that deletion of Nox2 in 
ApoEKO mouse inhibits endothelial dysfunction as these mice are characterised by low ROS 
production in the vasculature. Also, it has been shown that Nox2/ApoE D-KO mice exhibited 
decreased macrophage recruitment and endothelial cell activation, two of the key factors in the 
initiation of atherosclerosis in ApoEKO
 
mice. Previous studies have also shown that VCAM-1 
plays a major role in the initiation of atherosclerosis (Cybulsky et al., 2001). In addition, Ang II 
treatment has previously been shown to increase VCAM-1 expression in endothelial cells (Pueyo et 
al., 2000). It is well established that Nox isoforms are involved in the pathophysiology of Ang II-
dependent hypertension and endothelial dysfunction (Brandes et al., 2010). Studies in tissues from 
human patients with hypertension, diabetes, heart failure or aging have correlated endothelial 
vasodilator dysfunction with increased Nox2 expression and activity (Dworakowski et al., 2008). 
 Nox2 knockout mice show improved endothelial dysfunction in a model of renovascular 
hypertension (Jung et al., 2004). Murdoch et al. (2011) have demonstrated that increases in 
endothelial levels of Nox2 in vivo contribute significantly to the enhancement of Ang II-dependent 
hypertension, vascular remodeling and endothelial dysfunction. Therefore, VCAM-1 expression 
was also determined in this study and it has been shown that ApoEKO mice had high levels of 
VCAM expression. These data is in agreement with the study of Douglas et al. (2012) where it has 
been shown that increased endothelial Nox2-derived superoxide production results in increased 
VCAM-1 expression, which is likely to bring increase in monocyte recruitment. This result is 
important because Nox2 has been previously implicated in atherosclerosis in both humans and in 
animal models. Both Nox2 and Nox4 have been shown to be localised within the plaque of 
diseased human coronary arteries (Lassegue and Griendling, 2010) and also Guzik et al. (2006) 
demonstrated that in diseased human coronary arteries mRNA expression of Nox2 correlated with 
NADPH oxidase activity. A direct relationship between Nox2 and atherosclerosis has also been 
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observed in mice. However, detailed investigation of the role of Nox2 in atherosclerosis is still 
missing. ApoEKO mice have increased expression of aortic Nox2 compared with WT mice and 
ApoEKO mice lacking Nox2 in all cells have reduced aortic atherosclerosis compared with 
ApoEKO mice (Judkins et al., 2010).  
In summary, this chapter demonstrates that diet-induced obesity in ApoEKO mice is linked to 
vascular dysfunction and insulin resistance. Studying Nox2 intracellular events has shown that 
HFD ApoEKO mice have activated MAPK pathway, whereas Akt/eNOS cascades are attenuated 
resulting in decreased NO bioavailability. At the same time Nox2-induced ROS production due to 
obesity induced aortic Akt downregulation, endothelial cell activation and macrophage recruitment. 
Nox2/ApoEDKO mice did not exhibit any of the delirious effects of HFD. Furthermore, 
Nox2/ApoE D-KO mice abolished HFD-induced vascular ROS production preserved Akt 
phosphorylation and endothelial function and mice were normotensive. Therefore, Nox2 targeting 
may represent an effective therapy to reduce dietary obesity-related oxidative stress, increase 
insulin sensitivity and improve vascular function. 
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CHAPTER 4 
Nox2-derived vascular ROS, vascular dysfunction and insulin 
receptor expression in insulin resistance 
4.1 Introduction 
Insulin’s effect on the endothelium is mediated through the insulin receptor (IR). The insulin 
receptor has 2 isoforms formed by alternative splicing of exon 11. IR-α lacks exon 11 while exon 
11 is present in IR-β (Denley et al., 2007). Cells that express both the insulin receptor and IGF-1 
receptor can also express hybrid receptors, consisting of an α and β subunit from an insulin receptor 
bound to an α and β subunit of an IGF-1 receptor (Samani et al., 2007). IR-α is ubiquitously 
expressed and has potent mitogenic and anti-apoptotic functions playing a key role in cell 
proliferation (Denley et al., 2004), whereas IR-β is predominantly expressed in liver and also 
substantially expressed in muscle, adipose tissue, and kidney, which are all target tissues of the 
metabolic effects of insulin (Belfiore et al., 2009; Mosthaf et al., 1990) and is a classical IR that 
regulates glucose uptake (Denley et al., 2004). Moreover, IR-α is predominantly expressed in fetal 
and cancer tissues. A high IR-α: IR-β ratio has been implicated in the insulin resistance of patients 
with myotonic dystrophy and possibly in patients with type-2 diabetes (Denley et al., 2003).  The 
intracellular signalling cascades include the PI3K/Akt (is linked to NO release) and the MAPKs 
pathways. Insulin’s vascular functions are compromised in pathological states such as obesity, 
type-2 diabetes and hypertension which could contribute to the increased rates of CVDs in these 
groups. Insulin-resistance in obesity or type-2 diabetes is manifested through a plethora of 
metabolic abnormalities that could cause vascular dysfunction (Steinberg and Baron, 2002).  
In general, insulin resistance can be due to a pre-receptor (e.g. insulin antibodies, abnormal insulin 
molecule), receptor (e.g. decreased numbers), or post-receptor (e.g. intracellular pathways 
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impairment) abnormality (McFarlane et al., 2001). Insulin binding to its receptor located in the cell 
surface causes conformational changes that result in intracellular tyrosine kinase activation (Rhodes 
and White, 2002) and autophosphorylation (White et al., 1988). Activation of the tyrosine kinase of 
the IR also leads to a rapid phosphorylation of the so-called “docking proteins”, such as IRSs and 
several Shc proteins that, in turn, attract multiple intracellular signalling intermediates (Draznin, 
2006). As mentioned before, the intracellular pathways of insulin signalling include the PI3K-Akt 
and the MAPKs. Akt plays a central role in mediating many other insulin actions by regulating the 
expression and activity of a wide range of proteins, including enzymes, transcription factors, cell 
cycle regulating proteins, or apoptosis and survival proteins (Manning and Cantley, 2007) 
including eNOS, which catalyses the production of the vasodilator and anti-inflammatory molecule 
NO, providing a potential link between insulin resistance and CVD (Yu et al., 2011). MAPK 
pathway involves the phospholylation and activation of ERK1/2 which play a direct role in cell 
proliferation or differentiation, regulating gene expression or extra-nuclear events, such as 
cytoskeletal reorganisation, through phosphorylation and activation of targets in the cytosol and 
nucleus (Boucher, 2014). 
 In insulin-resistant states, the selective loss of insulin action on the vascular endothelium via the 
loss of insulin activation of IRS/p-Akt can cause endothelial dysfunction, which correlates with the 
increased risk of coronary artery disease and accelerated development of atherosclerosis (Rask-
Madsen et al., 2010). Park et al. (2013) have reported that endothelial insulin receptor 
apolipoprotein E knockout mice (EIRAKO) with double knockout of apolipoprotein E and insulin 
receptor developed significantly more atherosclerosis than ApoEKO mice, suggesting the 
physiological importance of insulin for endothelial cells. On the same note, Rask-Madsen et al. 
(2010) using the same mouse model have demonstrated that loss of insulin signalling in the 
vascular endothelium promotes early events in atherogenesis and accelerates the progression of 
advanced atherosclerotic disease. These outcomes support the hypothesis previously examined by 
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others like Laakso (2010) and Caballero (2003) proposing that, in patients with obesity or type-2 
diabetes, insulin resistance in endothelial cells may contribute to increased risk for development of 
CVD.  
Specific protein kinase C-β2 activation in the endothelial cells of ApoEKO mice with PKC-β2 
overexpressed caused dysfunction and accelerated atherosclerosis because of loss of insulin-
stimulated Akt/eNOS activation (Li et al., 2013). More specifically, PKC-β selectively inhibits 
insulin activation of Akt and eNOS in endothelial cells of diabetic animals and patients by 
decreasing the phosphorylation of Akt at Ser473 and eNOS at Ser1177 (Tabit et al., 2013; Naruse 
et al., 2006) indicating that PI3K/Akt pathway impairment is linked to atherosclerosis via NO 
production decrease. The anti-atherosclerotic role of endogenous eNOS has been demonstrated in 
ApoEKO mice (Chen et al., 2001; Kuhlencordt et al., 2001). ApoE/eNOS D-KO mice displayed 
accelerated atherosclerosis, and they developed abdominal aortic aneurysm formation and ischemic 
heart disease compared with ApoEKO mice. Likewise, pharmacological inhibition of eNOS causes 
accelerated atherosclerosis in rabbits (Cayatte et al., 1994) and in mice (Kauser et al., 2000). In 
humans, the importance of eNOS on CVD has been demonstrated by Galluccio et al. (2013) who 
studied a particular polymorphism of the eNOS gene. They found that coronary artery disease 
patients carrying the rs753482-C genotype in intron 18 express a novel stable truncated form of 
eNOS due to the fact that this particular polymorphism influences the splicing dynamics of the 
surrounding exons. In this manner, 3 alternatively spliced eNOS isoforms lacking exon 20, 21 or 
both are formed. eNOS isoform lacking both exons is stable, forming heterodimers with the full 
length eNOS and exhibiting a faulty activation response with altered enzymatic activity that 
influences NO production and endothelial function. This finding further supports the role of the 
eNOS variant in accelerating atherosclerosis and CVD. eNOS polymorphisms have been studied in 
relation to insulin resistance as well. Yoshimura et al. (2003) investigated the association between 
eNOS polymorphisms and insulin resistance in patients with coronary artery disease and found 
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that the T(-786)-->C mutation in the eNOS gene decreases plasma insulin sensitivity in those 
subjects. However, as they state this tendency is not sufficient to conclude that the eNOS 
polymorphism is solely responsible for insulin resistance. Their results demonstrate that insulin 
sensitivity is not affected by eNOS polymorphisms directly rather through changes in endothelial 
function and eNOS production in skeletal muscle. Mice lacking all isoforms of NOS, demonstrate 
increased visceral obesity, hypertension, hypertriglyceridaemia, and impaired glucose tolerance and 
have spontaneous myocardial infarctions, apparently due to unstable coronary arteriosclerotic 
lesions (Nakata et al., 2008). The importance of eNOS on insulin sensitivity was further supported 
by studies in mice over-expressing dimethylarginine dimethylaminohydrolase - an enzyme that 
catalyses the breakdown of the endogenous inhibitor of NOS, asymmetric-dimethylarginine 
(ADMA). Those mice exhibit increased insulin sensitivity (Sydow et al., 2008). 
Although the PI3K/Akt pathway is impaired in virtually all states of insulin resistance, the MAPK 
pathway –including ERK1/2 and p38- remains intact if not enhanced (Montagnani et al., 2002; 
Cusi et al., 2000) activating proliferative, inflammatory, and mitogenic pathways, including 
vasoconstrictor factors such as ET-1 (Bender et al., 2013). ET-1 plays a role in progression of 
atherosclerosis by changing gene expression that enhances lipid biosynthesis, decreasing HDL 
through a mechanism that needs further study and increasing oxidative stress. The latter is achieved 
via various mechanisms including  increased activity of reduced NADPH oxidase or uncoupling of 
eNOS, or both, inflammatory cell infiltration via paracrine stimulation of monocyte production in 
the periphery, monocyte recruitment to atherosclerotic plaques and monocyte differentiation into 
macrophages and matrix metalloproteinase-2 secretion from macrophages and monocytes in 
perivascular fat, vascular wall, and atherosclerotic lesions (Li et al., 2013). Maintenance of insulin 
stimulation of the MAPK pathway which is largely responsible for ET-1 production, may be 
important in the development or maintenance of insulin resistance. ERKs can phosphorylate IRS-1 
and serine phosphorylation of IRS-1 and the IR itself has been implicated in desensitising IR 
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signalling (Dunaif et al., 1995). Continued ERK activity when IRS-1 function is already impaired 
could lead to insulin resistance aggravation. Liu and Cao (2009) have indicated that the activation 
of p38-MAPK is responsible in part as a causative mechanism for cardiovascular complications in 
the insulin resistant heart. In addition, several anti-diabetic drugs have been shown to affect the 
myocardial p38-MAPK pathway. The effect of these drugs on p38-MAPK could be associated with 
their cardiovascular results in patients with insulin resistance. In humans, Cusi et al. (2000) 
demonstrated that insulin caused an increase in MEK1 and ERK1/2 phosphorylation to the same 
extent both in lean controls as well as in insulin-resistant obese nondiabetic and type-2 diabetic 
patients.  Therefore, MAPK pathway in humans remains unaffected by insulin resistance. It is 
possible that in diabetes insulin induces sufficient activation of the IR tyrosine kinase to increase 
Shc - an alternative to IRS-1- phosphorylation normally. p53 is a transcription factor induced by 
stress, which can promote cell cycle arrest, apoptosis and senescence (Levine and  Oren, 2009), 
which are all processes related to tumour suppression. However, recent studies have challenged the 
relative importance of these canonical cellular responses for p53-mediated tumour suppression and 
have highlighted roles for p53 in modulating other cellular processes, including metabolism, stem 
cell maintenance, invasion and metastasis (Bieging et al., 2014). p53 is also emerging as an 
important regulator of metabolic pathways (Maddoks and Vousden, 2011) as it was found to 
influence glycolysis by downregulating the expression of glucose transporter 1 and 4 (GLUT1, 
GLUT4) (Schwartzenberg-Bar-Yoseph et al., 2004), repressing insulin receptor promoter thus 
limiting glucose transport into cells (Webster et al., 1996), inducing TP53-induced glycolysis and 
apoptosis regulator (TIGAR) lowering the rate of glycolysis (Bensaad et al., 2006), and 
downregulating the expression of phosphoglycerate mutase (PGM), thus reducing glycolytic rate 
(Puzio-Kuter, 2011). Overall, there is convincing evidence that p53 can be a negative regulator of 
glycolysis, although there is also evidence to suggest that p53 can enhance some steps in this 
pathway. p53 activates the transcription of the muscle isoform of PGM (PGM-M) in cardiac 
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myocytes (Ruiz-Lozano et al., 1999) and hexokinase II (HK2), which catalyses the first step in 
glycolysis, is under the control of a p53-responsive promoter (Mathupala et al., 2006). It has long 
been suggested that ROS are downstream mediators of p53. Macip et al. (2003) showed that the 
increase in intracellular ROS associated with the magnitude of p53 expression and correlated with 
the induction of either senescence or apoptosis in both normal and cancer cells. ROS inhibitors 
ameliorated both p53- dependent cell fates, implicating ROS accumulation as an effector in each 
case. Polyak et al. (1997) showed that many of the genes that were up-regulated by p53 encoded 
proteins that could generate or respond to ROS. At the same time, components of the redox system 
have regulatory effects on p53 as well. While the apoptotic response to p53 is linked to p53-
dependent elevation of ROS, basal p53 expression drives a number of antioxidant responses that 
can limit oxidative stress. p53 induces a range of antioxidant targets such as GPX1, MnSOD, 
ALDH4 (aldehyde dehydrogenase 4) and TPP53INP1 (Budanov et al., 2010), (Pani and Galeotti, 
2011). It is likely that under normal conditions or mild stress p53 augments the antioxidant 
response, protecting cells from potential oxidative damage. However, under severe stress, p53 
utilises its ability to promote ROS to facilitate apoptosis (Bensaad and Vousden, 2005). More 
importantly, Italiano et al. (2012) have demonstrated that p53 can bind to the promoter of 
neutrophil cytosolic factor 2 (NCF2)-the gene encoding p76 
phox
 which is Nox2 cytosolic subunit 
and activator- and activate gene expression. This indicates that p53 is a transcriptional factor for 
Nox2. However, under which circumstances p53 activates Nox2 and how they modulate the cell 
fate are still questions of interest at the moment.  
Another transcription factor that is regulated by ROS is NF-κΒ. The transcription of NF-κB-
dependent genes influences the levels of ROS in the cell, and in turn, the levels of NF-κB activity 
are also regulated by the levels of ROS. Depending on the context, ROS can both activate and 
inhibit NF-κB signalling (Morgan and Liu, 2011). It has been shown that NF-κB can be activated 
by NADPH oxidase through ROS intermediates (Clark and Valente, 2004; Fan et al., 2002; Bonizzi 
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et al., 1999). Anrather et al. (2006) showed that the gp91
phox
 subunit of NADPH oxidase is 
regulated by NF-kB.  
NF-κB is the most extensively studied intracellular pathway that is a target of hyperglycaemia, 
ROS, and oxidative stress (Bierhaus et al., 2001; Mohamed et al., 1999; Barnes and Karin, 1997). 
NF-κB plays a critical role in mediating immune and inflammatory responses and apoptosis. It 
regulates the expression of a large number of genes, including several of those linked to the 
complications of diabetes like VEGF, the receptor for advanced glycation endproducts (RAGE) 
(Mohamed et al., 1999) and VCAM-1 (Xia et al., 2001). Many of the gene products regulated by 
NF-κB in turn activate NF-κB (e.g., VEGF, RAGE), leading to a vicious circle. The aberrant 
regulation of NF-κB is associated with a number of chronic diseases, including diabetes and 
atherosclerosis. The normal endothelium does not in general support binding of white blood cells. 
However, early after initiation of an atherogenic diet, arterial endothelial cells begin to express on 
their surface selective adhesion molecules that bind to various classes of leukocytes. In particular, 
VCAM-1 binds precisely the types of leukocytes found in early human and experimental atheroma, 
the monocyte and T lymphocyte (Libby et al., 2002). Not only does VCAM-1 expression increase 
on endothelial cells overlying nascent atheroma (Li et al., 1993) but mice genetically engineered to 
express defective VCAM-1 show interrupted lesion development (Cybulsky et al., 2001). Increased 
expression of VCAM-1 is a direct effect of impaired insulin-stimulated activation of the PI3K/Akt 
pathway, which is normally downregulated by insulin. Rask-Madsen et al. (2010) have 
demonstrated that VCAM-1 expression was up-regulated in endothelial cells or in aortas from mice 
with insulin receptors specifically deleted from the endothelial cells with concomitant 
atherosclerosis acceleration. Furthermore, VCAM-1 expression is increased in atherosclerotic 
vessels and plays a key role in mediating infiltration of both monocytes and lymphocytes into the 
vasculature (Blankenberg et al., 2003).  In hypercholesterolaemic animals, VCAM-1 expression is 
upregulated over early foam cell lesions, particularly at the periphery (Iiyama et al., 1999) where 
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monocyte adhesion is maximal (Walker et al., 1986). Cybulsky et al. (2001) using mice that 
express low levels of VCAM-1, have demonstrated that VCAM-1 deficiency significantly 
diminishes early foam cell lesion formation throughout the aorta of Ldlr knockout mice suggesting 
that it has a major role in the initiation of atherosclerosis. In humans, Ingelsson et al. (2008) 
demonstrated a strong association between VCAM-1 and insulin resistance. VCAM-1 also 
activates Nox2 in endothelial cells for the production of ROS (Cook-Mills et al., 2011).   
Formation of ROS is associated with inflammation and vasculature dysfunction. Clinical studies 
also have implicated elevated oxidant stress as an important mechanism linking obesity and the 
increased risk of CVDs (Keaney et al., 2003; Morrow, 2003). There are several studies that 
highlight the role of Nox in respect to diabetes and atherosclerosis. Nox subunit proteins are 
increased in animal models of obesity and in the internal mammary arteries of patients with 
diabetes (Dobrian et al., 2004; Sonta et al., 2004; Guzik et al., 2002). ESMIRO mice with Nox2 
deletion showed reduced superoxide production and improved vascular function mediated by Nox2 
(Sukumar et al., 2013). ESMIRO stands for endothelial specific mutant insulin receptor transgenic 
mouse and their characteristic is their endothelial-specific insulin resistance caused by the 
expression of a dominant negative mutant human insulin receptor specifically in the endothelium. 
C242T polymorphism of the p22
phox 
gene has been found to be associated with insulin resistance in 
non-diabetic subjects (Hayaishi-Okano et al., 2003). In ESMIRO mice, insulin-stimulated 
phosphorylation of eNOS is blunted and accompanied by increased ROS generation and mRNA 
expression of Nox2 and Nox4 isoforms in the endothelium. The loss of insulin sensitivity leads to 
decreased insulin-induced vasodilation and endothelial dysfunction, also due to an increased ROS 
production by vascular NADPH oxidase and eNOS uncoupling (Oak and Cai, 2007). Ex vivo and in 
vivo pharmacological inhibition of Nox2 under insulin-resistant conditions resulted in decreased 
production of ROS and improvement in ACh-mediated vasodilation (Sukumar et al., 2013). 
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Endothelial dysfunction has been postulated as an initial trigger of the progression of 
atherosclerosis in diabetic patients, with eNOS uncoupling leading to endothelial dysfunction 
(Guzik et al., 2002; Guzik et al., 2000). High concentrations of glucose and insulin resistance are 
associated with endothelial dysfunction in vitro and in vivo (Gao et al., 2008). To date, 
accumulating evidence suggests that sustained ROS generation derived from NADPH oxidase 
contributes to endothelial dysfunction in diabetes (Duncan et al., 2008; Lopez-Lopez et al., 2008). 
Lack of endothelial-derived NO may provide the link between insulin resistance and endothelial 
dysfunction (Kuboki et al., 2000). NO deficiency results from decreased synthesis and release, 
combined with an exaggerated consumption in tissues exposed to an overabundance of ROS 
(Cersosimo and DeFronzo, 2006). 
This study tested the hypothesis that increased Nox2-derived ROS production links insulin-
resistance with atherosclerosis and is manifested by endothelial dysfunction, impaired insulin 
receptor expression and down-stream signalling and endothelial cell activation. 
4.2 Methods 
In this section the role of Nox2 in insulin resistance was investigated using aortic homogenates and 
aortic rings from WT, Nox2KO, ApoEKO and Nox2/ApoE D-KO mice. Specifically, an ex-vivo 
approach was used to examine the mechanisms of high glucose and insulin-induced Nox2 
activation and redox-signalling. The parameters that were measured were:  
1. Aortic vasomotor function (see 2.10). 
2. NO levels by measuring serum nitrite (one of the primary stable and non-volatile breakdown 
products of NO) using the Griess assay (see 2.12).  
3. NADPH-dependent superoxide production by lucigenin chemiluminescence and in situ DHE 
fluorescence (see 2.17 and 2.18 respectively). 
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4. Nox2, p47phox and p38 expression by western blotting (see 2.20). 
5. ERK, eNOS and Akt phosphorylation by both immunoblotting and immunofluorescence (see 2.20 
and 2.21). 
6. p53, NF-kB and VCAM-1 expression by immunoblotting (see 2.20). 
7. Nox2 and VCAM-1 expression by immunofluorescence (see 2.21). 
8. IR expression and eNOS phosphorylation by immunofluorescence (see 2.21). 
4.3 Results 
4.3.1 The effect of insulin and high glucose on vasomotor function of 
C57BL/6 WT and Nox2KO aorta 
In order to test the effect of insulin on aortic vasomotor function, aortic rings from 16 weeks old (4 
months), male C57BL/6 WT and Nox2KO mice fed with NCD were pre-incubated with insulin 
(1.2nM) as opposed to control (2% FCS/DMEM) (Fig. 4.1.1).  To determine the contribution of 
endothelial NO to the vascular effects of insulin, insulin pre-incubation was prepared in WT and 
Nox2KO (Fig. 4.1.2) aortic rings in the presence of L-NAME (100μM).  To mimic insulin-
resistance, aortic rings from WT and Nox2KO mice were incubated with insulin (1.2nM) and high 
glucose (30mM; Fig. 4.1.3). All incubations were in 2% FCS/DMEM for 2 hours.  Then aortic 
rings were hung in an organ bath for the assessment of vascular function.  
4.3.1.1 The effect of insulin on PE contractions of C57BL/6 WT and 
Nox2KO aorta 
The reduction of the contractile effect of insulin on the response of aortic rings to phenylephrine 
was confirmed in both WT and Nox2KO mice (Fig. 4.1.1). There was a significant decrease in 
tension generated by PE after insulin incubation in both WT (Emax vehicle 0.29 ± 0.02 versus 
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insulin 0.18 ± 0.01 g * p<0.05) and Nox2KO (Emax vehicle 0.26 ± 0.02 versus insulin 0.16 ± 0.02 
g * p<0.05) mice.  
 
 
 
 
 
 
 
 
 
 
Figure 4.1.1: The effect of pre-incubation with insulin on the contractile response to PE was 
assessed in aortic rings from WT (upper panel) and Nox2KO (lower panel) mice. PE contraction 
was assessed by adding cumulative concentrations (1nM to 10μM) of phenylephrine. EC50 values 
were derived from a non-linear dose response curve fit for control (open bar) and insulin (filled 
bar) stimulated aortic rings. Data are expressed as mean ± SEM with a number of 11 mice per 
group. Comparisons of Emax and EC50 values were made by the Student’s unpaired t-test * 
p<0.05 significantly different from vehicle values. 
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4.3.1.2 The effect of insulin and L-NAME on PE contractions of C57BL/6 
WT and Nox2KO aorta 
In order to test NO contribution to insulin vasoreactivity, aortic rings were pre-incubated with L-
NAME, a NOS inhibitor (Fig. 4.1.2). L-NAME not only completely abolished the reduction in PE-
induced contraction due to insulin but also significantly increased tension compared to controls in 
both WT (Emax vehicle 0.29 ± 0.02 versus insulin + L-NAME 0.71 ± 0.05 g * p<0.05) and 
Nox2KO (Emax vehicle 0.26 ± 0.02 versus insulin + L-NAME 0.68 ± 0.02 g * p<0.05) mice 
indicating that aortic vasorelaxation, both insulin-derived and intrinsic, is NO mediated.  
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Figure 4.1.2: To determine the contribution of endothelial NO to the vascular effects of 
insulin, insulin pre-incubation was prepared in WT (upper panel) and Nox2KO (lower panel) 
aortic rings in the presence of L-NAME. PE contraction was assessed by adding cumulative 
concentrations (1nM to 10μΜ) of phenylephrine. EC50 values were derived from a non-
linear dose response curve fit for control (open bar) and insulin+L-NAME (filled bar) 
stimulated aortic rings. Data are expressed as mean ± SEM with a number of 11 mice per 
group. Comparisons of Emax and EC50 values were made by the Student’s unpaired t-test * 
p<0.05 significantly different from vehicle values. 
173 
 
4.3.1.3 The effect of insulin and high glucose on PE contractions of 
C57BL/6 WT and Nox2KO aorta 
In the insulin-resistance state, glucose and insulin incubations (Fig. 4.1.3) significantly increased 
aortic ring tension of WT mice (Emax vehicle 0.29 ± 0.02 versus high glucose + insulin 0.69 ± 0.04 
g * p<0.05). The increase in aortic tension induced by high glucose and insulin was absent in 
Nox2KO mice (Emax vehicle 0.26 ± 0.02 versus high glucose + insulin 0.27 ± 0.01 g p>0.05). 
There was no difference between WT and Nox2KO PE responses in the absence of insulin/glucose. 
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Figure 4.1.3: The effect of high glucose (30mM) and insulin (1.2nM) on the contractile 
response to PE was assessed in aortic rings from WT (upper panel) and Nox2KO (lower 
panel) mice. PE contraction was assessed by adding cumulative concentrations (1nM to 
10μΜ) of phenylephrine. EC50 values were derived from a non-linear dose response curve fit 
for control (open bar) and high glucose+insulin (filled bar) stimulated WT aortic rings. Data 
are expressed as mean ± SEM with a number of 11 mice per group. Comparisons of Emax 
and EC50 values were made by the Student’s unpaired t-test * p<0.05 significantly different 
from vehicle values. 
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4.3.2 High glucose and insulin-induced effect on PE response in ApoEKO 
but not in Nox2/ApoE D-KO aortas  
4.3.2.1 The effect of insulin on PE contractions in ApoEKO but not in 
Nox2/ApoE D-KO aortas  
The effect of insulin on the contractile response of aortic rings to phenylephrine was confirmed in 
both ApoEKO and Nox2/ApoE D-KO mice (Fig. 4.2.1). There was a significant increase in tension 
after insulin incubation in ApoEKO (Emax vehicle 0.27 ± 0.01 versus insulin 0.44 ± 0.02 g * 
p<0.05). Insulin-induced aortic tension was absent in Nox2/ApoE D-KO mice (Emax vehicle 0.26 
± 0.02 versus insulin 0.27 ± 0.02 g p>0.05).  
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Figure 4.2.1: The effect of pre-incubation with insulin on the contractile response to PE was 
assessed in aortic rings from ApoEKO (upper panel) and Nox2/ApoE D-KO (lower panel) 
mice. PE contraction was assessed by adding cumulative concentrations (1nM to 10μM) of 
phenylephrine. EC50 values were derived from a non-linear dose response curve fit for 
control (open bar) and insulin (filled bar) stimulated aortic rings. Data are expressed as 
mean ± SEM with a number of 9 mice per group. Comparisons of Emax and EC50 values 
were made by the Student’s unpaired t-test * p<0.05 significantly different from vehicle 
values. 
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4.3.2.2 The effect of insulin and L-NAME on PE contractions in ApoEKO 
but not in Nox2/ApoE D-KO aortas  
In order to test NO contribution to insulin vasoreactivity, aortic rings were pre-incubated with L-
NAME, a NOS inhibitor (Fig. 4.2.2). Insulin pre-incubation in the presence of L-NAME 
significantly increased tension compared to controls in both ApoEKO (Emax vehicle 0.27 ± 0.01 
versus insulin + L-NAME 0.57 ± 0.04 g * p<0.05) and Nox2/ApoE D-KO (Emax vehicle 0.26 ± 
0.02 versus insulin + L-NAME 0.71 ± 0.04 g * p<0.05) mice indicating that aortic vasorelaxation, 
both insulin-derived and intrinsic, is NO mediated.  
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Figure 4.2.2: To determine the contribution of endothelial NO to the vascular effects of 
insulin, insulin pre-incubation was prepared in ApoEKO (upper panel) and Nox2/ApoE D-
KO (lower panel) aortic rings in the presence of L-NAME. PE contraction was assessed by 
adding cumulative concentrations (1nM to 10μΜ) of phenylephrine. EC50 values were 
derived from a non-linear dose response curve fit for control (open bar) and insulin+L-
NAME (filled bar) stimulated aortic rings. Data are expressed as mean ± SEM with a number 
of 9 mice per group. Comparisons of Emax and EC50 values were made by the Student’s 
unpaired t-test * p<0.05 significantly different from vehicle values. 
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4.3.2.3 The effect of insulin and high glucose on PE contractions in 
ApoEKO but not in Nox2/ApoE D-KO aortas  
In the insulin-resistance state, glucose and insulin incubations significantly increased aortic ring 
tension of ApoEKO mice (Emax vehicle 0.27 ± 0.01 versus high glucose + insulin 0.53 ± 0.02 g * 
p<0.05) whereas high glucose and insulin-induced aortic tension was absent in Nox2/ApoE D-KO 
mice (Emax vehicle 0.26 ± 0.02 versus high glucose + insulin 0.27 ± 0.02 g p>0.05) (Fig.4.2.3). 
There was no difference between ApoEKO and Nox2/ApoE D-KO PE responses in the absence of 
insulin/glucose. 
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Figure 4.2.3: The effect of high glucose (30mM) and insulin (1.2nM) on the contractile 
response to PE was assessed in aortic rings from ApoEKO (upper panel) and Nox2/ApoE D-
KO (lower panel) mice. PE contraction was assessed by adding cumulative concentrations 
(1nM to 10μΜ) of phenylephrine. EC50 values were derived from a non-linear dose response 
curve fit for control (open bar) and high glucose+insulin (filled bar) stimulated WT aortic 
rings. Data are expressed as mean ± SEM with a number of 9 mice per group. Comparisons 
of Emax and EC50 values were made by the Student’s unpaired t-test * p<0.05 significantly 
different from vehicle values. 
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4.3.3 Nitric oxide levels in high glucose and insulin C57BL/6 WT and 
Nox2KO supernatants  
Nitric oxide production and secretion was measured in aortic supernatants of WT and Nox2KO 
mice after incubation with insulin (1.2nM) or insulin (1.2nM) and high glucose (30mM) compared 
to control (2%FCS/DMEM (5.5mM Glucose) (Fig 4.3). Insulin significantly increased NO 
secretion from both WT (control 9.5 ± 1.1 versus  insulin 22.5 ± 1.1 μM * p<0.05) and Nox2KO 
(control 10.4 ± 0.9 versus insulin 23.7 ± 0.8 μM * p<0.05) aortas; however glucose and insulin 
incubation decreased NO secretion only in WT aortas (control 9.5 ± 1.1 versus high glucose and 
insulin 4.9  ± 0.2 μM * p<0.05) whereas there was no difference in Nox2KO between control and 
insulin-resistance conditions (control 10.4 ± 0.9 versus high glucose and insulin 10.9 ± 0.6 μM 
p>0.05). NO reduction in the presence of insulin and high glucose, mimicking an insulin-resistant 
state was ameliorated in the absence of Nox2 indicating its role in diabetes and that insulin-
resistance may be linked to decreased NO production/bioavailability. Consequently, there was a 
significant difference in NO secretion levels after high glucose and insulin incubation between WT 
and Nox2KO aortas (WT high glucose and insulin 4.9 ± 0.2 versus Nox2KO high glucose and 
insulin 10.9 ± 0.6 μM * p<0.05). Results are demonstrated in Fig. 4.3. 
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Figure 4.2.3 Nitric oxide levels in high glucose and insulin C57BL/6 WT and
Nox2KOsupernatants
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Figure 4.3: Nitrite concentration on supernatants of C57BL/6 WT (open bars) and Nox2KO 
(filled bars) aorta stimulated with insulin (1.2nM) or high glucose (30mM) and insulin 
(1.2nM) in 2% FCS/ DMEM/5.5mM Glucose for 24 hours. 2% FCS/DMEM (5.5mM glucose) 
represents the controls. Data are expressed as mean ± SEM with a number of 5-6 mice per 
group. Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from control values; * p<0.05 significantly different from WT values. 
 
183 
 
4.3.4 Nitric oxide levels in high glucose and insulin ApoEKO and 
Nox2/ApoE D-KO supernatants  
Nitric oxide availability was measured in aortic supernatants of ApoEKO and Nox2/ApoE D-KO 
mice after incubation with insulin (1.2nM) or insulin (1.2nM) and high glucose (30mM) compared 
to control (2%FCS/DMEM (5.5mM Glucose) (Fig. 4.4). In ApoEKO aortas there was a significant 
decrease in NO secretion after insulin incubation (control 9.1 ± 0.6 versus insulin 5.9 ± 0.3 μM * 
p<0.05) which became more prominent after high glucose and insulin addition (control 9.1 ± 0.6 
versus high glucose and insulin 4.6 ± 0.1 μM * p<0.05). Neither of these conditions had an effect 
on NO availability in Nox2/ApoE-DKO aortas (control 10.1 ± 1.2 versus insulin 9.5 ± 0.8 μM 
p>0.05; control 10.1 ± 1.2 versus high glucose and insulin 10.2 ± 0.7 μM p>0.05). As a result there 
was a significant difference in insulin-resistance conditions between ApoEKO and Nox/ApoE D-
KO aortas (ApoEKO high glucose and insulin 4.6 ± 0.1 versus D-KO high glucose and insulin 10.2 
± 0.7 μM * p<0.05). 
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Figure 4.2.4 Nitric oxide levels in high glucose and insulin ApoEKO and
Nox2/ApoE D-KO supernatants
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Figure 4.4: Nitrite concentration on supernatants of ApoEKO (open bars) and Nox2/ApoE 
D-KO (filled bars) mice stimulated with insulin (1.2nM) or high glucose (30mM) and insulin 
in DMEM/2% FCS for 24 hours. 2% FCS/DMEM (5.5mM glucose) represents the controls. 
Data are expressed as mean ± SEM with a number of 6 mice per group. Comparisons were 
made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 significantly different from 
control values; * p<0.05 significantly different from ApoEKO values. 
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4.3.5 High glucose and insulin-induced ROS production in C57BL/6 WT 
aortas  
Production of O2
.− by aortic tissue homogenates was measured by lucigenin chemiluminescence 
(Fig. 4.5A). NADPH-dependent superoxide production in WT aortas incubated with insulin 
(1.2nM) was significantly reduced compared to control (2% FCS/DMEM (5.5mM Glucose)) 
(control 19.0 ± 1.3 versus insulin 12.1± 0.5 MLU * p<0.05). The addition of high glucose (30mM) 
and insulin (1.2nM) significantly increased superoxide levels (control 19.0 ± 1.3 versus high 
glucose and insulin 32.7 ± 2.8 MLU * p<0.05). In order to further examine the enzymatic sources 
of superoxide production, a number of different inhibitors were used (Fig. 4.5B). Rotenone 
(mitochondria complex 1 enzyme inhibitor), oxypurinol (xanthine oxidase inhibitor) and L-NAME 
(NOS inhibitor) had no effect on superoxide production (high glucose and insulin 54.6 ± 3.0 versus 
rotenone 66.1 ± 4.3 MLU p>0.05; high glucose and insulin versus oxypurinol 67.5 ± 3.5 MLU 
p>0.05; high glucose and insulin versus L-NAME 63.6 ± 2.6 MLU p>0.05). However, DPI (a 
flavo-protein inhibitor) and apocynin (Nox2 inhibitor) greatly abolished superoxide production 
(high glucose and insulin versus DPI 6.9 ± 2.7 MLU * p<0.05; high glucose and insulin versus 
apocynin 7.7 ± 0.4 MLU * p<0.05). The specificity of O2
.− was confirmed by adding tiron (10 mM) 
to scavenge the O2
.− (high glucose and insulin versus tiron 6.4 ± 0.2 MLU * p<0.05). 
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Figure 4.2.5 High glucose and insulin-induced ROS production in C57BL/6 WT
aortas
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Figure 4.5: (A) Tiron-inhibitable superoxide anion production was detected by NADPH-
dependant lucigenin (5μΜ) chemiluminescence in aortic homogenates of C57BL/6 WT mice 
stimulated with insulin (1.2nM) or high glucose (30mM) and insulin (1.2nM) in 2% 
FCS/DMEM for 24 hours. 2% FCS/ DMEM (5.5mM glucose) represent the controls. (B) The 
source of NADPH-dependent superoxide production on WT aorta homogenates was 
examined using different inhibitors. Rot, rotenone; Oxy, oxypurinol; DPI, diphenylene 
iodonium; Apo, apocynin. Data are expressed as mean ± SEM with a number of 12 mice per 
group. Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from control values;* p<0.05 significantly different from NADPH 
values.  
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4.3.6 High glucose and insulin-induced ROS production in ApoEKO aortas 
NADPH-dependent superoxide production was also measured in ApoEKO aortas (Fig. 4.6A). It 
was found that ROS levels were significantly increased upon insulin stimulation (control 23.0 ± 1.3 
versus insulin 42.2 ± 2.2 MLU * p<0.05) and became more prominent after high glucose and 
insulin incubation (control 23.0 ± 1.3 versus high glucose and insulin 57.2 ± 3.2 MLU * p<0.05). 
Using inhibitors to determine the source of ROS production, it was found that (Fig.4.6B) rotenone, 
oxypurinol and L-NAME had no effect on superoxide production (high glucose and insulin 91.5 ± 
7.4 versus rotenone 101.1 ± 6.1 MLU p>0.05; high glucose and insulin versus oxypurinol 101.0 ± 
8.1 MLU p>0.05; high glucose and insulin versus L-NAME 87.8 ± 4.5 MLU p>0.05). However, 
DPI and apocynin greatly abolished superoxide production (high glucose and insulin versus DPI 
31.0 ± 3.1 MLU * p<0.05; high glucose and insulin versus apocynin 29.9 ± 3.0 MLU * p<0.05). 
The specificity of O2
.− was confirmed by adding tiron (10 mM) to scavenge the O2
.− (high glucose 
and insulin versus tiron 20.0 ± 2.0 MLU * p<0.05). 
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Figure 4.2.6 High glucose and insulin-induced ROS production in ApoEKO
aortas
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Figure 4.6: (A) Tiron-inhibitable superoxide anion production was detected by NADPH-
dependant  lucigenin (5μΜ) chemiluminescence in aortic homogenates of ApoEKO mice 
stimulated with insulin (1.2nM) or high glucose (30mM) and insulin (1.2nM) in 2% 
FCS/DMEM  for 24 hours.  2% FCS/DMEM (5.5mM Glucose) represent the controls. (B) 
The source of NADPH-dependent superoxide production of ApoEKO aorta homogenates was 
examined using different inhibitors. Rot, rotenone; Oxy, oxypurinol; DPI, diphenylene 
iodonium; Apo, apocynin. Data are expressed as mean ± SEM with a number of 9 mice per 
group. Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from control values; * p<0.05 significantly different from NADPH 
values. 
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4.3.7 High glucose and insulin-induced ROS production in C57BL/6 WT 
but not in Nox2KO aortas  
ROS production was also confirmed using in situ DHE fluorescence as an alternative method in 
both WT and Nox2KO aortas. As per previous results, insulin significantly decreased ROS 
production (control 35.7 ± 2.4 versus insulin 22.2 ± 3.9 Fluorescence Intensity * p<0.05) whereas 
high glucose and insulin significantly increased ROS levels (control 35.7 ± 2.4 versus high glucose 
and insulin 84.6 ± 4.5 Fluorescence Intensity * p<0.05) in WT aortas. However, in Nox2KO aortas, 
both insulin and high glucose and insulin had no effect on ROS production (control 23.2 ± 2.2 
versus insulin 22.0 ± 1.1 Fluorescence Intensity p>0.05; control versus high glucose and insulin 
23.2 ± 2.8 Fluorescence Intensity p>0.05) respectively. As a result, there was a difference between 
WT and Nox2KO aortas as far as ROS levels in response to high glucose and insulin were 
concerned, with the latter being significantly decreased compared to WT (WT high glucose and 
insulin 84.6 ± 4.5 versus Nox2KO high glucose and insulin 23.2 ± 2.2 Fluorescence Intensity * 
p<0.05) (Fig. 4.7). 
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Figure 4.2.7 High glucose and insulin-induced ROS production in C57BL/6 WT
but not in Nox2KO aortas
A In situ DHE Fluorescence
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Figure 4.7: (A) Representative images of in situ detection of ROS by DHE fluorescence 
microscope on aortic sections of C57BL/6 WT and Nox2KO mice stimulated with insulin 
(1.2nM) or high glucose (30mM) and insulin (1.2nM) in 2% FCS/ DMEM for 24 hours.  2% 
FCS/DMEM (5.5mM Glucose) represents the controls. (B) The fluorescence intensity was 
quantified and calculated for the tiron-inhibitable superoxide anion production. Data are 
expressed as mean ± SEM with a number of 5 mice per group (15 images per group). 
Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from control values; * p<0.05 significantly different from WT values.  
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4.3.8 High glucose and insulin-induced ROS production in ApoEKO but 
not in Nox2/ApoE D-KO aortas  
ROS production was also confirmed with in situ DHE fluorescence in ApoEKO and Nox2/ApoE 
D-KO models. Insulin significantly increased ROS production (control 52.0 ± 3.0 versus insulin 
67.3 ± 1.5 Fluorescence Intensity * p<0.05) in ApoEKO aortas, the difference being more 
prominent in high glucose and insulin conditions (control 52.0 ± 3.0 versus high glucose insulin 
90.7 ± 1.0 Fluorescence Intensity * p<0.05). Neither incubations had any effects on Nox2/ApoE D-
KO aortas (control 23.1 ± 1.7 versus insulin 24.2 ± 2.7 Fluorescence Intensity p>0.05; control 23.1 
± 1.7 versus high glucose and insulin 23.3 ± 1.0 Fluorescence Intensity p>0.05). As a result, there 
was a difference between ApoEKO and Nox2/ApoE D-KO aortas as far as ROS levels were 
concerned, with the former being significantly higher compared to Nox2/ApoE D-KO (ApoEKO 
high glucose and insulin 90.7 ± 1.0 versus D-KO high glucose and insulin 23.3 ± 1.0 Fluorescence 
Intensity * p<0.05) (Fig. 4.8). 
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Figure 4.2.8 High glucose and insulin-induced ROS production in ApoEKO but
not in Nox2/ApoE D-KO aortas
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Figure 4.8: (A) Representative images of in situ detection of  ROS by DHE fluorescence 
microscope on aortic sections of  ApoEKO and Nox2/ApoE D-KO mice stimulated with 
insulin (1.2nM) or high glucose (30mM) and insulin (1.2nM)  in 2% FCS/ DMEM for 24 
hours.  2% FCS/DMEM (5.5mM Glucose) represents the controls. (B) The fluorescence 
intensity was quantified and calculated for the tiron-inhibitable superoxide anion production. 
Data are expressed as mean ± SEM with a number of 5 mice per group (15 images per 
group). Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from control values; * p<0.05 significantly different from ApoEKO 
values. 
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4.3.9 High glucose and insulin increased Nox2 and p47
phox
 activity and p38 
phosphorylation in C57BL/6 WT aortas 
In order to determine the role of Nox2 in insulin resistance, the effect of high glucose and insulin in 
Nox2 (Fig. 4.9.A) and p47
phox 
(Fig. 4.9B) expression was examined using antibodies against 
gp91
phox
 and p47
phox
 in WT aortic homogenates. High glucose and insulin significantly increased 
Nox2 (control 0.097 ± 0.004 versus high glucose and insulin 0.176 ± 0.003 OD Units * p<0.05) 
and p47
phox 
(control 0.099 ± 0.010 versus high glucose and insulin 0.230 ± 0.012 OD Units * 
p<0.05) protein levels. In order to study Nox2 intracellular signalling cascades, p38 
phosphorylation levels (Fig. 4.9C) were determined using immunoblot in WT aortic homogenates. 
Total p38 levels were used as loading controls. It was found that high glucose and insulin increased 
p38 phosphorylation (control 0.241 ± 0.032 versus high glucose and insulin 0.361 ± 0.025 OD 
Units * p<0.05) significantly in WT aortas (Fig. 4.9).  
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Figure 4.2.9 High glucose and insulin increased Nox2 and p47phox activity and
p38 phosphorylation in C57BL/6 WT aortas
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Figure 4.9.1: Aortic rings form C57BL/6WT mice were cultured for 24h in the control 
medium (2% FCS/DMEM (5.5mM Glucose)) or stimulated with high glucose (30 mM) and 
insulin (1.2nM). Tissue homogenates were examined for (A) Nox2, (B) p47phox and (C) 
phosphorylated p38 protein expression using gp91
phox
, p47
phox
 and phosphorylated p38 
antibodies. Optical densities of gp91
phox
, p47
phox
 and phosphorylated p38 were quantified and 
normalised to the levels of α-tubulin and total p38 detected in the same sample. Data are 
expressed as mean ± SEM with a number of 3 measurements from 18 mouse aortas per 
group. Comparisons were made by Student’s unpaired t-test * p<0.05 significantly different 
from control values.  
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4.3.10 High glucose and insulin increased Nox2 and p47
phox
 activity and p38 
phosphorylation in ApoEKO aortas 
The effect of high glucose and insulin in Nox2 (Fig. 4.10A) and p47
phox
 (Fig. 4.10B) and 
phosphorylated p38 (Fig. 4.10C) expression was also examined using antibodies against gp91
phox
, 
p47
phox
 and phosphorylated p38 in ApoEKO aortic homogenates. High glucose and insulin 
significantly increased Nox2 (control 0.198 ± 0.018 versus high glucose and insulin 0.329 ± 0.028 
OD Units * p<0.05), p47
phox
 (control 0.164 ± 0.021 versus high glucose and insulin 0.443 ± 0.059 
OD Units * p<0.05) and phosphorylated p38 (control 0.443 ± 0.019 versus high glucose and insulin 
0.989 ± 0.178 OD Units * p<0.05) protein levels in ApoEKO aortas.  
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Figure 4.2.10 High glucose and insulin increased Nox2 and p47phox activity and
p38 phosphorylation in ApoEKO aortas
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Figure 4.10: Aortic rings form ApoEKO mice were cultured for 24h in the control medium 
(2% FCS/DMEM (5.5mM Glucose)) or stimulated with high glucose (30 mM) and insulin 
(1.2nM). Tissue homogenates were examined for (A) Nox2, (B) p47
phox
 and (C) 
phosphorylated p38 protein expression using gp91
phox
, p47
phox
 and phosphorylated p38 
antibodies. Optical densities of gp91
phox
, p47
phox 
and phosphorylated p38 were quantified and 
normalised to the levels of α-tubulin and total p38 detected in the same sample. Data are 
expressed as mean ± SEM with a number of 3 measurements from 18 mouse aortas per 
group. Comparisons were made by Student’s unpaired t-test * p<0.05 significantly different 
from control values.  
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4.3.11 High glucose and insulin increased ERK phosphorylation and 
decreased eNOS and Akt phosphorylation in C57BL/6 WT but not in 
Nox2KO aortas  
In order to further elucidate Nox2 intracellular signalling pathways, the effect of insulin resistance 
on ERK1/2 activation and eNOS and Akt phosphorylation was examined. WT and Nox2KO aortic 
homogenates after insulin or high glucose and insulin incubations were used and p-ERK1/2 and p-
eNOS were determined using immunofluorescence. It was found that insulin and high glucose 
induced ERK1/2 phosphorylation in WT (control 525.7 ± 5.7 versus high glucose and insulin 601.0 
± 13.4 Fluorescence Intensity * p<0.05). Insulin had no effect (control versus insulin 524.2 ± 7.2 
Fluorescence Intensity p>0.05). Neither condition had any effect on Nox2KO aortas (control 524.3 
± 0.9 versus insulin 525.3 ± 0.5 Fluorescence Intensity p>0.05; control versus high glucose and 
insulin 526.9 ± 0.6 Fluorescence Intensity p>0.05) (Fig. 4.11A). Insulin had no effect on eNOS 
phosphorylation in WT (control 599.2 ± 3.2 versus insulin 600.6 ± 3.6 Fluorescence Intensity 
p>0.05). High glucose and insulin significantly decrease eNOS phosphorylation in WT (control 
599.2 ± 3.2 versus high glucose and insulin 562.8 ± 8.6 Fluorescence Intensity * p<0.05), however 
it had no effect on Nox2KO (control 600.1 ± 0.9 versus insulin 600.7 ± 0.5 Fluorescence Intensity 
p>0.05; control versus high glucose and insulin 600.1 ± 0.5 Fluorescence Intensity p>0.05) (Fig. 
4.11A). The effect of high glucose and insulin in Akt phosphorylation (Fig. 4.11B) was also 
examined using antibodies against phosphorylated Akt in WT and Nox2KO aortic homogenates. 
High glucose and insulin significantly decreased phosphorylated Akt (control 3.621 ± 0.215 versus 
high glucose and insulin 2.130 ± 0.364 OD Units * p<0.05) protein levels in WT animal model. 
However it had no effect on Nox2KO (control 4.190 ± 0.084 versus high glucose and insulin 3.851 
± 0.143 OD Units p>0.05).  
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Figure 4.2.11 High glucose and insulin increased ERK phosphorylation and
decreased eNOS and Akt phosphorylation in C57BL/6 WT but not in Nox2KO
aortas
A p-ERK expression
Control Insulin Glucose+
Insulin
F
lu
o
In
te
n
s
it
y
450
500
550
600
650
WT
Nox2KO
* *
Control Insulin Glucose+
Insulin
F
lu
o
In
te
n
s
it
y
450
500
550
600
650
WT
Nox2KO
* *
p-eNOS expression
Control Insulin
Glucose
+ Insulin 
WT
Nox2KO
199 
 
 
 
Figure 4.11: Aortic rings form C57BL/6 WT and Nox2KO mice were cultured for 24h in the 
control medium (2% FCS/DMEM (5.5mM Glucose)) or stimulated with high glucose (30 
mM) and insulin (1.2nM).  (A) Immunofluorescence images of C57BL/6 WT and Nox2KO 
mouse aorta sections stained with p-eNOS and p-ERK. p-eNOS was labelled by Cy3 (red) 
and p-ERK was labelled by FITC (green) and nuclei was labelled by DAPI (blue). The 
fluorescent intensity of individual molecule was quantified. Data are expressed as mean ± 
SEM with a number of 4-6 mice per group. Comparisons were made by two-way ANOVA 
with Bonferroni post-hoc test. * p<0.05 versus control aortas * p<0.05 versus glucose and 
insulin aortas (B) Tissue homogenates were examined for phosphorylated Akt protein 
expression using phosphorylated Akt antibodies. Optical densities of phosphorylated Akt 
were quantified and normalised to the levels of total-Akt detected in the same sample. Data 
are expressed as mean ± SEM with a number of 3 measurements from 18 mouse aortas per 
group. Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
versus control aortas;* p<0.05 versus glucose and insulin aortas. 
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4.3.12 High glucose and insulin increased Nox2 and ERK phosphorylation 
and decreased Akt phosphorylation in ApoEKO but not in Nox2/ApoE D-
KO aortas 
Next, Nox2 and ERK phosphorylation in insulin resistance were measured in both ApoEKO and 
Nox2/ApoE D-KO aortas via Nox2 and phosphorylated ERK expression using 
immunofluorescence. In accordance with the immunoblot results, Nox2 expression significantly 
increased in both insulin and high glucose and insulin conditions in ApoEKO, with the latter 
increase being more prominent (control 422.2 ± 0.2 versus insulin 437.4 ± 1.5 Fluorescence 
Intensity * p<0.05; control versus high glucose and insulin 471.4 ±  6.0 Fluorescence Intensity * 
p<0.05) (Fig. 4.12). As far as ERK phosphorylation is concerned, insulin and high glucose and 
insulin both induced phosphorylated ERK expression in ApoEKO (control 546.3 ± 4.5 versus 
insulin 567.6 ± 4.1 Fluorescence Intensity * p<0.05; control versus high glucose and insulin 585.4 
± 1.0 Fluorescence Intensity * p<0.05), with the latter being more prominent. Neither condition had 
any effect on Nox2/ApoE D-KO model (control 529.8 ± 0.7 versus insulin 530.4 ± 1.8 
Fluorescence Intensity p>0.05; control versus high glucose and insulin 530.4 ± 0.9 Fluorescence 
Intensity p>0.05) (Fig. 4.12). 
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Figure 4.2.12 High glucose and insulin increased Nox2 and ERK
phosphorylation and decreased Akt phosphorylation in ApoEKO but not in
Nox2/ApoE D-KO aortas
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Figure 4.12: Aortic rings form ApoEKO and Nox2/ApoE D-KO mice were cultured for 24h 
in the control medium (2% FCS/DMEM (5.5mM Glucose)) or stimulated with high glucose 
(30 mM) and insulin (1.2nM). (A) Immunofluorescence images of ApoEKO and Nox2/ApoE 
D-KO mouse aorta sections stained with Nox2 and p-ERK. Nox2/CD31 was labelled by Cy3 
(red) and p-ERK was labelled by FITC (green) and nuclei was labelled by DAPI (blue). The 
fluorescent intensity of individual molecule was quantified. Data are expressed as mean ± 
SEM with a number of 5-6 mice per group. Comparisons were made by two-way ANOVA 
with Bonferroni post-hoc test * p<0.05 versus control aortas;* p<0.05 versus glucose and 
insulin aortas. (B) Tissue homogenates were examined for phosphorylated Akt protein 
expression using phosphorylated Akt antibodies. Optical densities of phosphorylated Akt 
were quantified and normalised to the levels of total-Akt detected in the same sample. Data 
are expressed as mean ± SEM with a number of 3 measurements from 18 mouse aortas per 
group. Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
versus control aortas;* p<0.05 versus glucose and insulin aortas. 
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4.3.13 High glucose and insulin increased p53, NFkB and endothelial cell 
activation in ApoEKO but not in Nox2/ApoE D-KO aortas 
Next, p53 (Fig. 4.13A), NFkB (Fig. 4.13B) and endothelial cell activation (Fig. 4.13C) in insulin 
resistance were measured in both ApoEKO and Nox2/ApoE D-KO aortas via p53, NFkB and 
VCAM-1 expression using immunoblotting. High glucose and insulin significantly increased p53 
(control 0.593 ± 0.049 versus high glucose and insulin 1.024 ± 0.112 OD Units * p<0.05), NFkB 
(control 0.978 ± 0.092 versus high glucose and insulin 1.459 ± 0.037 OD Units * p<0.05) and 
VCAM-1 (control 0.574 ± 0.042 versus high glucose and insulin 1.238 ± 0.056 OD Units * p<0.05) 
protein levels in ApoEKO aortas. However, high glucose and insulin had no effect on p53 (control 
0.355 ± 0.054 versus high glucose and insulin 0.363 ± 0.050 OD Units p>0.05), NFkB (control 
0.657 ± 0.046 versus high glucose and insulin 0.674 ± 0.037 OD Units p>0.05) and VCAM-1 
(control 0.303 ± 0.027 versus high glucose and insulin 0.481 ± 0.065 OD Units p>0.05) protein 
levels in Nox2/ApoE D-KO aortas. The effect of high glucose and insulin in Nox2 and VCAM-1 
(Fig. 4.13D) expression was also examined by immunofluorescence in ApoEKO and Nox2/ApoE 
D-KO aortic homogenates. Insulin and high glucose and insulin significantly increased Nox2 
(control 411.9 ± 0.7 versus insulin 421.3 ± 0.7 Fluorescence Intensity * p<0.05; control versus high 
glucose and insulin 466.5 ± 1.0 Fluorescence Intensity * p<0.05) and VCAM-1 (control 413.0 ± 0.3 
versus insulin 436.8 ± 4.2 Fluorescence Intensity * p<0.05; control versus high glucose and insulin 
487.9 ± 8.6 Fluorescence Intensity * p<0.05) expression in ApoEKO aortas. However, high glucose 
and insulin had no effect on VCAM-1 (control 396.5 ± 0.3 versus insulin 395.9 ± 0.3 Fluorescence 
Intensity p>0.05; control versus high glucose and insulin 396.4 ± 0.3 Fluorescence Intensity 
p>0.05) expression in Nox2/ApoE D-KO aortas.  
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Figure 4.2.13 High glucose and insulin increased p53, NFkB and endothelial cell
activation in ApoEKO but not in Nox2/ApoE D-KO aortas
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Figure 4.13: Aortic rings form ApoEKO and Nox2/ApoE D-KO mice were cultured for 24h in the 
control medium (2% FCS/DMEM (5.5mM Glucose)) or stimulated with high glucose (30 mM) and 
insulin (1.2nM). Tissue homogenates were examined for (A) p53, (B) NFkB and (C) VCAM-1 
protein expression using p53, NFkB and VCAM-1 antibodies. Optical densities of p53, NFkB and 
VCAM-1 were quantified and normalised to the levels of α-tubulin in the same sample. Data are 
expressed as mean ± SEM with a number of 3 measurements from 18 mouse aortas per group. 
Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 versus 
control aortas;* p<0.05 versus glucose and insulin aortas. (D) Immunofluorescence images of 
ApoEKO and Nox2/ApoE D-KO mouse aorta sections stained with Nox2/CD31 and VCAM-1. 
Nox2/CD31 was labelled by Cy3 (red) and VCAM-1 was labelled by FITC (green) and nuclei was 
labelled by DAPI (blue). The fluorescent intensity of individual molecule was quantified. Data are 
expressed as mean ± SEM with a number of 5-6 mice per group. Comparisons were made by two-
way ANOVA with Bonferroni post-hoc test * p<0.05 versus control aortas;* p<0.05 versus glucose 
and insulin aortas. 
4.3.14 High glucose and insulin decreased insulin receptor and eNOS 
phosphorylation in ApoEKO but not in Nox2/ApoE D-KO aortas 
To examine the relationship between insulin receptor and eNOS expression in insulin resistance, 
the effect of high glucose and insulin on insulin receptor and eNOS phosphorylation has been 
determined in ApoEKO and Nox2/ApoE D-KO aortas using IR-α and phosphorylated eNOS 
antibodies. It was found that insulin significantly increased Nox2 (control 422.1 ± 0.2 versus 
insulin 437.9 ± 2.7 Fluorescence Intensity * p<0.05) and significantly decreased insulin receptor 
expression (control 414.9 ± 0.3 versus insulin 408.8 ± 1.0 Fluorescence Intensity * p<0.05) in 
ApoEKO. High glucose and insulin significantly increased Nox2 (control 422.1 ± 0.2 versus high 
glucose and insulin 503.4 ± 3.3 Fluorescence Intensity * p<0.05) and caused a further decrease in 
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insulin receptor expression (control 414.9 ± 0.3 versus high glucose and insulin 405.7 ± 0.3 
Fluorescence Intensity * p<0.05). There was no effect on insulin receptor expression in Nox2/ApoE 
D-KO (control 420.3 ± 0.6 versus insulin 420.9 ± 0.6 Fluorescence Intensity p>0.05; control versus 
high glucose and insulin 420.1 ± 0.7 Fluorescence Intensity p>0.05) (Fig. 4.14A). eNOS 
phosphorylation followed the same trend. ApoEKO eNOS phosphorylation decreased upon insulin 
incubation (control 422.8 ± 0.5 versus insulin 419.3 ± 0.2 Fluorescence Intensity * p<0.05) and 
Nox2 expression significantly increased (control 423.5 ± 0.1 versus insulin 433.7 ± 2.5 
Fluorescence Intensity * p<0.05). High glucose and insulin caused a further decrease in eNOS 
phosphorylation (control versus high glucose and insulin 418.1 ± 0.03 Fluorescence Intensity * 
p<0.05) and Nox2 expression significantly increased (control versus high glucose and insulin 486.8 
± 4.3 Fluorescence Intensity * p<0.05). There was no difference in Nox2/ApoE D-KO (control 
425.7 ± 0.7 versus insulin 425.9 ± 0.6 Fluorescence Intensity p>0.05; control versus high glucose 
and insulin 426.3 ± 0.5 Fluorescence Intensity p>0.05) (Fig. 4.14B) aortas. 
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Figure 4.2.14 High glucose and insulin decreased insulin receptor and eNOS
phosphorylation in ApoEKO but not in Nox2/ApoE D-KO aortas
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Figure 4.14: Aortic rings form ApoEKO and Nox2/ApoE D-KO mice were cultured for 24h in the 
control medium (2% FCS/DMEM (5.5mM Glucose)) or stimulated with high glucose (30 mM) and 
insulin (1.2nM). (A) Immunofluorescence images of ApoEKO and Nox2/ApoE D-KO mouse aorta 
sections stained with Nox2/CD31 and IR-α. (B) Immunofluorescence images of high glucose and 
insulin ApoEKO and Nox2/ApoE D-KO mouse aorta sections stained with Nox2/CD31 and 
phosphorylated eNOS. Nox2/CD31 was labelled by Cy3 (red) and IR-α /p-eNOS was labelled by 
FITC (green) and nuclei was labelled by DAPI (blue). The fluorescent intensity of individual 
molecule was quantified. Data are expressed as mean ± SEM with a number of 5-6 mice per group. 
Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 versus 
control aortas;* p<0.05 versus glucose and insulin aortas. 
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4.4 Discussion 
In this chapter, the role of Nox2 in insulin-resistance was investigated in respect to Nox2-induced 
ROS production, vascular function and IR function using Nox2KO, ApoEKO and Nox2/ApoE D-
KO aortic homogenates and sections. The key findings are that Nox2-induced ROS production in 
ApoEKO models is significantly attenuated in Nox2/ApoE D-KO resulting in endothelial function 
improvement. More importantly, Nox2/ApoE-DKO mice maintained normal insulin receptor 
function as well as downstream signaling cascades involving the MAPK and PI3K/Akt/eNOS 
pathways. Furthermore, Nox2/ApoE-DKO mice showed reduced endothelial cell activation 
compared to ApoEKO. 
High glucose and insulin are potent activators of the endothelial Nox2 enzyme (Sukumar et al., 
2013). This study extends our understanding of insulin resistance in dietary obesity by showing that 
high glucose/insulin via Nox2 stress signalling pathways promote endothelial dysfunction. In 
response to high glucose and insulin challenge, ApoEKO aortas increased ROS production, which 
resulted in ERK1/2 activation and increased p53 expression. Knockout of Nox2 in ApoEKO mouse 
model not only abolished high glucose/insulin-induced ROS production but also protected cells 
from senescence. These data are in support with our in vivo observation that Nox2 activation in 
response to dietary obesity-associated hyperglycaemia and hyperinsulinaemia plays a crucial role in 
the oxidative damage of vascsular function. 
Insulin exposure of WT and Nox2KO aortas stimulated reduction in PE-induced contraction 
through a NO-dependent mechanism as it has been generally accepted (Wheatcroft et al., 2004; 
Steinberg and Baron, 2002).  Metabolic actions of insulin tend to be mediated by PI3K–dependent 
signalling pathways (Nystrom and Quon, 1999). NO is produced by activation of eNOS (Dudzinski 
and Michel, 2007). Inactivation of NO by enhanced production of ROS in the vasculature can 
significantly reduce NO bioavailability. This contributes to endothelial dysfunction and promotes 
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the development of atherosclerosis (Muniyappa et al., 2008). Insulin resistance leads to decreased 
insulin-induced vasodilation, probably as a result of increased production of ROS by vascular 
NADPH oxidase, leading to decreased NO bioavailability (Katakam et al., 2005). It is characterised 
by pathway-selective impairment in PI3K-dependent signalling in both metabolic and vascular 
insulin target tissues (Jiang et al., 1999). This is the first time it is demonstrated that insulin 
resistance had no effect on endothelial function in Nox2KO mice and these results are in agreement 
with Sukumar et al., (2013) who found that inhibition of Nox using gp91ds-tat enhances vasomotor 
function in insulin resistant vessels, indicating the protective role of Nox2 depletion on vascular 
function. Gp91ds-tat is a selective Nox peptide inhibitor. However, one should consider that 
inhibitors are not always completely selective for a single target and therefore, results of this kind 
should be interpreted with caution. This study however is using Nox2KO mice and shows beyond 
any doubt that the protective effect on endothelial function is due to Nox2 depletion alone. 
Considering that NO/ROS balance is important for normal endothelial function, the role of NO and 
ROS on endothelial dysfunction in insulin resistance and atherosclerosis was explored. Insulin 
resistance is characterised by endothelial dysfunction, which is a pivotal step in the 
initiation/progression of atherosclerosis. As stated above, a hallmark of endothelial dysfunction is 
an unfavourable imbalance between the bioavailability of the antiatherosclerotic signalling 
molecule NO and proatherosclerotic ROS (Imrie et al., 2010). It was found that increased Nox-
derived ROS may be a unifying mechanism underlying insulin resistance–related oxidative stress 
and atherosclerosis (Duncan et al., 2008; Duncan et al., 2007). In this study insulin exerts its anti-
oxidative effects on WT aortas possibly by increasing NO production in WT aortas through 
induction of eNOS expression (Toba et al., 2006) and upregulation of the PI3K/Akt pathway 
(Kuboki et al., 2000) and decreasing ROS production. Insulin resistance decreases NO 
bioavailability and increases superoxide generation as it was previously stated (Sukumar et al., 
2013). It is found that reduced NO production is detected shortly after the onset of vascular insulin 
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resistance (Kim et al., 2008). NO inhibition by L-NMMA, a competitive inhibitor of all NOS 
isoforms, was found to completely abolish insulin-induced increase in limb blood flow in humans 
(Baron et al., 2000). Intravenous administration of the same inhibitor in rats was found to induce 
hypertension and insulin resistance (Baron et al., 1995). NO bioavailability was found to be 
decreased in animal models of obesity and diabetes (Kim et al., 2008; Bender et al., 2007), and in 
obese and diabetic humans (Gruber et al., 2008; Higashi et al., 2001). Because its bioavailability is 
dependent upon the balance between its generation and its degradation, diminished levels of NO in 
obese states may be due to decreased expression of NOS, impairments in NOS activity, or the 
reaction of NO with reactive species (e.g., superoxide) (Sansbury and Hilla, 2014). In accordance 
with the above, our ApoEKO aorta experiments showed that there is impairment in NO 
secretion/bioavailability which can be due to increased ROS production reducing NO availability 
or eNOS phosphorylation reduction which reduces NO production. These results will be discussed 
further along in the chapter. However, our results from the Nox2KO model indicate the protective 
role of Nox2 depletion as far as endothelial dysfunction is concerned, which suggests the 
importance of ROS production. Studies in ApoEKO and Nox2/ApoE D-KO mouse models have 
shown that elevated superoxide production by Nox2 during hypercholesterolaemia causes 
decreased NO (Miller et al., 2010). In hypercholesterolaemia, increased superoxide production via 
activation of NADPH oxidase may play a key role in compromised NO function and promote the 
development of atherosclerosis (Kitayama et al., 2007). NO inactivation by Nox2-derived 
superoxide has a dual effect in promoting atherogenesis; reduction in the bioavailability of 
vasoprotective endothelium-derived NO, predisposing the vessel wall to vascular inflammation and 
generation of peroxynitrite, a powerful oxidising agent, from superoxide and NOS reaction 
(Judkins et al., 2010). Nox2 depletion offers a protective role in the atherosclerotic model since it 
ameliorates atherosclerosis-induced vascular dysfunction.  Nox2-deficiency protects against 
ischaemia in conditions of increased oxidative stress, through improved neovascularisation, 
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preserved activation of the VEGF/NO angiogenic pathway and improved functional activities of 
endothelial progenitor cells (Haddad et al., 2009). In our study, Nox2/ApoE-DKO mice had 
improved NO bioavailability and reduced superoxide production in insulin resistance, similar to the 
atherosclerotic model which agrees with studies (Judkins et al., 2010). We found that insulin 
resistance increases ROS production in both WT and ApoEKO aortas. The source of this 
production was Nox2. Hence, to define the role of Nox2 in insulin-resistance induced endothelial 
dysfunction and oxidative stress, we studied Nox2 protein expression. In human atherosclerotic 
coronary arteries, it was found an up-regulation of Nox2 expression which correlated with the 
severity of the disease (Sorescu et al., 2002), while Azumi et al., (1999) showed that p22
phox 
is 
more abundant in advanced atherosclerotic plaques than in non-atherosclerotic arteries. In 
pathological states, hyperactivity of Nox induces oxidative stress. Nox-derived ROS interact and 
stimulate other enzymatic sources of oxygen/nitrogen reactive intermediates, and amplify the initial 
response to insults. In atherosclerosis, Nox-induced lipid peroxidation is highly deleterious and 
expands the free radical reactions initially produced by activated Nox (Manea and Simionescu, 
2012). Nox2 protein expression is up-regulated in aortas form ApoEKO mice. The young age of the 
mice (12 weeks, upregulated Nox2 expression, minimal lesion burden vs 19 weeks, upregulated 
Nox2 expression also but with atherosclerostic lesions) indicate that Nox2 elevation is an early 
event of the atherosclerotic process and Nox2 deletion inhibited atherosclerotic plaque formation 
(Judkins et al., 2010). In our study insulin resistance was found to up-regulate Nox2 expression 
both in insulin-resistant and atheroscelotic mouse models. In insulin resistance, there is a reduced 
ability of insulin to activate the Akt/eNOS pathway, at least partly mediated by increased Nox2 
expression (Kanter and Bornfeldt, 2013). Using ApoEKO mice expressing a dominant negative 
mutant human insulin receptor specifically in the endothelium (ApoEKO/ESMIRO) it was found 
that insulin resistance specifically at the level of the endothelium promotes atherosclerosis at least 
partly through ROS generation (Gage et al., 2013).  Our results so far show that insulin exerts its 
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protective effects on WT aortas by inducing reduction in PE-induced contraction through insulin-
induced NO production and ROS generation reduction. Insulin resistance causes endothelial 
dysfunction by decreased NO bioavailability and increased ROS production, through Nox2 
upregulation. In atherosclerosis NO bioavailability is compromised resulting in Nox2-mediated 
ROS production. Insulin resistance causes further imbalance of the NO/ROS pathways by Nox2 
up-regulation. Nox2 knockout models restore NO/ROS imbalance indicating the protective role of 
Nox2 deletion in insulin resistance and diabetes. 
Once activated, the insulin receptor phosphorylates the IRS family (IRS1/2/3/4) which in turn 
activates a number of adaptor proteins including PI3K, initiating the PI3K/Akt/eNOS pathway and 
leading to NO synthesis and vasorelaxation. Insulin also activates the MAPK pathway which 
involves the phosphorylation of various intracellular proteins like ERK1/2 (Vicent et al., 2003). 
This pathway leads to ET-1 production, eNOS inhibition and subsequent vasoconstriction 
(Muniyappa et al., 2007; Kim et al., 2006; Potenza et al., 2005). Several studies have indicated that 
insulin resistance changes the dynamics of these pathways causing impairment of the 
PI3K/Akt/eNOS pathway and favouring the MAPKs (Potenza et al., 2005; Montagnani et al., 2002; 
Jiang et al., 1999). Molnar et al., (2005) however have shown in obese, glucose intolerant mice 
that insulin-mediated Akt/eNOS phosphorylation was preserved, but NO-mediated vasorelaxation 
was blunted due to a decrease in eNOS protein dimers, suggesting that insulin-mediated endothelial 
dysfunction may not be due to defective Akt/eNOS signalling. Studies with endothelial cell-
specific conditional knockout mice of the IR gene (Insr) in ApoEKO mice revealed that complete 
loss of insulin signalling in endothelium accelerated atherosclerosis, suggesting an important role 
of insulin signalling in atherogenesis (Rask-Madsen et al., 2010). Alterations in the expression 
levels of the IR and IRS-1 have been reported in the onset of type-2 diabetes in animal models
 
(Saad et al., 1992) and humans with type-2 diabetes (Goodyear et al., 1995). Galkina et al., (2012) 
using ApoEKO mice heterozygous for the IR and the IRS-1 have demonstrated that impaired 
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IR/IRS-1 signalling promotes accelerated atherogenesis via increased vascular dysfunction 
concluding that impaired insulin signalling might be an important component in the mechanism 
that increases the relative risk of CVDs in patients with metabolic syndrome and type-2 diabetes. In 
our ApoEKO aortic homogenates insulin resistance down-regulated IR, further verifying the 
connection between insulin resistance, atherosclerosis and insulin receptor dysfunction. Reduced 
IR expression was due to Nox2-derived oxidative stress since in Nox2/ApoE D-KO models, insulin 
receptors were restored.  
In order to explore the effect of Nox2-derived oxidative stress on MAPK pathway activation in 
insulin-resistance and atherosclerosis we examined the phosphorylation status of p38 and ERK1/2. 
Exposure to short-term high glucose negatively affects insulin signalling even when physiological 
insulin concentrations are added. The impairment of the PI3K/Akt/eNOS pathway after 
physiological insulin treatment could contribute to detrimental effects on cardiovascular 
homeostasis under high glucose conditions, and might shift toward the activation of certain 
mitogenic effectors, such as ERK1/2, p38 and JNK, the only ones that respond to physiological 
insulin treatment in high glucose. (De Nigris et al., 2015). ERK1/2 is activated by several growth 
factors but also by inflammatory cytokines. The contribution of ERK pathway in the development 
of obesity and insulin resistance was first demonstrated by Bost et al., (2005) on ERK1-deficient 
mice that were protected against obesity when fed a HFD, because of a decrease in adipogenesis 
and an increase in postprandial energy expenditure. The lack of obesity was associated with a better 
glucose and insulin tolerance compared to WT  mice. Conversely, over-activation of the ERK 
pathway resulted in the development of mature-onset obesity and insulin resistance (Rodriguez et 
al., 2006). This phenotype was probably due to the over-activation of ERK1 rather than ERK2 
since ERK1 deletion reversed the phenotype (Lee et al., 2010). Treatment of ApoEKO mice with a 
p38 inhibitor reduces atherosclerosis progression (Seeger et al., 2010). Therefore, p38/ERK 
pathways are activated in both insulin resistance and atherosclerosis. However, Nox2 depletion in 
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both models abolished the insulin-resistant phenotype by maintaining p38 and ERK 
phosphorylation levels at baseline. 
Next we sought to examine the contribution of the PI3K/Akt/eNOS pathway in insulin resistance 
and atherosclerosis. We found that eNOS phosphorylation decreased in both WT and ApoEKO 
models, indicating an impairment of the PI3K/Akt/eNOS pathway, leading to reduced NO 
production. The critical role of eNOS in atherogenesis has been demonstrated by Kuhlencordt et 
al., (2001) among others, who found that ApoE/eNOS D-KO mice showed significant 
atherosclerosis acceleration compared to ApoEKO. Moreover, Vecoli et al., (2014) found that 
cardiac ERK1-2/Akt ratio, increased in animals with eNOS gene deletions compared with WT.  As 
far as insulin resistance is concerned, mice with VENIRKO were shown to have impaired ET-1 and 
eNOS expression (Vicent et al., 2003) whereas human aortic endothelial cells exposed to high 
glucose show decreased eNOS–derived NO release (Salt et al., 2003; Morigi et al., 1998). Genetic 
deletion or inhibition of eNOS in preclinical models increases atherosclerotic burden significantly, 
providing clear evidence of the antiatherogenic role of eNOS (Kuhlencordt et al., 2001). Deletion 
of insulin receptors on vascular endothelial cells (VENIRKO or vascular endothelium insulin 
receptor knockout mice) have been shown to decrease eNOS and ET-1 mRNA levels (Vicent et al., 
2003). Also Akt-deficient mice decreased eNOS phosphorylation state which was reinstated after 
Akt reintroduction (Ackah et al., 2005). Li et al., (2010) studied spontaneously hypertensive rats 
(SHRs) and assessed insulin resistance. They found that SHR rats showed significant 
downregulated expression of PI3-kinase and decreased insulin-stimulated phosphorylations of Akt 
and eNOS in vascular tissues. Treatment with rosiglitazone, an insulin sensitizer, restored 
PI3K/Akt/eNOS-mediated signalling pathway, however only in young SHRs. From the above, the 
relationship between obesity, insulin resistance and down-regulation of Akt/eNOS is apparent.  
ESMIRO mice -overexpressing a dominant-negative mutant human IR containing a mutation in the 
tyrosine kinase domain- were found to have decreased response to acetylcholine as well as blunted 
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vascular responses to insulin stimulation and augmented Nox2- derived superoxide production 
(Duncan et al., 2008). Genetic deletion of Nox2 resulted in improved aortic response to ACh and 
decreased oxidative stress.  Apocynin, a Nox inhibitor, reversed the upregulation of Nox isoforms, 
increased eNOS function, and reduced endothelial dysfunction in STZ-induced and fructose-fed 
rats (Olukman et al., 2010; Unger and Patil, 2009). In our study, high glucose decreased Akt and 
eNOS phosphorylation, further supporting the hypothesis that in insulin resistance there is a 
dysfunction of intracellular signalling pathways favouring the MAPK over the PI3K/Akt/eNOS 
causing decreased NO bioavailability. eNOS phosphorylation status was not affected in both Nox2-
deficient and Nox2/ApoE D-KO mice suggesting the protective role of Nox2 depletion/inhibition 
in atherogenesis and insulin resistance. 
Aortas from ApoEKO mice with insulin resistance showed a marked increase in both p53 and NF-
kB. Yokoyama et al. (2014) demonstrated that endothelial p53 regulates glucose metabolism by 
modulating mitochondrial biogenesis and glucose uptake in skeletal muscle. By establishing mice 
with endothelial cell-specific p53 deficiency on a high-calorie diet they found that disruption of 
endothelial p53 activation improved dietary inactivation of eNOS. Endothelial p53 deficient mice 
showed improvement of insulin sensitivity and less fat accumulation compared with control 
littermates. On the other hand Kumar et al. (2011) demonstrated that over-expression of p53 
suppressed eNOS and stimulated ET-1 expression in HUVEC cells. ROS have been implicated in 
the phosphorylation of p53 mediated via protein kinases, including p38α MAPK (Bragado et al., 
2007) and ERK (Persons et al., 2000). In HUVEC cells it was found that H2O2 induces p53 
phosphorylation (Chen et al., 2003). ROS are also required for p53 activation in lymphocytes 
(Karawajew et al., 2005). Cells lacking antioxidant defence have decreased p53 expression and 
antioxidants were found to inhibit p53 (Sablina et al., 2005).  High lipid levels (i.e., obesity) 
increase oxidative stress levels and lead to p53 induction. This activation of p53 may help to curtail 
lipid accumulation by enhancing lipid catabolism (Goldstein & Rotter, 2012) but could also result 
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in insulin resistance and diabetes (Minamino et al., 2009). Li et al. (2007) investigated the role of 
Nox2 in nutrient deprivation-induced cell cycle arrest and apoptosis in proliferating human dermal 
microvascular endothelial cells (HMEC1). They found that Nox2 upregulation was correlated with 
p53 expression induction. In vitro deletion of Nox2 of coronary microvascular endothelial cells 
isolated from Nox2KO mice significantly inhibited p53 expression. The above studies are in 
accordance with the results from WT and ApoEKO aortas under conditions of insulin resistance 
that is Nox2-derived ROS up-regulates p53 expression. 
NF-kB was also upregulated in both WT and ApoEKO aortas in insulin resistance. Activation of 
NF-κB mediated signal transduction has been established at different stages of atherosclerosis, 
beginning from plaque formation to its destabilisation and rupture (Pamukcu et al., 2011). Gareus 
et al. (2008) found that endothelium-restricted inhibition of NF-kB activation, achieved by ablation 
of NF-kB essential modifier  (NEMO)/IkB kinase gamma (IKKγ) or expression of dominant-
negative IκBα specifically in endothelial cells, resulted in strongly reduced atherosclerotic plaque 
formation in ApoEΚΟ mice fed with a cholesterol-rich diet. Inhibition of NF-kB abrogated 
adhesion molecule induction in endothelial cells, impaired macrophage recruitment to 
atherosclerotic plaques, and reduced expression of cytokines and chemokines in the aorta. Also 
Mackesy and Goalstone (2011) showed that hyperinsulinaemia and insulin resistance appear to 
augment the inflammatory effects of TNF-α on VCAM-1 expression and NF-kB translocation, both 
of which are markers of inflammation in the vasculature. Also several studies have shown that 
hyperglycaemia promotes leukocyte adhesion to the endothelium at least in part through NF-κB–
dependent upregulation of adhesion molecules (Morigi et al., 1998; Barnes and Karin, 1997; 
Collins et al., 1993; Dosquet et al., 1992). NF-κB can be activated by NADPH oxidase through 
ROS intermediates (Clark & Valente, 2004; Fan et al., 2002; Bonizzi et al., 1999). In their study 
Anrather et al. (2006) investigated whether subunits of NADPH oxidase might be regulated by NF-
κB. In many pathological conditions such as atherosclerosis ROS production and NF-κB activation 
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are intrinsically related. In these conditions, ROS might activate NF-κB, which, in turn, induces 
gp91
phox
 expression to further enhance ROS production. They found that gp91
phox
 expression and 
transcription is dependent on p65/RelA, but they also indentified two potential cis-acting elements 
in the murine gp91
phox
 promoter that control NF-kB-dependent regulation, thus suggesting that 
there is a possibility of a positive feedback loop in which NF-kB activation by ROS leads to further 
radical production via NADPH oxidase. This study demonstrated that p53 and NF-kB levels from 
ApoEKO aortic homogenates increased under insulin resistant conditions. Nox2/ApoE D-KO 
homogenates showed no difference in either p53 or NF-kB. This is possibly due to Nox2 dependent 
ROS production which activates p53 through MAPK pathways and NF-kB, a marker of vascular 
inflammation. Our results involving increased p38 and ERK and decreased eNOS which were 
explained in previous paragraphs and increased VCAM-1, which will be explained in detail in the 
following paragraph, strongly support this hypothesis. In addition, these changes were absent in 
Nox2/ApoE D-KO mice aortas further supporting this hypothesis and suggesting a possible 
therapeutic role for Nox2 inhibition. 
Expression of VCAM-1 is induced on endothelial cells during inflammatory diseases by several 
mediators, including ROS. It functions as leukocyte migration scaffold and also endothelial 
signalling trigger through Nox-generated ROS. These ROS induce signals that facilitate leukocyte 
trans-endothelial migration (Cook-Mills et al., 2011). In atherosclerosis, VCAM-1 is the first 
adhesion molecule expressed before atherosclerotic plaque development (Iiyama et al., 1999). In 
the rodent carotid artery, neointimal formation is reduced by VCAM-1 siRNA or by antibody 
blockade of α4β1-integrin (Qu et al., 2009; Barringhaus et al., 2004). In advanced atherosclerosis, 
VCAM-1 can be expressed by smooth muscle cells (Hastings et al., 2009; Braun et al., 1999).  In 
hyperinsulinemia, VCAM-1 expression is up-regulated through Akt, p38 and ERK, among others 
(Wang et al., 2005; Jiang et al., 2004) while p38 down-regulation contribute to observed decreases 
in total and surface VCAM-1 expression in rat aorta endothelial cells (Pott et al., 2016). 
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Endothelial over-expression of Nox2 in ApoEKO mice significantly increased vascular superoxide 
production compared with ApoEKO. Increased endothelial superoxide production increased 
endothelial levels of VCAM-1 and enhanced macrophage recruitment in early lesions in the aortic 
roots of 9-week-old mice, indicating increased atherosclerotic plaque initiation (Douglas et al., 
2012). Blocking gp91
phox
 expression using antisense RNA induces a decrease in VCAM-1-
mediated H2O2 production in endothelial cells (Cook-Mills et al., 2004). Apocynin blocks VCAM-
1-stimulated H2O2 generation in endothelial cell lines and primary cultures of endothelial cells 
(Matheny et al., 2000). Mice deficient in non-hematopoietic Nox2 exhibit a reduction in VCAM-1-
dependent recruitment of leukocytes (Abdala-Valencia et al., 2007). In this study, in insulin 
resistant ApoEKO mice, Nox2-derived ROS was linked to increased endothelial cell activation. In 
Nox2/ApoE DKO mice, insulin resistance had no effect on VCAM-1 expression. 
In summary, my study indicated that insulin-resistance in atherosclerosis is linked to Nox2-induced 
ROS production which results in endothelial dysfunction, endothelial cell activation and IR 
impairment. IR dysfunction has an effect on downstream signalling pathways, attenuating the 
PI3K/Akt/eNOS branch in favour of the MAPK one.  Insulin resistance had no effect on 
Nox2/ApoE D-KO mice models indicating the therapeutic potential of Nox2 inhibition in the 
involvement of obesity related metabolic syndrome and endothelial dysfunction. 
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CHAPTER 5 
White adipose tissue formation, Nox2-derived oxidative stress, 
endothelial cell activation, insulin receptor expression and 
inflammation in obesity 
5.1 Introduction 
Obesity is characterised by excessive body fat leading to health problems and is now considered to 
be a form of chronic mild inflammation. Current studies have demonstrated that adipose tissue is an 
active endocrine and paracrine organ that releases a large number of cytokines and bioactive 
mediators that influence not only body weight homeostasis but also inflammation, coagulation, 
fibrinolysis, insulin resistance, diabetes, atherosclerosis as well as some forms of cancer 
(Kopelman, 2000; Mohamed-Ali et al., 1997; Lau et al., 1996). The cellular mechanisms linking 
obesity and atherosclerosis are complex and have not been fully elucidated.  
The stress imposed on adipocytes by lipid droplet creation and expansion takes place mainly in the 
endoplasmic reticulum (ER) and mitochondria. The ER dysfunction that accompanies adipocyte 
hypertrophy can result in impaired post-translational modification of proteins, which can result in 
improper folding of newly synthesized proteins, the formation of lipid droplets and impaired 
cholesterol sensing (de Ferranti and Mozaffarian, 2008). The accumulation of unfolded proteins in 
the cytosol of adipocytes can lead to increased release of free fatty acids and inflammatory 
mediators, which in turn can activate JNK in muscle, liver, and adipose cells, thereby promoting 
insulin resistance in these tissues (de Ferranti and Mozaffarian, 2008). Mitochondrial dysfunction 
also appears to add to the stress experienced by hypertrophied adipocytes. Mitochondrial 
uncoupling caused by the processing of excess fatty acids in adipocytes can result in an enhanced 
production of ROS (Wojtczak and Schonfeld, 1993).  
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Activated adipocytes secrete in an endocrine way a variety of biological peptides with cytokine-like 
properties called adipokines differentiating monocytes to macrophages and recruiting these 
activated macrophages into the adipose tissue thus leading to ROS and inflammatory cytokine 
production. Two types of mediator in a paracrine loop produce and release more ROS, recruiting 
more macrophages in the adipose tissue and thus leading to a vicious cycle (Surmi & Hasty, 2010). 
Macrophages strongly express Nox2. It has been found that ROS activates ERK in various cell 
types (Guyton et al., 1996b) and redox regulation is important for the ERK pathway during 
lymphocyte activation (Hardy and Hunt, 2004). Mendez-Samperio et al., (2010) demonstrated that 
ROS increased ERK and p38 activation and phosphorylation in monocytes. Zhang et al., (2013) 
demonstrated that for monocyte differentiation ROS is generated and is essential for ERK 
activation. ROS inhibition inactivated ERK and blocked differentiation. Moreover Xu et al., (2016) 
demonstrated that Nox2 specifically is important for ERK activation during differentiation of 
monocytes to macrophages. ERK deficiency or Nox2 deletion caused failure in monocyte to 
macrophage differentiation. ERK pathway is also activated in adipocytes. Ozaki et al., (2016) 
found that enhanced ERK signalling was associated with dysregulation of adipokine expression and 
is associated with insulin resistance in obesity. In vivo studies with ERK1 knockout (ERK1KO) 
mice have indicated that ERK1 but not ERK2, is the isoform active in adipogenesis. ERK1KO 
mice are protected from insulin resistance and HFD-induced obesity (Bost et al., 2005). As with 
ERK, p38 and JNK show an induced activation immediately after induction of adipogenesis in 
3T3-L1 cells (Pagano et al., 2008). Therefore ERK pathway is activated both in macrophages and 
adipocytes in obesity. However, ERK activation due to Nox2-induced ROS production occurs only 
in macrophages since adipocytes express Nox4 rather than Nox2 (Han et al., 2012).   
Since obesity is characterised as a chronic, low-grade inflammation, macrophages play an 
important role in its development and propagation. In obesity, hypertrophied adipocytes secrete 
various adipokines and cytokines such as leptin and TNF-α (Xu, 2003). Leptin facilitates 
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macrophage infiltration into adipose tissue (Sierra-Honigmann et al., 1998) and monocyte 
chemoattractant protein-1 (MCP-1) is also essential for macrophage recruitment. Moreover 
decreased adiponectin promotes macrophage adhesion to endothelial cells (Maeda, 2002) 
perpetuating a vicious cycle of macrophage recruitment, cytokine production and adipose 
dysfunction.  For macrophage infiltration, first monocytes from the bloodstream go through the 
process of adhesion and migration. Inhibition of this process has been shown to ameliorate 
atherotic plaque development (Mestas and Ley, 2008). Cellular adhesion and migration is mediated 
via cell adhesion molecules such as ICAM-1. Increased ICAM-1 levels result from increased TNF-
, leptin and resistin levels, reduced adiponectin and the oxidative stress elicited in obese adipose 
tissue (Singer and Granger, 2007). Brake et al., (2006) after feeding mice with HFD found 
increased ICAM-1 expression in adipose tissue which may assist macrophage recruitment and 
signalling in an obese state. Moreover, Bosanska et al., (2010) examined mRNA expression and 
protein levels of ICAM-1, VCAM-1 and E-selectin in subcutaneous (SAT) and visceral adipose 
tissue (VAT) of obese and lean healthy women. They found that obesity increased ICAM-1 and 
VCAM-1 mRNA expression and protein levels in VAT. 
Macrophages infiltrating adipose tissue initiate inflammatory pathways and can disrupt function by 
promoting insulin resistance (Hill et al., 2014). Several studies have shown that reversal of the 
imbalance between ROS and antioxidants improves insulin resistance in mice and 
humans suggesting that oxidative stress is a causative factor in the development of insulin 
resistance (Fridlyand & Philipson, 2006; Maddux et al., 2001). Several recent studies have 
addressed the molecular mechanisms by which oxidative stress might lead to insulin resistance. In 
vitro ROS and oxidative stress lead to the activation of multiple serine/threonine kinase signalling 
cascades (Evans et al., 2003). These kinases can act on a number of potential targets in the insulin 
signalling pathway, including the insulin receptor and the family of IRS proteins. For IRS-1 and 
IRS-2 an increase in serine phosphorylation decreases the extent of the activating tyrosine 
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phosphorylation (Evans et al., 2003). The kinases that have been shown to be activated by 
oxidative stress include JNK, p38 MAPK and IKKβ (Hirosumi et al., 2002; Yuan et al., 2001; Blair 
et al., 1999).  
Insulin resistance has also been shown to negatively affect macrophage function itself, especially in 
the context of atherosclerotic disease. Although glucose uptake primarily takes place via insulin-
independent pathways involving GLUT1, circulating monocytes express the insulin receptor 
machinery and develop resistance to the effects of insulin. Interestingly, insulin receptor deficiency 
on macrophages reduces their infiltration into the adipose tissue and alleviates the development of 
low-grade inflammation and systemic insulin resistance in mice on an HFD (Mauer et al., 2010). 
Functional consequences of insulin resistance include a failure to deal with ER stress, which 
enhances the risk of macrophage apoptosis and subsequent loss of function (Han et al., 2006).   
In addition to apoptosis primary macrophages isolated from ob/ob mice have a defect in the process 
of removal of dead cells by phagocytosis that was associated with defective PI3K activity, whereas 
cells lacking the insulin receptor were protected (Tabas et al., 2010). The insulin signalling 
pathway involves both PI3K/Akt/eNOS and MAPK activation pathways. More specifically, IRS1 
and IRS2 deficiency causes biased PI3K inactivation and sustained MAPK activation (Qi et al., 
2013; Dong et al., 2008). IRS1 and IRS2 inhibition inactivates PI3K disrupting nutrient 
homeostasis and prolongs activation of MAP kinases (ERK1/2, p38 and JNK), resulting in obesity. 
Moreover, mice lacking either the PI3K catalytic subunit or Akt2 exhibited insulin resistance and 
type-2 diabetes (Brachmann et al., 2005; Cho et al., 2001). On the contrary deletion of ERK1 in 
mice prevented growth of adipocytes and improved insulin resistance following a HFD treatment 
(Bost et al., 2005). 
Uncoupling protein-1 is mainly expressed in BAT, and acts in thermogenesis, regulation of energy 
expenditure, and protection against oxidative stress. All these mechanisms are associated with the 
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pathogenesis of obesity (Brondani et al., 2012). It has recently been reported that UCP1 is also 
present in WAT of mouse and humans in various tissues (Nagase et al., 1996). However, the 
physiological role of UCP1 in these tissues is still a matter of debate. UCP1 activity allows a more 
rapid flux of electrons through the inner mitochondrial membrane, reducing membrane potential 
and therefore decreasing ROS production (Fisler and Warden, 2006). Thus, the main role of UCP1 
in these tissues seems to be protection against oxidative stress (Brand, 2004). Superoxide anions 
could activate UCPs through lipid peroxidation products (Brand et al., 2004). On the other hand, 
SOD enzymes inhibit UCP1 activity (Echtay et al., 2002). There are limited studies on the effect of 
ROS on UCP1 and most of them involve mitochondrial ROS. Therefore the role of Nox2-derived 
ROS on UCP1 expression in adipose tissue is an uncharted territory. In this chapter the relationship 
of Nox2-induced ROS due to obesity and adipose tissue dysfunction was examined.  
5.2 Methods 
In order to examine Nox2-induced ROS production due to obesity C57BL/6 WT and Nox2KO 
mice under NCD and HFD were used. Epididymal fat pads were used due to the fact that they can 
be examined more accurately due to the ease of dissection and the morphology of adipose cells is 
more homogeneous. Fat pads were excised and the expression of the following proteins was 
determined by immunofluorescence: Nox2, ICAM-1, macrophage recruitment, insulin receptor and 
eNOS phosphorylation (see 2.21). Also obesity induced ROS production due to Nox2 was linked 
with atherosclerosis using ApoEKO and Nox2/ApoE DKO mice under NCD and HFD by the 
determination of ROS production by DHE fluorescence microplate reader (see 2.19), Nox2, p47
phox
 
and p-ERK expression by western blot (see 2.20) and UCP1 expression by immunofluorescence 
(see 2.21). In this Chapter epididymal fat pads from transgenic mice with endothelial-targeted 
overexpression of Nox2 were used as well at two different age groups (3-4 months and 15-17 
months old). These tissues have been donated by Oxord University from Professor Channon’s lab.   
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5.3 Results 
5.3.1 Gross appearance of HFD-fed ApoEKO and Nox2/ApoE D-KO mice 
and abdominal view of their epididymal fat pads 
In order to test the effect of obesity on white adipose tissue HFD ApoEKO and Nox2/ApoE D-KO 
epididymal fat pads were collected as previously described (see chapter 2.7). It was found that 
ApoEKO mice and their epididymal fat pads were considerably larger than the respective 
Nox2/ApoE D-KO (Fig. 5.1). 
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Figure 5.1: Gross appearance of HFD-fed ApoEKO and Nox2/ApoE D-KO mice and 
abdominal view of their epididymal fat pads. 
 
ApoEKO D-KO
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5.3.2 HFD-induced ROS production in C57BL/6 WT and ApoEKO 
epididymal fat pads 
Production of O2
.−
 by epididymal fad pads from C57BL/6 WT, Nox2KO, ApoEKO and 
Nox2/ApoE D-KO mice was measured by DHE Fluorescence Microplate (Fig. 5.2). Measurements 
were conducted on fat pads from NCD and HFD mice. There was a significant increase in ROS 
production in HFD WT epididymal fat pad homogenates compared with NCD WT controls (NCD 
319.5 ± 12.6 versus HFD 406.5 ± 11.1 Fluorescence Intensity * p<0.05). There was also a 
significant increase in ROS production in HFD ApoEKO epididymal fat pad homogenates 
compared with NCD ApoEKO controls (459.7 ± 7.4 versus 611.5 ± 37.7 Fluorescence Intensity * 
p<0.05). There was no significant difference between NCD and HFD in Nox2KO (258.1 ± 7.6 
versus 277.9 ± 2.7 Fluorescence Intensity p>0.05) and Nox2/ApoE D-KO (264.3 ± 23.1 versus 
269.1 ± 13.5 Fluorescence Intensity p>0.05) epididymal fat pads. There was however a significant 
decrease in ROS production in Nox2KO and Nox2/ApoE D-KO compared with WT and ApoEKO 
HFD epididymal fat pad homogenates respectively (WT 406.5 ± 11.1 versus Nox2KO 277.9 ± 2.7 
Fluorescence Intensity * p<0.05; ApoEKO 611.5 ± 37.7 versus Nox2/ApoE D-KO 269.1 ± 13.5 
Fluorescence Intensity *  p<0.05).  
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Figure 5.2: Quantitative analysis of ROS by DHE fluorescence microplate reader on 
epididymal fat pad homogenates of WT, Nox2KO, ApoEKO and Nox2/ApoE D-KO mice 
under normal chow diet (NCD) and high fat diet (HFD).  Data are expressed as mean ± SEM 
with a number of 3-6 mice per group. Comparisons were made by two-way ANOVA with 
Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * p<0.05 
significantly different from WT/ApoEKO values. 
 
5.3.3 Epididymal fat pad ROS production in endothelial specific Nox2-Tg mice 
Production of O2
.−
 by epididymal fad pads from mice overexpressing Nox2 specifically in the 
endothelium (Nox2-Tg) was measured by lucigenin chemiluminescence (Fig. 5.3A and Fig. 5.3B) 
and DHE Fluorescence Microplate (Fig. 5.3C). Measurements were conducted using 3-4 and 15-17 
month old mice.  
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There was a significant increase in ROS production by lucigenin chemiluminescence (Fig. 5.3A) in 
ageing WT epididymal fat pad homogenates compared with young WT controls (3-4 months 27.0 ± 
1.2 versus 15-17 months 94.2 ± 5.1 MLU * p<0.05). There was also a significant increase in ROS 
production in ageing Nox2-Tg epididymal fat pad homogenates compared with young Nox2-Tg 
controls (111.9 ± 5.14 versus 143.1 ± 6.9 MLU * p<0.05). In order to further examine the 
enzymatic sources of superoxide production, a number of different inhibitors were used (Fig. 5.3B). 
Rotenone (mitochondria complex 1 enzyme inhibitor; WT ROS 100.8 ± 4.5 versus Rotenone 96.7 
± 7.8; Nox2-Tg ROS 154.1 ± 11.7 versus Rotenone 156.4 ± 11.1 MLU p>0.05) and oxypurinol 
(xanthine oxidase inhibitor; 100.8 ± 4.5 versus 110.9 ± 10.4; 154.1 ± 11.7 versus 156.3 ± 5.2 MLU 
p>0.05) had no effect on superoxide production. However, DPI (a flavo-protein inhibitor; 100.8 ± 
4.5 versus 27.5 ± 1.4; 154.1 ± 11.7 versus 41.8 ± 4.2 MLU * p<0.05), apocynin (Nox2 inhibitor; 
100.8 ± 4.5 versus 24.3 ± 3.3; 154.1 ± 11.7 versus 36.1 ± 5.0 MLU * p<0.05) and L-NAME (NOS 
inhibitor; 100.8 ± 4.5 versus 80.7 ± 4.5 MLU * p<0.05 by unpaired t-test; 154.1 ± 11.7 versus 
107.3 ± 6.6 MLU * p<0.05) greatly reduced superoxide production. The specificity of O2
.−
 was 
confirmed by adding tiron (10 mM; 100.8 ± 4.5 versus 6.8 ± 1.2; 154.1 ± 11.7 versus 8.9 ± 2.5 
MLU * p<0.05) to scavenge the O2
.−
. There was also a significant increase in ROS production by 
DHE fluorescence (Fig. 5.3C) in ageing WT epididymal fat pad homogenates compared with 
young WT controls (3-4 months 147.7 ± 11.2 versus 15-17 months 199 ± 5.3 Fluorescence 
Intensity * p<0.05). There was also a significant increase in ROS production in ageing Nox2-Tg 
epididymal fat pad homogenates compared with young Nox2-Tg controls (270.3 ± 5.5 versus 337.0 
± 12.5 Fluorescence Intensity * p<0.05). 
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5.3.4 Increased Nox2, p47
phox
 and p-ERK expression in HFD C57BL/6 WT 
epididymal fat pads 
In order to test the effect of obesity on Nox2 expression and downstream signalling pathways, 
Nox2, p47
phox
 and p-ERK protein levels were determined using the respective antibodies in 
epididymal fat pads from WT and Nox2KO mice under NCD and HFD (Fig.5.4). It was found that 
Figure 5.3: (A) Tiron-inhibitable superoxide anion production was detected by NADPH-dependant  
lucigenin (5μΜ) chemiluminescence in epididymal fat pad homogenates of  3-4 month and 15-17 
month old WT and Nox2-Tg mice. (B) The source of NADPH-dependent superoxide production of 
15-17 month WT and Nox2-Tg epididymal fat pad homogenates was examined using different 
inhibitors. Rot, rotenone; Oxy, oxypurinol; L-NAME; DPI, d phenylene iodonium; Apo, apocynin; 
Tiron. (C) Quantitative analysis of ROS by DHE fluorescence microplate reader on epididymal fat 
pad homogenates of 3-4 month and 15-17 month old WT and Nox2-Tg mice.  Data are expressed as 
mean ± SEM with a number of 3-6 mice per group. Comparisons were made by two-way ANOVA 
with Bonferroni post-hoc test * p<0.05 significantly different from WT values; * p<0.05 
significantly different from ROS values. 
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HFD induced Nox2 expression in WT epididymal fat pads compared to NCD (Fig. 5.4A; NCD 
0.25 ± 0.02 versus HFD 0.75 ± 0.06 OD Units * p<0.05). HFD also induced WT mice p47
phox
 (Fig. 
5.4B; 0.26 ± 0.02 versus 0.67 ± 0.05 OD Units * p<0.05) and ERK phosphorylation protein levels 
(Fig. 5.4C; 0.79 ± 0.08 versus 1.76 ± 0.04 OD Units * p<0.05). HFD had no effect on Nox2KO 
mice (Fig. 5.4B; 0.12 ± 0.02 versus 0.17 ± 0.04 OD Units p>0.05) (Fig. 5.4C; 0.30 ± 0.01 versus 
0.44 ± 0.05 OD Units p>0.05). 
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Figure 5.4:  
Figure 5.4: C57BL/6 WT and Nox2KO epididymal fat pad homogenates were examined for (A) 
Nox2, (B) p47phox and (C) phosphorylated ERK protein expression using gp91
phox
, p47
phox
 and 
phosphorylated ERK antibodies. Optical densities of gp91
phox
, p47
phox
 and phosphorylated ERK 
were quantified and normalised to the levels of α-tubulin and total ERK detected in the same 
sample. Data are expressed as mean ± SEM with a number of 3 mouse epididymal fat pads per 
group. Comparisons were made by Student’s unpaired t-test or two-way ANOVA with 
Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * p<0.05 
significantly different from WT values. 
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5.3.5 Increased Nox2, p47
phox
, p22
phox
 and p-ERK expression in HFD 
ApoEKO epididymal fat pads 
In order to test the effect of obesity in Nox2 expression and Nox2 regulatory molecules and 
intracellular signalling cascades, gp91
phox
, p47
phox 
and p22
phox 
were determined as well as ERK1/2 
phosphorylation levels by western blot using the respective antibodies. The samples consisted of 
epididymal fat pad homogenates from both ApoEKO and Nox2/ApoE D-KO mice under NCD and 
HFD. It was found that HFD induced Nox2 expression in ApoEKO epididymal fat pads compared 
to NCD (Fig. 5.5A; NCD 0.64 ± 0.06 versus HFD 1.19 ± 0.05 OD Units * p<0.05). p47
phox
 (Fig. 
5.5B; 0.52 ± 0.07 versus 0.95 ± 0.05 OD Units * p<0.05) and p22
phox
 (Fig. 5.5C; 0.23 ± 0.01 versus 
0.47 ± 0.01 OD Units * p<0.05) were also up-regulated under the same conditions (Fig. 5.5B; Fig. 
5.5C). ERK1/2 phosphorylation levels normalised against total ERK were increased in HFD 
ApoEKO epididymal fat pad homogenates compared to NCD (Fig. 5.5D; 1.56 ± 0.13 versus 3.28 ± 
0.18 OD Units * p<0.05) (Fig. 5.5D). There was no significant difference between NCD and HFD 
in Nox2/ApoE D-KO epididymal fat pads (Fig. 5.5B; 0.11 ± 0.01 versus 0.15 ± 0.03 OD Units 
p>0.05) (Fig. 5.5C; 0.18 ± 0.02 versus 0.16 ± 0.02 p>0.05) (Fig. 5.5D; 0.39 ± 0.03 versus 0.42 ± 
0.01 OD Units p>0.05). 
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Figure 5.5: ApoEKO and Nox2/ApoE D-KO epididymal fat pad homogenates were examined for (A) 
Nox2, (B) p47
phox
, (C) p22
phox 
 and (D) phosphorylated ERK  protein expression using gp91
phox
, 
p47
phox
, p22
phox
 and phosphorylated ERK antibodies. Optical densities of gp91
phox
, p47
phox
, p22
phox 
and 
phosphorylated ERK were quantified and normalised to the levels of α-tubulin and total ERK detected 
in the same sample. Data are expressed as mean ± SEM with a number of 3-4 mouse epididymal fat 
pads per group. Comparisons were made by Student’s unpaired t-test or two-way ANOVA with 
Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * p<0.05 significantly 
different from ApoEKO values. 
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Nox2-Tg mice have been studied at 3-4 month and 15-17 month old. First Nox2 expression has 
been determined using gp91
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 and p22
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 antibodies in western blot experiments (Fig. 5.6). It 
was found that ageing induced Nox2 expression in WT (3-4 months 0.84 ± 0.01 versus 15-17 
months 1.20 ± 0.00 OD Units * p<0.05) and Nox2-Tg (1.93 ± 0.01 versus 3.37 ± 0.19 OD Units * 
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Figure 5.6: C57BL/6 WT and Nox2-Tg epididymal fat pad homogenates were examined for Nox2 
and p22
phox
 protein expression using gp91
phox
 and p22
phox
 antibodies. (A) Representative 
immunoblot images showing Nox2 and p22
phox 
protein expression. (B) Optical densities of 
gp91
phox
, p22
phox
 were quantified and normalised to the levels of α-tubulin detected in the same 
sample. Data are expressed as mean ± SEM with a number of 3-4 mouse epididymal fat pads per 
group. Comparisons were made by two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from 3-4 month values; * p<0.05 significantly different from WT values. 
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5.3.7 Increased p-38 and decreased Akt phosphorylation in endothelial  
specific Nox2-Tg mice 
In order to study Nox2 intracellular cascades in obesity, p-38 and Akt phosphorylation levels were 
determined using immunoblots in both WT and Nox2-Tg mice (Fig. 5.7). It was found that ageing 
induced p-p38 expression in WT (3-4 months 0.09 ± 0.01 versus 15-17 months 0.37 ± 0.04 OD 
Units * p<0.05) and Nox2-Tg (0.62 ± 0.04 versus 0.87 ± 0.01 OD Units * p<0.05) epididymal fat 
pads compared to young. p-Akt was downregulated under HFD (WT 0.61 ± 0.01 versus 0.42 ± 0.05 
OD Units * p<0.05; Nox2-Tg 0.34 ± 0.02 versus 0.09 ± 0.00 OD Units * p<0.05).  
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Figure 5.7: C57BL/6 WT and Nox2-Tg epididymal fat pad homogenates were examined for 
phosphorylated p38 and phosphorylated Akt protein expression using phosphorylated p38 and 
Akt antibodies. (A) Representative immunoblot images showing phosphorylated p38 and 
phosphorylated Akt protein expression. (B) Optical densities of phosphorylated p38 and Akt 
were quantified and normalised to the levels of total p38 and Akt detected in the same sample. 
Data are expressed as mean ± SEM with a number of 3-4 mouse epididymal fat pads per group. 
Comparisons were made by Student’s unpaired t-test or two-way ANOVA with Bonferroni post-
hoc test * p<0.05 significantly different from 3-4 month values; * p<0.05 significantly different 
from WT values. 
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5.3.8 Increased Nox2 expression and reduced UCP1 in WT epididymal fat 
pads 
Next we focused on epididymal fat pad Nox2 expression and signalling molecules. First Nox2 and 
UCP1 expression in WT and Nox2KO mice was determined using immunofluorescence (Fig. 5.8). 
Nox2 expression was up-regulated in WT epididymal fat pads under HFD compared to NCD (NCD 
525.5 ± 3.6 versus HFD 574.4 ± 0.7 Fluorescence Intensity * p<0.05) whereas HFD UCP1 
expression was reduced compared to NCD (545.4 ± 0.6 versus 418.0 ± 7.6 Fluorescence Intensity * 
p<0.05). There was no effect in Nox2KO mice (546.5 ± 5.5 versus 545.7 ± 3.1 Fluorescence 
Intensity p>0.05). 
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Figure 5.8: Immunofluorescence images of HFD C57BL/6 WT and Nox2KO mouse 
epididymal fat pad sections stained with Nox2 and UCP1. Nox2KO mouse epididymal fat pad 
sections stained only with UCP1.  Nox2  was labelled by Cy3 (red) and UCP1 was labelled 
by FITC (green) and nuclei was labelled by DAPI (blue). The fluorescent intensity of 
individual molecule was quantified. Data are expressed as mean ± SEM with a number of 4-6 
mice per group. Comparisons were made by Student’s unpaired t-test or two-way ANOVA 
with Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * p<0.05 
significantly different from WT values. 
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5.3.9 Increased Nox2 expression and reduced UCP1 in ApoEKO 
epididymal fat pads 
The same experiment as 5.3.8 was performed in ApoEKO and Nox2/ApoE D-KO mice using both 
western blotting against α-tubulin and anti-UCP1 antibody (Fig. 5.9A) and immunofluorescence 
(Fig. 5.9B) for the simultaneous detection of Nox2/CD31 and UCP1. Both techniques showed a 
decrease in UCP1 (immunofluorescence NCD 500.3 ± 5.8 versus HFD 404.4 ± 0.6 Fluorescence 
Intensity * p<0.05) expression in epididymal fat pad homogenates from ApoEKO mice. There was 
no difference in Nox2/ApoE D-KO mice (immunofluorescence 574.5 ± 1.2 versus 572.7 ± 4.1 
Fluorescence Intensity p>0.05).  Nox2 expression was up-regulated in HFD ApoEKO epididymal 
fat pads compared to NCD (Fig. 5.9B; 571.9 ± 7.1 versus 668.5 ± 6.4 Fluorescence Intensity * 
p<0.05).  
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Figure 5.9: (A) Tissue homogenates were examined for UCP1 protein expression using 
UCP1 antibodies. α-tubulin was used as a loading control. (B) Immunofluorescence images 
of HFD ApoEKO and Nox2/ApoE D-KO mouse epididymal fat pad sections stained with 
Nox2 and UCP1. Nox2/ApoE D-KO mouse epididymal fat pad sections stained only with 
UCP1.  Nox2 was labelled by Cy3 (red) and UCP1 was labelled by FITC (green) and nuclei 
was labelled by DAPI (blue). The fluorescent intensity of individual molecule was quantified. 
Data are expressed as mean ± SEM with a number of 6 mice per group. Comparisons were 
made by Student’s unpaired t-test  or two-way ANOVA with Bonferroni post-hoc test * 
p<0.05 significantly different from NCD values; * p<0.05 significantly different from 
ApoEKO values. 
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5.3.10 Increased Nox2 expression and ERK phosphorylation in HFD 
ApoEKO epididymal fat pads 
Next, Nox2 activated intracellular signalling pathways were investigated by examining the 
phosphorylation levels of ERK1/2 on epididymal fat pad homogenates after NCD and HFD in both 
ApoEKO and Nox2/ApoE D-KO mice (Fig. 5.10). HFD increased levels of Nox2 (NCD 367.0 ± 
3.9 versus HFD 477.2 ± 0.6 Fluorescence Intensity * p<0.05) and phospho-ERK1/2 (449.1 ± 4.8 
versus 523.6 ± 5.3 Fluorescence Intensity * p<0.05) in ApoEKO mice compared to NCD. There 
was no effect on phospho-ERK1/2 levels in Nox2/ApoE D-KO mice (428.3 ± 0.4 versus 428.5 ± 
0.4 Fluorescence Intensity p>0.05).  
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Figure 5.10: Immunofluorescence images of HFD ApoEKO and Nox2/ApoE D-KO mouse 
epididymal fat pad sections stained with Nox2 and phosphorylated ERK. Nox2/ApoE D-KO 
mouse epididymal fat pad sections stained only with phosphorylated ERK. Nox2 was labelled 
by Cy3 (red) and phosphorylated ERK was labelled by FITC (green) and nuclei was labelled 
by DAPI (blue). The fluorescent intensity of individual molecule was quantified. Data are 
expressed as mean ± SEM with a number of 4-6 mice per group. Comparisons were made by 
Student’s unpaired t-test or two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from NCD values; * p<0.05 significantly different from ApoEKO values. 
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5.3.11 Increased Nox2 and ICAM expression in HFD C57BL/6 WT 
epididymal fat pads 
Nox2 and ICAM expression was determined in epididymal fat pad homogenates from both WT and 
Nox2KO mice under NCD and HFD. It was found that WT mice had increased Nox2 levels in 
epididymal fat pads under HFD when compared to NCD (Fig. 5.11; NCD 423.4 ± 0.3 versus HFD 
529.8 ± 1.8 Fluorescence Intensity * p<0.05). ICAM-1 expression was also increased in the same 
conditions (363.1 ± 0.2 versus 520.3 ± 12.1 Fluorescence Intensity * p<0.05). There was no 
difference in Nox2KO mice (362.7 ± 0.7 versus 362.8 ± 2.3 Fluorescence Intensity p>0.05).  
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Figure 5.11: Immunofluorescence images of HFD C57BL/6 WT and Nox2KO mouse 
epididymal fat pad sections stained with Nox2 and ICAM-1. Nox2KO mouse epididymal fat 
pad sections stained only with ICAM-1. Nox2 was labelled by Cy3 (red) and ICAM-1 was 
labelled by FITC (green) and nuclei was labelled by DAPI (blue). The fluorescent intensity of 
individual molecule was quantified. Data are expressed as mean ± SEM with a number of 4-6 
mice per group. Comparisons were made by Student’s unpaired t-test or two-way ANOVA 
with Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * p<0.05 
significantly different from WT values. 
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5.3.12 Increased Nox2 and ICAM expression and macrophage recruitment 
in HFD ApoEKO epididymal fat pads 
The same experiment as 5.11 was performed in ApoEKO and Nox2/ApoE D-KO mice under NCD 
and HFD. It was found that ApoEKO epididymal fat pad homogenates under HFD had significant 
increased levels of Nox2 (NCD 472.0 ± 5.0 versus HFD 546.8 ± 0.5 Fluorescence Intensity * 
p<0.05) and ICAM-1 (414.0 ± 5.4 versus 599.0 ± 0.7 Fluorescence Intensity * p<0.05) expression 
compared to NCD (Fig. 5.12A). For the determination of macrophage recruitment in epididymal fat 
pads immunofluorescence using F4/80 antibody was applied. F4/80 is a well-characterised 
membrane protein and is the best known mature mouse macrophage marker. Epididymal fat pads 
from ApoEKO mice under HFD had increased Nox2 (671.4 ± 6.6 versus 733.0 ± 1.2 Fluorescence 
Intensity * p<0.05) and F4/80 expression (441.0 ± 7.4 versus 502.0 ± 0.2 Fluorescence Intensity * 
p<0.05) and therefore macrophage recruitment compared to NCD (Fig. 5.12B). There was no 
difference on either ICAM-1 (363.5 ± 2.4 versus 363.8 ± 0.6 Fluorescence Intensity p>0.05) or 
F4/80 (400.1 ± 4.5 versus 409.3 ± 12.8 Fluorescence Intensity p>0.05) expression in Nox2/ApoE 
D-KO mice. 
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Figure 5.12: Immunofluorescence images of HFD ApoEKO and Nox2/ApoE D-KO mouse 
epididymal fat pad sections stained with Nox2 and ICAM-1/F4/80.  Nox2/ApoE D-KO mouse 
epididymal fat pad sections stained only with ICAM-1 and F4/80 respectively. Nox2 was 
labelled by Cy3 (red) and ICAM-1/F4/80 was labelled by FITC (green) and nuclei was 
labelled by DAPI (blue). (A) The fluorescence intensity of Nox2 and ICAM-1 was quantified. 
(B) The fluorescence intensity of Nox2 and F4/80 was quantified. Data are expressed as mean 
± SEM with a number of 3-6 mice per group. Comparisons were made by Student’s unpaired 
t-test or two-way ANOVA with Bonferroni post-hoc test * p<0.05 significantly different from 
NCD values; * p<0.05 significantly different from ApoEKO values. 
252 
 
5.3.13. Increased Nox2 expression and reduced insulin receptor and eNOS 
phosphorylation in HFD C57BL/6 WT epididymal fat pads 
Finally, the relationship between Nox2 expression and insulin receptor/eNOS phosphorylation was 
investigated. The simultaneous expression of Nox2 and IRα was determined using Nox2/CD31 and 
IRα antibodies by immunofluorescence in epididymal fat pad homogenates from C57BL/6 WT and 
Nox2KO mice under NCD and HFD (Fig. 5.13A). It was found that HFD significantly increased 
Nox2 expression (NCD 465.1 ± 2.0 versus HFD 892.1 ± 16.7 Fluorescence Intensity *  p<0.05) 
while IRα expression was significantly decreased (436.5 ± 0.7 versus 359.9 ± 1.6 Fluorescence 
Intensity * p<0.05) in epididymal fat pads from WT mice. Nox2 and eNOS phosphorylation were 
determined using Nox2/CD31 and phospho-eNOS antibodies by immunofluorescence in the same 
samples (Fig. 5.13B). Again it was found that HFD increased significantly Nox2 (760.8 ± 2.4 
versus 782.5 ± 5.0 Fluorescence Intensity * p<0.05) expression while phospho-eNOS was 
significantly decreased (383.9 ± 1.5 versus 357.1 ± 1.9 Fluorescence Intensity * p<0.05) in WT 
mice under HFD compared to NCD. There was no effect on Nox2KO mice (IRα 436.8 ± 0.4 versus 
436.0 ± 0.4 Fluorescence Intensity p>0.05; p-eNOS 385.0 ± 1.6 versus 385.2 ± 2.6 Fluorescence 
Intensity p>0.05). 
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Figure 5.13: Immunofluorescence images of HFD WT and Nox2KO mouse epididymal 
fat pad sections stained with Nox2 and IR-α/phosphorylated eNOS. Nox2KO mouse 
epididymal fat pad sections stained only with IR-α and phosphorylated eNOS 
respectively. Nox2 was labelled by Cy3 (red) and IR-α /p-eNOS was labelled by FITC 
(green) and nuclei was labelled by DAPI (blue). (A) The fluorescence intensity of Nox2 
and IR-α was quantified. (B) The fluorescence intensity of Nox2 and phosphorylated 
eNOS was quantified.  Data are expressed as mean ± SEM with a number of 5-6 mice 
per group. Comparisons were made by Student’s unpaired t-test or two-way ANOVA 
with Bonferroni post-hoc test * p<0.05 significantly different from NCD values; * 
p<0.05 significantly different from WT values. 
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5.3.14. Increased Nox2 expression and reduced insulin receptor and eNOS 
phosphorylation in HFD ApoEKO epididymal fat pads 
The same experiment as 5.13 was performed in epididymal fat pad homogenates from ApoEKO 
and Nox2/ApoE D-KO mice under NCD and HFD. Nox2 and IRα expression and eNOS 
phosphorylation were determined using immunofluorescence as described in 5.13. It was found that 
ApoEKO fat pads had increased Nox2 expression (Fig. 5.14A NCD 511.0 ± 4.7 versus HFD 907.3 
± 2.1 Fluorescence Intensity * p<0.05; Fig.5.14B 781.1 ± 0.4 versus 804.9 ± 0.9 Fluorescence 
Intensity * p<0.05), decreased IRα expression (Fig. 5.14A; 431.7 ± 1.2 versus 357.5 ± 0.3 
Fluorescence Intensity * p<0.05) and decreased phospho-eNOS (Fig. 5.14B; 381.0 ± 0.5 versus 
352.3 ± 0.4 Fluorescence Intensity * p<0.05) levels under HFD compared to NCD. There was no 
difference in Nox2/ApoE D-KO mice (IRα; 435.2 ± 3.4 versus 436.2 ± 0.5 Fluorescence Intensity 
p>0.05; p-eNOS 384.4 ± 0.3 versus 385.2 ± 0.5 Fluorescence Intensity p>0.05). 
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Figure 5.14: Immunofluorescence images of HFD ApoEKO and Nox2/ApoE D-KO mouse 
epididymal fat pad sections stained with Nox2 and IR-α/phosphorylated eNOS. Nox2/ApoE D-
KO mouse epididymal fat pad sections stained only with IR-α and phosphorylated eNOS 
respectively. Nox2 was labelled by Cy3 (red) and IR-α /p-eNOS was labelled by FITC (green) 
and nuclei was labelled by DAPI (blue). (A) The fluorescence intensity of Nox2 and IR-α was 
quantified. (B) The fluorescence intensity of Nox2 and phosphorylated eNOS was quantified. 
Data are expressed as mean ± SEM with a number of 4-6 mice per group. Comparisons were 
made by Student’s unpaired t-test or two-way ANOVA with Bonferroni post-hoc test * p<0.05 
significantly different from NCD values; * p<0.05 significantly different from ApoEKO values. 
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5.4 Discussion 
In this chapter the relationship of Nox2-induced ROS due to obesity and adipose tissue dysfunction 
was examined using WT and Nox2KO mice under NCD and HFD. Also obesity induced ROS 
production due to Nox2 was investigated in atherosclerosis-prone ApoEKO and Nox2/ApoE D-KO 
mice under NCD and HFD. Nox2 expression and intracellular pathway was examined by 
measuring p-ERK and p-p38, insulin resistance by IR expression and eNOS phosphorylation, 
macrophage infiltration and ICAM-1 expression and UCP1 protein levels.  
ApoEKO mice are the most widely studied animal model for atherosclerosis. They are 
hypercholesterolaemic and spontaneously develop atherosclerotic plaques in the aorta and arterial 
branches. Nox2/ApoE D-KO mice exhibited lower epididymal fat mass under HFD when 
compared to ApoEKO. Therefore, Nox2 deletion has a beneficial effect on obesity and 
atherosclerosis. Pepping et al., (2013) demonstrated the role of Nox2 on obesity by studying WT 
and Nox2KO mice under HFD. They found that Nox2 deletion attenuated adipose pathology, 
decreased visceral adipose deposition and macrophage infiltration. Other studies as well have 
demonstrated the role of Nox2 expression in obesity (Bruce-Keller et al., 2010; Zhang et al., 2005). 
Nox2 is a powerful mediator of diet induced obesity in various cell types. These effects could arise 
from macrophages that are recruited into adipose tissue, since they highly express Nox2. 
Macrophages are recruited into adipose tissue due to adipokines secreted by hypertrophic 
adipocytes. Activated macrophages in turn also secrete inflammatory mediators that affect both 
macrophages and adipocytes thus propagating a vicious cycle in the inflamed adipose tissue. 
In order to examine Nox2-induced ROS production due to obesity C57BL/6 WT and Nox2KO 
mice under NCD and HFD were used. Epididymal fat pads were excised and examined for Nox2 
expression, Nox2 activation by p47
phox
 determination and Nox2 intracellular pathway activation by 
ERK phosphorylation. It was found that HFD induced Nox2 expression and activation as evident 
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from the increase in p47
phox
 and ERK phosphorylation levels. In a previous study (Du et al., 2013) 
we found that Nox2 and p47
phox 
expression as well as ERK1/2 phosphorylation were increased in 
HFD WT aortas compared to NCD demonstrating that diet-induced obesity is linked with vascular 
Nox2 activation. Taking these experiments once step further, in this study it is demonstrated that 
diet-induced obesity is linked to adipose Nox2 activation as well. The relationship between diet-
induced obesity and Nox2 activation has been demonstrated by other researchers as well. Jiang et 
al., (2013) have found that Nox isoforms were upregulated in various tissues in a diet-induced 
obesity rat model. More specifically p22
phox
 and p47
phox
 were upregulated in adipose tissue among 
others, suggesting that multiple tissue Nox upregulation could be a systemic response. Matsuzawa-
Nagata et al. (2008) investigated mechanisms which have the potential to cause insulin resistance 
in HFD mice. They found that these mice had upregulated Nox and increased ROS production in 
adipose tissue. Finally, Coate et al. (2010) using C57BL/6 mice found that HFD mice had 
increased Nox2 expression and decreased antioxidant enzyme expression (catalase, GPx and SOD) 
in their adipose tissue. Therefore, the role of Nox2 in adipose responses to HFD has been 
demonstrated by various studies. It is known that obese patients have increased Nox2 expression, 
activated NF-kB and matrix-metallopeptidase-9 (MMP-9) plasma levels when compared to normal 
weight subjects. All of the above mechanisms are known to produce ROS (Patel et al., 2007). Fat 
accumulation increases Nox activity and ER stress leading to ROS production (Furukawa et al., 
2004).  
Visceral fat is a source but also a target of inflammatory cytokines and growth factors which may 
affect directly pre-adipocyte differentiation via signalling cascades such as Ras-Raf-ERK-1/2 
(Porras et al., 1988). In this study it was found that HFD upregulated ERK phosphorylation. ERK 
pathway was linked to adipogenesis in 1991 when it was shown that ectopic expression of an active 
Ras mutant - by constructing expression vectors and cloning led to growth arrest and terminal 
differentiation of 3T3-L1 cells in the absence of insulin and IGF-1 (Benito, 1991). Later ERK 
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inhibition was found to suppress adipogenesis (Sale et al., 1995). Bost et al., (2005) demonstrated 
that ERK1KO mice that were protected against obesity when fed a HFD due to a decrease in 
adipogenesis and an increase in postprandial energy expenditure. Jager et al., (2011) using ob/ob–
Erk1 knockout mice further demonstrated that ERK1 inhibition could partially protect obese mice 
against insulin resistance and liver steatosis by decreasing adipose tissue inflammation and by 
increasing muscle glucose uptake. Thus ERK regulates adipocyte differentiation, adiposity, and 
HFD–induced obesity.  In addition, ERK activation in adipocytes due to inflammatory cytokines 
also resulted in IRS-1 mRNA reduction leading to a decrease in insulin signalling and glucose 
transport (Jager et al., 2007). ERK activation could also indirectly promote insulin resistance by the 
stimulation of adipocyte lipolysis and the release of free fatty acids (Souza et al., 2003) but the 
result of HFD on insulin signalling will be discussed further along this chapter. Therefore, although 
adipocytes contribute to ROS production in obese adipose tissue they achieve this effect mainly 
through Nox4 and not Nox2 (Han et al., 2012; Mouche et al., 2007; Furukawa et al., 2004). Nox2 
expression should be studied in another cell type and an attractive candidate is infiltrating 
macrophages. Activated macrophage presence in adipose tissue will be discussed further along. 
Unlike Nox2 expression, ERK activation can be attributed to both macrophages through Nox2 
intracellular cascade activation for ROS production (Keshari et al., 2013) and adipocytes through 
inflammatory cytokines for the production of growth factors implicated in adipogenesis (Jager et 
al., 2007; Bhattacharya and Ullrich, 2006; Kahler et al., 2000). However, the fact that ERK 
phosphorylation levels in Nox2KO mice under HFD where not different from NCD suggests that 
elevated ERK phosphorylation levels are attributed to Nox2 expression and Nox2-induced ROS 
generation. 
Next the role of Nox2 in obesity induced ROS and atherosclerosis was investigated using ApoEKO 
and Nox2/ApoE D-KO mice. It was found that similar to WT, ApoEKO adipose tissue expressed 
increased Nox2, p-ERK and p-p38 protein levels under HFD compared to NCD. Several 
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epidimiological, clinical and animal studies have demonstrated that obesity is associated with is 
redox imbalance (Warolin et al., 2014). Chronic hypernutrition can lead to the activation of 
intracellular pathways leading to oxidative stress production through Nox, oxidative 
phosphorylation, PKC activation or glyceraldehyde oxidation (Serra et al., 2012; Sies et al., 2005). 
Obesity per se can cause systemic oxidative stress by Nox activation in adipocytes. Indeed, 
Furukawa et al., (2004) have studied both animal and human subjects and they found that increased 
oxidative stress in adipocytes is associated with metabolic syndrome. More specifically they used 
KKAy mice, a model of type-2 diabetes that exhibit severe obesity, hyperlipidaemia, and insulin 
resistance. They found increased ROS levels in the bloodstream and when they determined the 
tissue type responsible for that production they found increased lipid peroxidation levels in WAT. 
The source of ROS production was Nox2 since mRNA of all Nox2 subunits were elevated in WAT 
of KKAy mice. Human studies were in accordance with animal models since they found that fat 
accumulation itself could increase systemic oxidative stress and that increased oxidative stress in 
obesity might relate to the dysregulated production of adipokines. Nox2 downstream signalling 
molecules such as ERK and p38 were enhanced in ApoEKO mice under HFD as well.  MAP 
kinases, ERK, JNK and p38, are activated and involved in macrophage differentiation (Wang et al., 
2007; Himes et al., 2006; Wang and Studzinski, 2001). Zhang et al., (2013) demonstrated that ROS 
generation is needed for the late-phase ERK activation and monocyte-macrophage differentiation 
and ROS inhibition specifically inhibits M2 macrophage differentiation. Oxidized low-density 
lipoprotein is an important biomarker of CVDs. Ox-LDL levels were found elevated in patients 
with chronic metabolic disorders (Witztum and Steinberg, 1991) and in ApoEKO mice, there is a 
transient increase in circulating Ox-LDL levels during the progression of atherosclerosis (Kato et 
al., 2009). Ox-LDL is found in atherosclerotic lesions and one of its many proatherogenic 
properties is its cytotoxicity toward all vascular cells and macrophages (Heinloth et al., 
2000). Enhanced macrophage death in atherosclerotic lesions promotes the formation of necrotic 
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cores, a characteristic feature of advanced atherosclerotic plaques (Seimon and Tabas, 2009). 
Furthermore, both MCP-1 and TNF-α which are found in abundance in adipose tissue were found 
to increase ERK and p38 activation contributing to inflammation and atherogenicity 
(Parameswaran and Patial, 2010; Werle et al., 2002). In adipose tissue the simultaneous expression 
of Nox2 and pERK could be either from activated macrophages through Nox2 dependent ROS 
pathways which involve intracellular ERK activation or from adipocytes as an inflammatory 
molecule. Whichever the source of ERK and p38 activation they can lead to macrophage 
activation, recruitment and differentiation but also adipocyte differentiation and adipogenesis 
(Engelman et al., 1999; Hata et al., 2003) and thus propagating the inflammatory environment of 
the adipose tissue contributing to obesity and atherosclerosis. Using Nox2/ApoE D-KO mice I 
found that increased ERK phosphorylation levels were due to Nox2 and the activation of Nox2-
dependent ROS production. 
Next, the degree of macrophage infiltration into adipose tissue due to obesity induced ROS was 
studied. Adipose tissue from WT and Nox2KO mice under HFD and NCD were studied for 
macrophage presence and ICAM expression. It was found that HFD increased macrophage 
infiltration and ICAM expression in adipose tissue. Obesity has been associated with macrophage 
infiltration into adipose tissue (Weisberg et al., 2003) suggesting that obesity is a chronic mild 
inflammatory state (Wellen and Hotamisligil, 2003). Resident macrophages are necessary in order 
to maintain adipose tissue homeostasis however they can also be activated and recruited to adipose 
tissue. These two different macrophage populations are known as M1 and M2, M1 being 
inflammatory macrophages and M2 resident ones (Hill et al., 2014). In addition to these different 
populations, it has been shown that total macrophage number increases in the context of obesity. 
Studies in rodents have suggested that these infiltrating macrophages may originate from bone 
marrow and are recruited as a response to hypertrophied adipocyte apoptosis (Cinti et al., 2005) 
or/and due to inflammatory cytokine production from adipose tissue such as MCP-1 (Weisberg et 
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al., 2006). Recruited macrophages initiate a cascade of inflammatory pathways that can lead to 
insulin resistance, induce adipocyte chemokine and cytokine production and induce adipose tissue 
expansion capacity during obesity (Hill et al., 2014). Nox2 can be found in various cell types but 
the majority of Nox2 expression occurs in phagocytes and more specifically macrophages (Bedard 
and Krause, 2007). As stated previously Nox2 expression in adipocytes is quite low (Han et al., 
2012), suggesting that Nox2 expression may occur in the macrophage cells in adipose tissue. A 
very important question is whether macrophage infiltration is a consequence of obesity or a cause. 
A causal role has been suggested in HFD mice models where it was found an increase in 
macrophage specific gene expression in adipose tissue coincided or preceded a decrease in insulin 
sensitivity (Xu, 2003). MCP-1 knockout mice demonstrated reduced insulin resistance (Kanda et 
al., 2006; Weisberg et al., 2006). In humans macrophage infiltration in adipose tissue in obesity has 
been demonstrated (Cinti et al., 2005) which was shown to decrease upon weight loss (Cancello et 
al., 2005). What is interesting is that MCP-1 gene expression has been associated with ERK. It was 
found that HFD WT mice had increased levels of MCP-1 and ERK mRNA in epididymal adipose 
tissue. It is possible that ERK is an important mediator in ROS-induced MCP-1 expression in the 
adipocytes of obese patients resulting in macrophage infiltration and adipose tissue inflammation 
(Nayoung and Kijin, 2014). Therefore, in this study Nox2 as well as p-ERK and p-p38 expression 
in adipose tissue which were discussed before can be considered to be derived from infiltrating 
macrophages and not from adipocytes.  
 ICAM-1 is an immunoglobulin (Ig)-like cell adhesion molecule constitutively expressed at low 
levels on endothelial cells and leukocytes and upregulated following exposure to pro-inflammatory 
stimuli. It was found that increased ICAM-1 expression was correlated with increased recruitment 
of activated leukocytes and platelet-leukocyte aggregate formation (Nishimura et al., 2008). 
Increased ICAM-1 levels result from increased TNF-α, leptin and resistin levels, reduced 
adiponectin and the oxidative stress elicited in obese adipose tissue (Singer and Granger, 2007). 
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Since ICAM-1 immunoneutralisation blocks the leukocyte-endothelial cell interactions as well as 
the vascular permeability response, leukocyte adhesion-dependent mechanisms are likely 
responsible for the altered endothelial barrier function observed in obese adipose tissue (Nishimura 
et al., 2008). The stress that is imposed on adipocytes due to lipid droplet formation and expansion 
caused ER and mitochondria dysfunctions leading to ROS production as already stated. In response 
to ROS adipocytes secrete numerous biological peptides known as adipokines. One of these 
adipokines is resistin which is produced by both adipocytes and macrophages and induces insulin 
resistance (Yang et al., 2007). Resistin is considered an inflammatory mediator and acts on 
endothelial cells to induce oxidative stress, increase MCP-1, VCAM-1 and ICAM-1 expression and 
stimulate ET-1 secretion. Macrophages also respond to resistin by inflammatory cytokine 
production such as TNF-α, IL-12, and IL-6 (Fu et al., 2006). Visfatin is another adipokine secreted 
by activated adipocytes. Kim et al. (2008) demonstrated that visfatin is a vascular inflammatory 
molecule that increases ICAM-1 and VCAM-1 expression through ROS-dependent NF-κB 
activation in endothelial cells. ICAM-1-deficient mice were found to spontaneously develop 
maturity-onset obesity and fatty livers without an increase in food intake. They were also 
susceptible to obesity induced by HFD (Dong et al., 1997) therefore they postulated that there is a 
link between leukocyte adhesion and lipid metabolism regulation. Leukocytes could be directly 
engaged in removal of excess fat from tissues or indirectly by signalling to adipose tissue thus 
maintaining the correct adipocyte number and function. Activated leukocytes are also a major 
source of TNF-α which affects adiposity (Spiegelman and Hotamisligil, 1993). Two single-base 
pair polymorphisms of ICAM-1 have been described, which are located in exon 4 and exon 6. The 
respective domains they affect are not associated with ligand binding per se but are involved in the 
protein stability and therefore might affect ligand binding. Those polymorphisms have been 
associated with coronary heart disease, myocardial infarction (Jiang et al., 2002) and peripheral 
artery disease (Gaetani et al., 2002). In this study increased ICAM-1 expression in adipose tissue 
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was due to Nox2-induced ROS since Nox2KO mice had no differences under either NCD or HFD. 
As it was stated before, the source of ROS production is infiltrating macrophages. It is possible that 
in adipose tissue from mice fed a HFD, inflamed adipocytes secrete a milieu of cytokines and 
adipokines which recruit and activate macrophages. Infiltrating macrophages in turn are under the 
influence of various inflammatory stimuli including oxidative stress, adipokines and cytokines and 
one of the inflammatory molecules they secrete is ICAM-1. Nox2 deletion inhibited ICAM-1 
expression and thus its production is Nox2 dependent. 
Adipose tissue from ApoEKO mice under HFD were found to be infiltrated by macrophages, 
express higher levels of ICAM-1 and at the same time Nox2 expression was also higher than NCD. 
Once again, obesity and atherosclerosis are inflammatory diseases and activated macrophages are a 
key characteristic for both of them. Hirata et al. (2011) examined epicardial adipose tissue in 
respect to atherosclerosis and macrophage activation. They found that infiltration of macrophages 
and expression of pro- and anti-inflammatory cytokines were enhanced in epicardial fat of patients 
with coronary artery disease compared with that in non-coronary artery disease patients. ICAM-1 
has been shown to be present and involved in the progression of atherosclerotic lesions (Poston et 
al., 1992). The involvement of ICAM-1 in atherosclerosis has been demonstrated in ApoEKO mice 
deficient in ICAM-1, which were shown to have reduced lesion size (Nageh et al., 1997). Time 
course analysis in mice revealed that ICAM- 1 is not only involved in the initial plaque formation 
but also in the subsequent progression (Kitagawa et al., 2002; Bourdillon et al., 2000). These data 
were supported by results obtained in ApoEKO mice treated with anti-ICAM-1 neutralising 
antibodies (Patel et al., 1998). In this study, Nox2 deletion in Nox2/ApoE D-KO mice ameliorated 
macrophages recruitment and ICAM-1 expression demonstrating the beneficial effect of Nox2 
inhibition/deletion in obesity induced ROS and atherosclerosis. 
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Next the relationship between obesity induced ROS, IR and eNOS was explored.  WT and 
Nox2KO mice were used under HFD and NCD and their adipose tissue was examined for Nox2 
and IR expression and eNOS phosphorylation. It was found that HFD decreased both IR expression 
and eNOS phosphorylation. Under normal circumstances, insulin triggers Nox induced ROS 
production (Mahadev et al., 2004). With this mechanism ROS induce adipocyte differentiation thus 
allowing glucose uptake (Krieger-Brauer and Kather, 1995). However, in obese animals ROS 
production occurs not only as a response to insulin but also spontaneously. Nox2, specifically, 
appears to be upregulated in obese rats (Furukawa et al., 2004). ROS were also found to decrease 
adiponectin, a protein involved in glucose regulation and insulin sensitisation (Furukawa et al., 
2004). Additionally, prolonged exposure to ROS induces a decrease in glucose transporter 
expression and glucose uptake (Rudich et al., 1998). A study using rats showed that Nox2 induced 
ROS contributed to the deterioration of β-cell function. This study also showed that Nox2 
suppression reverses the glucose-induced dysfunction of pancreatic NIT-1 cells (Yuan et al., 2010). 
Adipocytes and macrophages secrete MCP-1 and other inflammatory cytokines such as TNF-α 
(Lagathu et al., 2006). Stephens et al. (1997) found that prolonged exposure of 3T3-L1 adipocytes 
to TNF-α causes a substantial reduction in IRS-1 and GLUT4 mRNA and protein as well as insulin 
receptor expression causing insulin resistance to adipocytes. Analysis of adipose infiltrating 
macrophages in obese mice suggests that these cells predominantly express the classically activated 
phenotype (Bouloumié et al., 2005). Obesity activates various protein kinases, including IκB kinase 
β and JNK which promote insulin resistance (Hotamisligil, 2003). Activation of the stress kinase 
JNK-1 results in inhibitory serine phosphorylation of IRS-1, leading to decreased tyrosine kinase 
signalling from the insulin receptor. Rodent studies demonstrated an increase in adipose TNF-α in 
rodent models of insulin resistance (Hotamisligil et al., 1993). TNF-α expression was increased in 
the adipose tissue obtained from obese subjects, was related to insulin resistance (Hotamisligil et 
al., 1995). The source of TNF-α in obese adipose tissue is recruited macrophages. Eventually 
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altered adipokine expression and excess of fatty acids contribute to the insulin resistant state 
detected in obesity (Heilbronn and Campbell, 2008). The fact that Nox2 deletion maintained IR 
levels unaffected from HFD suggests that the majority of the IR detected comes from infiltrating 
macrophages and highlights the possibility of Nox2 inhibition as a therapeutic approach for obesity 
induced ROS production. Normally insulin signalling though the metabolic PI3K/PKB cascade 
results in increased activation and phosphorylation of eNOS with consequent elevation in 
bioavailable NO (Guo, 2014). Nox2 induced ROS production and decreased IR both contribute to 
insulin resistance in adipose tissue. Nox2 downregulation improves insulin signalling. However, 
vascular NO reductions could affect adipose inflammation as well. Handa et al. (2010) 
demonstrated that vascular NO reduction increases the susceptibility of peripheral tissue like 
adipose to the inflammatory effects of HFD. They found that macrophage recruitment into adipose 
tissue is increased in mice lacking eNOS/VASP even when under HFD. Moreover, in db/db mice 
which is a model for severe obesity, adipose tissue inflammation and macrophage infiltration were 
reduced by sildenafil which enhances NO pathway. They also demonstrated that HFD reduced 
vascular NO signalling in adipose tissue and this reduction was associated with adipose 
inflammation and resistance, whereas mice lacking eNOS had induced adipose inflammation even 
on a low fat diet. Vascular NO reduction was discussed in a previous chapter (Chapter 4) and will 
not be discussed here. 
Using ApoEKO mice under NCD and HFD it was demonstrated that Nox2-induced ROS due to 
obesity in this atherosclerotic mouse model also decreased IR expression and eNOS 
phosphorylation. Again, activated macrophages and adipokines secreted by the inflamed adipose 
tissue contribute to insulin resistance. Insulin resistance was demonstrated by IR downregulation 
and eNOS phosphorylation reduction. Adipose tissue cells proliferate in a milieu of inflammatory 
cytokines including TNF-α. It was found that TNF-α markedly decreased both eNOS expression 
and mitochondrial biogenesis due to oxidative stress in cultured adipose and muscle cells. eNOS 
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downregulation is the major molecular mechanism by which TNF-α affects mitochondrial 
biogenesis in in vitro models, as clearly shown by the full reversal of the effects of TNF-α on 
mitochondria by the NO donors diethylenetriamine (DETA)-NO and S-nitroso-N-acetyl-l,l-
penicillamine (SNAP). Together, these results suggest that TNF-α plays an important role in 
decreasing eNOS expression and mitochondrial biogenesis in metabolically active tissues of obese 
animals (Valerio et al., 2006). TNF-α is also overproduced in WAT of obese patients  and 
mitochondrial biogenesis in WAT, BAT, and muscle was at least partially restored in the obese 
mice with defective TNF-α signalling (Hotamisligil et al., 1995). Using transgenic mice it was 
found that eNOS knockout mice showed a reduction in mitochondrial biogenesis and developed 
visceral obesity (Nisoli et al., 2003). Also a decrease in eNOS expression in total abdominal WAT 
of male diet-induced obesity mice (Moraes et al., 2003) and an inverse correlation among the 
skeletal muscle eNOS content, percent body fat, and body mass index in young adult women 
(Hickner et al., 2006) have previously been described. Using eNOS knockout mice Cook et al., 
(2003) demonstrated that eNOS deficiency causes a clustering of cardiovascular risk factors in 
young mice. Nitric oxide synthesis could trigger many of the abnormalities making up the 
metabolic syndrome in humans. However, the results from HFD Nox2/ApoE D-KO mice 
demonstrate that insulin resistance could be ameliorated upon Nox2 deletion showing the beneficial 
effect of Nox2 inhibition on obesity induced stress and atherosclerosis. 
Finally, the relationship between UCP1 and ROS was investigated. Adipose tissue from WT and 
Nox2KO mice under HFD and NCD was examined for Nox2 and UCP1 expression. The results 
were that HFD increased Nox2 expression and decreased UCP1 protein levels. Transgenic mice 
models are commonly used in order to examine the role of UCP1 in obesity or more correctly in 
resistance against obesity. Lowell et al. (1993) were the first to provide evidence for a causal 
relationship between BAT thermogenesis and obesity by demonstrating that UCP1 knockout mice 
had reduced brown fat and were obese. Kontani et al. (2005) using again UCP1 knockout mice 
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under HFD found increased expression of thermogenesis and fatty acid metabolism-related in 
adipose tissue bringing them to late-onset obesity. On the other hand, transgenic mice with 
increased UCP1 expression in WAT are obesity-resistant under HFD (Dalgaard and Pedersen, 
2001). Kopecky et al. (1995) used mice where their Ucp gene is driven by the fat-specific aP2 
promoter thus increasing UCP1 expression in both BAT/WAT and found that those mice not only 
had reduced adipose tissue but were also resistant to obesity. UCP1 has also been ectopically 
expressed in skeletal muscle of mice, and these animals showed improved glucose tolerance after 
being fed a HFD, when compared with wild-type mice (Dalgaard and Pedersen, 2001). In humans 
intraperitoneal fat UCP1 expression in obese subjects is 50% lower compared to normal weight 
subjects (Virtanen and Nuutila, 2011). Association studies regarding UCP1 polymorphisms are 
mostly focused on -3826A/G (rs1800592) polymorphism. This allele has been associated with 
reduced UCP1 mRNA expression in intraperitonial adipose tissue of obese subjects highlighting its 
functional importance (Esterbauer et al., 1998). Several independent studies support the association 
between the -3826G allele and obesity, BMI or other obesity-related parameters (Ramis et al., 
2004; Forga et al., 2003; Heilbronn et al., 2000; Clément et al., 1996).  Additionally, other studies 
indicate that the -3826G allele might be associated with reduced HDL-cholesterol levels (Oh et al., 
2004; Kiec-Wilk et al., 2002), increased triglycerides (Kiec-Wilk et al., 2002) or LDL-cholesterol 
levels (Proenza et al., 2000) and increased systolic and/or diastolic BP (Oh et al., 2004). In current 
literature it is suggested that increased ROS levels are associated with increased UCP1 as a defence 
mechanisms against oxidative stress diminishing oxidative damage (Chouchani et al., 2015). We 
found that Nox2-induced ROS decreased UCP1. This contradiction could be explained by the fact 
that the previous studies were focused solely on mitochondrial ROS. There is no study to my 
knowledge that associates Nox-dependent ROS and UCP1 in adipose tissue apart from the present. 
However, there are studies that pinpoint the important role of NO and eNOS on UCP1. More 
specifically, UCP1 induction in adipose tissue is stimulated by NO (Janković et al., 2009) whereas 
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eNOS knockout mice have impaired BAT function and decreased UCP1 expression (Nisoli et al., 
2003). In this study it is demonstrated that eNOS and NO expression induction are associated with 
Nox2-induced ROS production. Nox2 deletion decreases ROS and increases eNOS and NO levels 
and this mechanism could also cause an increase in UCP1 expression. 
When using NCD and HFD ApoEKO mice it was found that adipose tissue expression of UCP1 
was downregulated while Nox2 expression was upregulated. One of the major adipokines secreted 
by activated adipocytes is PAI-1 and has been implicated in atherosclerosis by various studies. 
Vaughan (2005) stated that elevated PAI-1 levels appear to increase the risk of atherothrombotic 
events. Moreover, cytokines that induce PAI-1 production such as TNF-α which is also secreted by 
activated macrophages and adipocytes, are also thought to promote vascular inflammation and 
atherosclerosis. It has been reported that plasminogen deficiency accelerates the development of 
atherosclerosis in ApoEKO mice (Xiao et al., 1997) whereas several groups have reported excess 
PAI-1 in atherosclerotic plaques in humans (Raghunath et al., 1995; Schneiderman et al., 1992). 
Adipose tissue from Nox2KO and Nox2/ApoE D-KO mice under HFD showed an increase in 
UCP1 in WAT. Browning of adipose tissue has a beneficial effect on both obesity and 
atherosclerosis and the role of Nox inhibition as a therapy should be considered. 
In this study, endothelium Nox2-Tg mice were kept under NCD and various target-molecules were 
studied as a type of proof of principal that increasing Nox2 would affect adipose tissue function. 
More specifically: Nox2 and p22
phox
 expression, ROS production, and phosphorylation status of 
intracellular signalling molecules such as p38 and Akt. Endothelium Nox2-Tg mice are transgenic 
mice with targeted overexpression of Nox2 in the endothelium and are useful for the examination 
of the specific role of Nox2 in regulation of vascular oxidative stress. Also two age groups were 
used-young and ageing mice- in order to examine age-related differences in Nox2 expression and 
pathway. 
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Under NCD Nox2-Tg mice had increased Nox2 expression and Nox2-dependent ROS production, 
increased p38 and decreased Akt phosphorylation in the adipose tissue. There was therefore a 
connection between Nox2-induced ROS production in the endothelium and endothelial dysfunction 
and Nox2-induced ROS production in the adipose tissue. Increased endothelial ROS production 
resulted in increased adipose tissue ROS generation. Studies with Nox2-Tg mice that are lacking 
ApoE have demonstrated that Nox2 overexpression in the endothelium increases VCAM-1 and 
macrophages recruitment possibly via activation of endothelial cells (Douglas et al., 2012). 
Moreover, Fan et al., (2012) demonstrated that endothelial cells from Nox2-Tg mice had increased 
ROS production accompanied by increased cyclophilin A secretion and ERK1/2 activation. 
Therefore, macrophage recruitment, expression of cell adhesion molecules, growth factor and 
MAPK activation in endothelial cells may cause signalling molecules that can affect adipose tissue 
via paracrine or endocrine manner. Also 1-10% of WAT consists of endothelial cells (Hauner, 
2005). Since Nox2 was established to correlate with mass of epididymal fat pads, it was 
demonstrated that adipose tissue from Nox2-Tg mice had increased ROS, increased p38 and 
decreased Akt phosphorylation. MAPK in general and p38 specifically are Nox2 downstream 
signalling molecules and their phosphorylation is indicative of an active Nox2 pathway (Noguchi et 
al., 2008). Akt on the other hand is involved in insulin signalling. It has been demonstrated that 
Nox2-induced ROS production leads to insulin resistance and Akt inactivation (Du et al., 2013). 
The effect of Nox2 pathway and ROS generation on p38 and Akt has been discussed extensively in 
a previous chapter (chapter 4) and will be discussed in brief in the following paragraphs. An 
interesting aspect of Nox2-Tg experiments was the fact that two age groups were used – 3-4 
months and 15-17 months - so the effect of ageing on Nox2 expression, ROS production and p38 
and Akt phosphorylation was also studied. It was found that ageing increased Nox2-induced ROS 
generation and therefore also increased the downstream intracellular signalling molecule p38, 
whereas Akt phosphorylation levels were decreased. Cahill-Smith et al. (2013) have studied young 
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and ageing WT and Nox2KO mice for the investigation of Nox2 in age-related oxidative stress. 
They found that ageing WT mice had higher blood pressure, developed insulin resistance, vascular 
dysfunction and increased ROS production. Nox2KO mice were protected from oxidative stress 
and ageing-associated metabolic disorders. Moreover, Turgeon et al. (2012) also studied young and 
old WT and Nox2KO mice. They demonstrated an age-dependant pathological increase of ROS in 
endothelial progenitor cells that was not present in Nox2KO mice. In this chapter it is demonstrated 
that ageing in mice with over-expressed Nox2 induces Nox2 expression even further as well as 
ROS generation, activates p38 intracellular cascades and decreases Akt phosphorylation as an 
indication of insulin resistance. The effects on WT mice are less prominent. 
In summary the relationship of Nox2-induced ROS due to obesity and adipose tissue dysfunction 
was examined using WT and Nox2KO mice under NCD and HFD. Also obesity induced ROS 
production due to Nox2 was linked with atherosclerosis using ApoEKO and Nox2/ApoE D-KO 
mice under NCD and HFD. The parameters that were measured were Nox2, IR and ICAM-1 
expression, ERK, p38 and eNOS phosphorylatiion, macrophage infiltration into adipose tissue and 
UCP1 expression. We found that adipose tissue in obesity is infiltrated by macrophages thus 
contributing to inflammation and ICAM-1 expression is increased. IR expression is decreased 
whereas ERK phosphorylation is increased and eNOS phosphorylation is decreased suggesting 
impaired insulin signalling. UCP1 levels are also decreased. The effect of obesity in the parameters 
measured is due to Nox2-induced ROS since Nox2KO mice did not show any changes in those 
protein levels. Since Nox2 is expressed only in macrophages in the adipose tissue we can postulate 
that the above changes, except from UCP1 levels, are due to the activation of macrophages and not 
adipocytes. Nox2 deletion is an attractive therapeutic target since Nox2KO were protected from 
adipose inflammation and insulin resistance and at the same time they expressed increased levels of 
UCP1 which is known for its protective role.  Obesity induced ROS due to Nox2 was also linked 
with atherosclerosis. Nox2 deletion also protected the atherosclerotic mice model ApoEKO from 
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adipose tissue dysfunction further confirming the therapeutic role of Nox2 deletion in obesity 
induced ROS production and atherosclerosis. The role of Nox2-induced ROS in adipose 
dysfunction was also confirmed using Nox2-Tg mice that were found to have increased Nox2-
induced ROS production, activated Nox2 pathway and insulin resistance. Finally, it was shown that 
there are age-related differences in Nox2 expression and pathway. 
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CHAPTER 6 
6.1 Discussion 
The obesity epidemic has become a major public health problem around the world (Tucker, 2014). 
Consumption of food rich in dietary fat in modern societies has been one of the main contributors 
to the obesity epidemic (Hurt et al., 2010). Obesity is a central feature of the metabolic syndrome 
and is associated with increased risk for insulin resistance, type-2 diabetes, hypertension and 
atherosclerosis (Du et al., 2013; Maison et al., 2001). Recently, evidence have suggested that 
systemic (multi-organ) oxidative stress is one of the dominant mechanisms contribute to diet-
induced obesity-related CVDs. 
Obesity has been shown to be closely related to endothelial dysfunction. Endothelial dysfunction 
characterised by excessive ROS production from Nox2 activation has been discovered to play a 
pivotal role in the pathogenesis of CVDs such as atherosclerosis. For this reason, therapeutic 
targets to inhibit the up-regulation of Nox2 require immediate action to protect the endothelium 
from ROS damage thus decreasing the risk of developing CVDs. The resulting decrease of NO has 
been shown to be through the increased production of ROS. Additionally, oxidative modification of 
LDL by ROS such as superoxide also plays a critical role in atherosclerosis development 
(Förstermann and Münzel, 2006). The dysregulation of Nox2 due to obesity is of importance due to 
the direct effects on the activity of the NO and obesity-related molecules result in the down-
regulation of eNOS. 
Obesity also results in impaired insulin signalling. Elevation of ROS causes increased proteasomal 
degradation of IRS-1, increased JNK 1-mediated-serine phosphorylation of IRS-1 and impaired 
insulin-stimulated redistribution of IRS-1 and PI3K activity. It has been proposed that ROS 
produced by Nox2 is converted into H2O2 which can inhibit IRS-1 activation. Nox2 activity and 
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expression is associated with insulin resistance (Fortuño et al., 2009) and increased Ang II levels 
resulted in insulin resistance alongside increased expression of rac1, p67
phox
, p22
phox
 and Nox2 and 
increased Nox2-derived ROS (Wei et al., 2007). Apocynin, a Nox inhibitor, has been shown to 
ameliorate hyperglycaemia and insulin resistance in mice fed a HFD diet by reducing oxidative 
stress (Meng et al., 2011). Obesity per se can induce oxidative stress through various biochemical 
mechanisms, such as superoxide generation from Nox, oxidative phosphorylation, PKC activation, 
and polyol and hexosamine pathways to name a few (Manna and Jain, 2015). In addition, recent 
studies suggest that adipose tissue plays a critical role in regulating the pathophysiological 
mechanisms of obesity (Hajer et al., 2008). Furthermore, obesity-induced inflammation is 
frequently associated with increased oxidative stress. Specifically, leptin, an adipocyte-derived 
hormone, is elevated in obese individuals and can induce oxidative stress (Korda et al., 2008) and 
plays a key role in mediating a pro-inflammatory state in obesity. Wannamethee et al. (2007) 
indicated that this physiological link may help to explain the relationship of obesity, oxidative 
stress, and inflammation. 
The aim of this thesis was to investigate Nox2-induced ROS production in obesity, insulin 
resistance and adipose tissue dysfunction. 
First, the effect of obesity and Nox2-induced ROS production in respect to metabolic parameters, 
vascular dysfunction and insulin resistance was explored. In addition to this, Nox2 intracellular 
cascades were also examined. More specifically MAPK and Akt/eNOS pathway activation, 
endothelial cell activation and macrophage recruitment were determined. A previous colleague in 
our group (Dr Junjie Du) found that HFD promoted obesity, hyperglycaemia, hyperinsulinaemia 
and accelerated the accumulation of low-density lipoprotein in ApoEKO mice. HFD also attenuated 
the endothelium-dependent relaxation responses of aortas accompanied with higher BP and 
decrease NO bioavailability in ApoEKO mice (unpublished data). Moreover, HFD induced 
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vascular dysfunction and at the same time HFD ApoEKO mice exhibited increased ROS 
production in metabolic organs. More specifically heart, aorta, lung, kidney, spleen and epididymal 
fat from HFD ApoEKO mice were found to have increased ROS levels. All of the above 
parameters were attenuated in Nox2/ApoE D-KO mice demonstrating the importance of Nox2-
derived ROS production in the pathogenesis of CVDs-associated with metabolic disorders. Nox2 
intracellular events demonstrated that HFD ApoEKO mice have activated MAPK pathway, 
whereas Akt/eNOS cascades are attenuated resulting in decreased NO bioavailability. At the same 
time Nox2-induced ROS production due to obesity induced aortic Akt downregulation, VCAM-1 
expression and macrophage recruitment indicating endothelial cell activation and inflammation. 
Nox2/ApoE D-KO mice did not exhibit any of the delirious effects of HFD. Therefore, Nox2 
targeting may represent an effective therapy to reduce dietary obesity-related oxidative stress, 
increase insulin sensitivity and improve vascular function. 
Next, the role of Nox2 in insulin-resistance was investigated in respect to Nox2-induced ROS 
production, vascular function and IR function using Nox2KO, ApoEKO and Nox2/ApoE D-KO 
aortic homogenates and sections. It was found that insulin-resistance in atherosclerosis is linked to 
Nox2-induced ROS production which results in endothelial dysfunction, endothelial cell activation 
and IR impairment. IR dysfunction has an effect on downstream signalling pathways, attenuating 
the PI3K/Akt/eNOS branch in favour of the MAPK one.  Insulin resistance had no effect on 
Nox2/ApoE D-KO mice models indicating the therapeutic potential of Nox2 inhibition in the 
involvement of obesity related metabolic syndrome and endothelial dysfunction. 
Finally, the relationship of Nox2-induced ROS due to obesity and adipose tissue dysfunction was 
examined using WT and Nox2KO mice under NCD and HFD. Also obesity induced ROS 
production due to Nox2 was linked with atherosclerosis using ApoEKO and Nox2/ApoE D-KO 
mice under NCD and HFD. Nox2 expression and intracellular pathway by measuring ERK and 
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p38, insulin resistance by IR expression and eNOS phosphorylation, macrophage infiltration and 
ICAM-1 expression and UCP1 protein levels were examined. It was found that adipose tissue in 
obesity is infiltrated by macrophages thus contributing to inflammation and ICAM-1 expression is 
increased. IR expression is decreased whereas ERK phosphorylation is increased and eNOS 
phosphorylation is decreased suggesting impaired insulin signalling. UCP1 levels are also 
decreased. The effect of obesity in the parameters measured is due to Nox2-induced ROS since 
Nox2KO mice did not show any changes in those protein levels. Since Nox2 is expressed only in 
macrophages in the adipose tissue we can postulate that the above changes, except from UCP1 
levels, are due to the activation of macrophages and not adipocytes. Nox2 deletion is an attractive 
therapeutic target since Nox2KO were protected from adipose inflammation and insulin resistance 
and at the same time they expressed increased levels of UCP1 which is known for its protective 
role.  Obesity induced ROS due to Nox2 was also linked with atherosclerosis. Nox2 deletion also 
protected the atherosclerotic mice model ApoEKO from adipose tissue dysfunction further 
confirming the therapeutic role of Nox2 deletion in obesity induced ROS production and 
atherosclerosis.  
One of the advantages of this study is the use of Nox2KO and Nox2/ApoE D-KO mice. Most 
studies on the effect of Nox2-induced ROS production and its effects on obesity or diabetes were 
performed using inhibitors. However, no matter how specific an inhibitor is one cannot be 
absolutely certain about its selectivity or specificity. This study proves beyond any doubt that Nox2 
deletion is the only factor affecting the parameters measured.  
On the other hand, significantly, by targeting Nox2 could create a background for chronic 
granulomatous disease, considering the Nox2 activity (the oxidative burst) that is vital for 
neutrophil function and resists against bacterial and fungal infection. Despite the structural 
similarity that exists between neutrophil and endothelial Nox2 enzymes, there are profound 
278 
 
biochemical and functional differences between them, coupled that the regulatory mechanism of 
Nox2 activation is completely different in endothelial cells from that in neutrophils (Li and 
Shah, 2002). So an effective method is to target the mechanism specifically for endothelial Nox2 
activation. Additionally, the overall endothelial Nox2 activity, even in a state of full activation, is 
only about 1% of that in the neutrophils (Drummond et al., 2011). In this way, there is a room for 
developing a specific Nox2 inhibitor that inhibits the activation of endothelial Nox2 at a low dose, 
which would not be enough to affect neutrophil Nox2 activity. 
To sum up, the novel discoveries from the current study are that (i) the HFD-induced Nox2 
activation was associated with reduced vascular Akt expression and profound endothelial 
dysfunction; (ii) HFD Nox2/ApoE D-KO mice preserved vascular Akt expression and endothelial 
function, and reduced symptoms of the metabolic syndrome; (iii) ex-vivo organ culture further 
confirmed that high levels of glucose (30mM) and insulin (1.2nM) caused damages to ApoEKO 
vessels (but not to vessels from Nox2/ApoE D-KO mice) characterised by ERK1/2 activation, 
reduced IR expression and deterioration of endothelial function and (iv) there was a close link 
between HFD-induced Nox2 activation and browning of WAT, as ApoEKO mice reduced UCP1 
levels compared to HFD Nox2/ApoE D-KO mice. Our study for the first time demonstrated a 
crucial role of global Nox2 activation (not restricted in the endothelium) in ApoEKO mouse model 
in response to dietary obesity-associated glucose metabolic disorders (i.e. hyperglycaemia and 
hyperinsulineamia) causing inflammation, cellular senescence and oxidative damage of endothelial 
function and insulin receptor function in major vessels and adipose tissue dysfunction. Also, it has 
demonstrated a positive feedback loop between progressive Nox2 activation in a high 
glucose/insulin environment and Nox2-derived oxidative stress causing further damage to the 
global metabolism in dietary obesity. Inhibition or knockout of Nox2 in ApoEKO mouse model not 
only reduced the levels of HFD-associated ROS production in cardiovascular and metabolic organs 
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but also helps to preserve endothelial function, improves global metabolism and browning and 
function of adipose tissue. 
In conclusion, the research presented in this thesis provides strong evidence that Nox2-derived 
oxidative stress plays an important role in the pathogenesis of dietary obesity-associated metabolic 
syndrome, Akt/eNOS inhibition, endothelial dysfunction and adipose tissue inflammation. As 
dietary obesity remains increasingly prevalent and seemingly resistant to clinical remediation, 
targeting Nox2-derived ROS represents a valuable therapeutic strategy to reduce dietary obesity-
related oxidative stress, to increase insulin sensitivity and to improve vascular and adipose tissue 
function.  
6.2 Future Work 
This research provides a thorough investigation into the role of a Nox2-containing NADPH oxidase 
in HFD-induced metabolic disorders, vascular and adipose tissue dysfunction. However, futher 
investigation needed for the mechanistic link between Nox2 and browning in WAT. 
Therefore, the next step will be to further elucidate the role of Nox2 in the adipose tissue by:  
 Investigating the effects of HFD on other adipose depots (e.g. subcutaneous inguinal adipose tissue, 
brown adipose tissue etc.) and their weights  
 Investigating Nox2 expression in HFD adipose depots along with other NADPH oxidase isoforms 
and subunits 
 Investigating the effects of HFD on adipocyte hypertrophy  
 Investigating the effects of HFD on markers of adipocyte function and injury by evaluating the 
expressions of TNF-α, IL-6, MCP-1, PPARγ (Peroxisome proliferator-activated receptor gamma), 
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adiponectin, leptin, GADD153/CHOP and GRP78 (glucose-regulated protein-78) by western 
blotting.  
 Uncovering the link between Nox2 and UCP1. Will be of interest to look at novel transcriptional 
regulators of brown and beige fat tissues like UCP1, CIDEA, Cox8b, PRDM16, Nrbf1, Cox4il etc 
 Targeting Nox2 deletion to macrophages 
Further investigation should also be focused on the exact mechanisms behind the effect of Nox2 
activation and oxidative stress in HFD-induced hypertension, metabolic disorders and endothelial 
dysfunction. In particular, it would be interesting to elucidate the redox signalling mechanisms 
involved with focus on the most common downstream targets of Nox2-derived ROS including PKC 
activation and MAPK-JNK. 
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